NO792233L - PROCEDURE FOR THE PREPARATION OF PHENYL PIPERIDE INGREDIENTS - Google Patents
PROCEDURE FOR THE PREPARATION OF PHENYL PIPERIDE INGREDIENTSInfo
- Publication number
- NO792233L NO792233L NO792233A NO792233A NO792233L NO 792233 L NO792233 L NO 792233L NO 792233 A NO792233 A NO 792233A NO 792233 A NO792233 A NO 792233A NO 792233 L NO792233 L NO 792233L
- Authority
- NO
- Norway
- Prior art keywords
- salt
- substituted
- residue
- piperidine
- hydroxy
- Prior art date
Links
- 238000000034 method Methods 0.000 title claims description 46
- 238000002360 preparation method Methods 0.000 title claims description 8
- CIUQDSCDWFSTQR-UHFFFAOYSA-N [C]1=CC=CC=C1 Chemical class [C]1=CC=CC=C1 CIUQDSCDWFSTQR-UHFFFAOYSA-N 0.000 title 1
- 239000004615 ingredient Substances 0.000 title 1
- 150000001875 compounds Chemical class 0.000 claims description 116
- -1 hydroxy- Chemical class 0.000 claims description 98
- 150000003839 salts Chemical class 0.000 claims description 81
- 125000000217 alkyl group Chemical group 0.000 claims description 70
- 239000002253 acid Substances 0.000 claims description 69
- 238000006243 chemical reaction Methods 0.000 claims description 51
- 229910052736 halogen Inorganic materials 0.000 claims description 39
- 150000002367 halogens Chemical class 0.000 claims description 37
- 125000002887 hydroxy group Chemical group [H]O* 0.000 claims description 32
- 239000000203 mixture Substances 0.000 claims description 31
- 125000004432 carbon atom Chemical group C* 0.000 claims description 30
- 125000003545 alkoxy group Chemical group 0.000 claims description 19
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims description 15
- 239000003795 chemical substances by application Substances 0.000 claims description 13
- JEIPFZHSYJVQDO-UHFFFAOYSA-N iron(III) oxide Inorganic materials O=[Fe]O[Fe]=O JEIPFZHSYJVQDO-UHFFFAOYSA-N 0.000 claims description 13
- 229910052751 metal Inorganic materials 0.000 claims description 13
- 239000002184 metal Substances 0.000 claims description 13
- 125000001797 benzyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])* 0.000 claims description 10
- NQRYJNQNLNOLGT-UHFFFAOYSA-N Piperidine Chemical compound C1CCNCC1 NQRYJNQNLNOLGT-UHFFFAOYSA-N 0.000 claims description 9
- 125000005936 piperidyl group Chemical group 0.000 claims description 9
- 241000206607 Porphyra umbilicalis Species 0.000 claims description 7
- 125000001140 1,4-phenylene group Chemical group [H]C1=C([H])C([*:2])=C([H])C([H])=C1[*:1] 0.000 claims description 6
- 230000008569 process Effects 0.000 claims description 6
- 125000001989 1,3-phenylene group Chemical group [H]C1=C([H])C([*:1])=C([H])C([*:2])=C1[H] 0.000 claims description 3
- 125000004435 hydrogen atom Chemical group [H]* 0.000 claims description 3
- 229960005222 phenazone Drugs 0.000 claims description 3
- 239000002243 precursor Substances 0.000 claims description 3
- 230000008901 benefit Effects 0.000 claims description 2
- 125000001589 carboacyl group Chemical group 0.000 claims 3
- JVAWBXVGAXVOID-UHFFFAOYSA-N 1-[(3,4-dichlorophenyl)methyl]-4-(4-ethylphenyl)piperidine Chemical compound C1=CC(CC)=CC=C1C1CCN(CC=2C=C(Cl)C(Cl)=CC=2)CC1 JVAWBXVGAXVOID-UHFFFAOYSA-N 0.000 claims 1
- ZQVYKGANYHYVKY-UHFFFAOYSA-N 1-[4-[1-[(2-chlorophenyl)methyl]piperidin-4-yl]phenyl]ethanone Chemical compound C1=CC(C(=O)C)=CC=C1C1CCN(CC=2C(=CC=CC=2)Cl)CC1 ZQVYKGANYHYVKY-UHFFFAOYSA-N 0.000 claims 1
- MZDJVWKANPQKFK-UHFFFAOYSA-N 4-(4-ethylphenyl)-1-[(3-methoxyphenyl)methyl]piperidine Chemical compound C1=CC(CC)=CC=C1C1CCN(CC=2C=C(OC)C=CC=2)CC1 MZDJVWKANPQKFK-UHFFFAOYSA-N 0.000 claims 1
- 241000220317 Rosa Species 0.000 claims 1
- 230000001335 demethylating effect Effects 0.000 claims 1
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 90
- 125000004356 hydroxy functional group Chemical group O* 0.000 description 47
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 46
- 125000004043 oxo group Chemical group O=* 0.000 description 43
- 239000000243 solution Substances 0.000 description 38
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 34
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 34
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 33
- 239000001257 hydrogen Substances 0.000 description 32
- 229910052739 hydrogen Inorganic materials 0.000 description 32
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 description 25
- 238000002844 melting Methods 0.000 description 23
- 230000008018 melting Effects 0.000 description 23
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 21
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 21
- WYURNTSHIVDZCO-UHFFFAOYSA-N Tetrahydrofuran Chemical compound C1CCOC1 WYURNTSHIVDZCO-UHFFFAOYSA-N 0.000 description 20
- VEXZGXHMUGYJMC-UHFFFAOYSA-M Chloride anion Chemical compound [Cl-] VEXZGXHMUGYJMC-UHFFFAOYSA-M 0.000 description 18
- 230000002829 reductive effect Effects 0.000 description 18
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 16
- 229960004132 diethyl ether Drugs 0.000 description 16
- 150000002148 esters Chemical class 0.000 description 15
- 239000002904 solvent Substances 0.000 description 15
- 239000007858 starting material Substances 0.000 description 15
- ZAMOUSCENKQFHK-UHFFFAOYSA-N Chlorine atom Chemical compound [Cl] ZAMOUSCENKQFHK-UHFFFAOYSA-N 0.000 description 14
- PMZURENOXWZQFD-UHFFFAOYSA-L Sodium Sulfate Chemical compound [Na+].[Na+].[O-]S([O-])(=O)=O PMZURENOXWZQFD-UHFFFAOYSA-L 0.000 description 14
- 150000007513 acids Chemical class 0.000 description 14
- 239000002585 base Substances 0.000 description 14
- 238000009835 boiling Methods 0.000 description 14
- 239000000460 chlorine Substances 0.000 description 14
- 229910052801 chlorine Inorganic materials 0.000 description 14
- 229960000583 acetic acid Drugs 0.000 description 13
- 239000013543 active substance Substances 0.000 description 13
- 229910052938 sodium sulfate Inorganic materials 0.000 description 13
- 235000011152 sodium sulphate Nutrition 0.000 description 13
- KDLHZDBZIXYQEI-UHFFFAOYSA-N Palladium Chemical compound [Pd] KDLHZDBZIXYQEI-UHFFFAOYSA-N 0.000 description 12
- 239000003054 catalyst Substances 0.000 description 12
- 239000000825 pharmaceutical preparation Substances 0.000 description 12
- BASFCYQUMIYNBI-UHFFFAOYSA-N platinum Chemical compound [Pt] BASFCYQUMIYNBI-UHFFFAOYSA-N 0.000 description 12
- YLQBMQCUIZJEEH-UHFFFAOYSA-N tetrahydrofuran Natural products C=1C=COC=1 YLQBMQCUIZJEEH-UHFFFAOYSA-N 0.000 description 12
- KWYUFKZDYYNOTN-UHFFFAOYSA-M Potassium hydroxide Chemical compound [OH-].[K+] KWYUFKZDYYNOTN-UHFFFAOYSA-M 0.000 description 11
- 229910052740 iodine Inorganic materials 0.000 description 11
- 238000010992 reflux Methods 0.000 description 11
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 10
- 229910052500 inorganic mineral Inorganic materials 0.000 description 10
- 235000010755 mineral Nutrition 0.000 description 10
- 239000011707 mineral Substances 0.000 description 10
- 229910052757 nitrogen Inorganic materials 0.000 description 10
- 230000009467 reduction Effects 0.000 description 10
- 238000006722 reduction reaction Methods 0.000 description 10
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 9
- QGZKDVFQNNGYKY-UHFFFAOYSA-N Ammonia Chemical compound N QGZKDVFQNNGYKY-UHFFFAOYSA-N 0.000 description 9
- UHOVQNZJYSORNB-UHFFFAOYSA-N Benzene Chemical compound C1=CC=CC=C1 UHOVQNZJYSORNB-UHFFFAOYSA-N 0.000 description 9
- 229920002472 Starch Polymers 0.000 description 9
- 229910052783 alkali metal Inorganic materials 0.000 description 9
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 description 9
- 150000004678 hydrides Chemical class 0.000 description 9
- 125000002768 hydroxyalkyl group Chemical group 0.000 description 9
- 238000003756 stirring Methods 0.000 description 9
- WKBOTKDWSSQWDR-UHFFFAOYSA-N Bromine atom Chemical compound [Br] WKBOTKDWSSQWDR-UHFFFAOYSA-N 0.000 description 8
- LYCAIKOWRPUZTN-UHFFFAOYSA-N Ethylene glycol Chemical compound OCCO LYCAIKOWRPUZTN-UHFFFAOYSA-N 0.000 description 8
- FYYHWMGAXLPEAU-UHFFFAOYSA-N Magnesium Chemical compound [Mg] FYYHWMGAXLPEAU-UHFFFAOYSA-N 0.000 description 8
- QAOWNCQODCNURD-UHFFFAOYSA-N Sulfuric acid Chemical class OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 description 8
- 125000002252 acyl group Chemical group 0.000 description 8
- 229910052782 aluminium Inorganic materials 0.000 description 8
- 229910052799 carbon Inorganic materials 0.000 description 8
- MTHSVFCYNBDYFN-UHFFFAOYSA-N diethylene glycol Chemical compound OCCOCCO MTHSVFCYNBDYFN-UHFFFAOYSA-N 0.000 description 8
- 239000000284 extract Substances 0.000 description 8
- 150000002431 hydrogen Chemical class 0.000 description 8
- 229910052749 magnesium Inorganic materials 0.000 description 8
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 7
- YXFVVABEGXRONW-UHFFFAOYSA-N Toluene Chemical compound CC1=CC=CC=C1 YXFVVABEGXRONW-UHFFFAOYSA-N 0.000 description 7
- 239000011230 binding agent Substances 0.000 description 7
- 239000011777 magnesium Substances 0.000 description 7
- 239000012074 organic phase Substances 0.000 description 7
- 239000011734 sodium Substances 0.000 description 7
- 229910052708 sodium Inorganic materials 0.000 description 7
- 235000011121 sodium hydroxide Nutrition 0.000 description 7
- 239000000725 suspension Substances 0.000 description 7
- 239000003826 tablet Substances 0.000 description 7
- CPELXLSAUQHCOX-UHFFFAOYSA-M Bromide Chemical compound [Br-] CPELXLSAUQHCOX-UHFFFAOYSA-M 0.000 description 6
- OAKJQQAXSVQMHS-UHFFFAOYSA-N Hydrazine Chemical compound NN OAKJQQAXSVQMHS-UHFFFAOYSA-N 0.000 description 6
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 6
- ZMXDDKWLCZADIW-UHFFFAOYSA-N N,N-Dimethylformamide Chemical compound CN(C)C=O ZMXDDKWLCZADIW-UHFFFAOYSA-N 0.000 description 6
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 6
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical class [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 6
- ZMANZCXQSJIPKH-UHFFFAOYSA-N Triethylamine Chemical compound CCN(CC)CC ZMANZCXQSJIPKH-UHFFFAOYSA-N 0.000 description 6
- 230000009471 action Effects 0.000 description 6
- XAGFODPZIPBFFR-UHFFFAOYSA-N aluminium Chemical compound [Al] XAGFODPZIPBFFR-UHFFFAOYSA-N 0.000 description 6
- GDTBXPJZTBHREO-UHFFFAOYSA-N bromine Substances BrBr GDTBXPJZTBHREO-UHFFFAOYSA-N 0.000 description 6
- 229910052794 bromium Inorganic materials 0.000 description 6
- 238000001816 cooling Methods 0.000 description 6
- 238000001704 evaporation Methods 0.000 description 6
- 229930195733 hydrocarbon Natural products 0.000 description 6
- 150000002430 hydrocarbons Chemical class 0.000 description 6
- 239000012442 inert solvent Substances 0.000 description 6
- 239000000463 material Substances 0.000 description 6
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 6
- 150000003254 radicals Chemical class 0.000 description 6
- 239000012279 sodium borohydride Substances 0.000 description 6
- 229910000033 sodium borohydride Inorganic materials 0.000 description 6
- 239000000126 substance Substances 0.000 description 6
- 125000000472 sulfonyl group Chemical group *S(*)(=O)=O 0.000 description 6
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 5
- VZCYOOQTPOCHFL-OWOJBTEDSA-N Fumaric acid Chemical compound OC(=O)\C=C\C(O)=O VZCYOOQTPOCHFL-OWOJBTEDSA-N 0.000 description 5
- PXHVJJICTQNCMI-UHFFFAOYSA-N Nickel Chemical compound [Ni] PXHVJJICTQNCMI-UHFFFAOYSA-N 0.000 description 5
- HCHKCACWOHOZIP-UHFFFAOYSA-N Zinc Chemical compound [Zn] HCHKCACWOHOZIP-UHFFFAOYSA-N 0.000 description 5
- 150000001298 alcohols Chemical class 0.000 description 5
- 150000008044 alkali metal hydroxides Chemical class 0.000 description 5
- 150000001340 alkali metals Chemical class 0.000 description 5
- 150000001412 amines Chemical class 0.000 description 5
- 125000003277 amino group Chemical group 0.000 description 5
- 125000004429 atom Chemical group 0.000 description 5
- 150000001732 carboxylic acid derivatives Chemical class 0.000 description 5
- 239000003638 chemical reducing agent Substances 0.000 description 5
- 239000003814 drug Substances 0.000 description 5
- 230000008020 evaporation Effects 0.000 description 5
- 239000000706 filtrate Substances 0.000 description 5
- 239000011261 inert gas Substances 0.000 description 5
- 150000002576 ketones Chemical class 0.000 description 5
- 239000007788 liquid Substances 0.000 description 5
- 229910052744 lithium Inorganic materials 0.000 description 5
- 239000012280 lithium aluminium hydride Substances 0.000 description 5
- VNWKTOKETHGBQD-UHFFFAOYSA-N methane Chemical compound C VNWKTOKETHGBQD-UHFFFAOYSA-N 0.000 description 5
- BWHMMNNQKKPAPP-UHFFFAOYSA-L potassium carbonate Substances [K+].[K+].[O-]C([O-])=O BWHMMNNQKKPAPP-UHFFFAOYSA-L 0.000 description 5
- 239000000047 product Substances 0.000 description 5
- 235000019698 starch Nutrition 0.000 description 5
- 239000000454 talc Substances 0.000 description 5
- 235000012222 talc Nutrition 0.000 description 5
- 229910052623 talc Inorganic materials 0.000 description 5
- 230000007306 turnover Effects 0.000 description 5
- 229940100445 wheat starch Drugs 0.000 description 5
- ZCYVEMRRCGMTRW-UHFFFAOYSA-N 7553-56-2 Chemical compound [I] ZCYVEMRRCGMTRW-UHFFFAOYSA-N 0.000 description 4
- HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 description 4
- XEEYBQQBJWHFJM-UHFFFAOYSA-N Iron Chemical compound [Fe] XEEYBQQBJWHFJM-UHFFFAOYSA-N 0.000 description 4
- NBIIXXVUZAFLBC-UHFFFAOYSA-N Phosphoric acid Chemical compound OP(O)(O)=O NBIIXXVUZAFLBC-UHFFFAOYSA-N 0.000 description 4
- 150000001335 aliphatic alkanes Chemical class 0.000 description 4
- 125000001931 aliphatic group Chemical group 0.000 description 4
- 125000004414 alkyl thio group Chemical group 0.000 description 4
- 229910021529 ammonia Inorganic materials 0.000 description 4
- 150000008064 anhydrides Chemical class 0.000 description 4
- 150000001662 cadmium compounds Chemical class 0.000 description 4
- YKYOUMDCQGMQQO-UHFFFAOYSA-L cadmium dichloride Chemical compound Cl[Cd]Cl YKYOUMDCQGMQQO-UHFFFAOYSA-L 0.000 description 4
- 150000001735 carboxylic acids Chemical class 0.000 description 4
- 238000009833 condensation Methods 0.000 description 4
- 230000005494 condensation Effects 0.000 description 4
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 description 4
- 239000008187 granular material Substances 0.000 description 4
- 238000010438 heat treatment Methods 0.000 description 4
- 238000005984 hydrogenation reaction Methods 0.000 description 4
- 230000007062 hydrolysis Effects 0.000 description 4
- 238000006460 hydrolysis reaction Methods 0.000 description 4
- 239000011630 iodine Substances 0.000 description 4
- 238000004519 manufacturing process Methods 0.000 description 4
- 229910052987 metal hydride Inorganic materials 0.000 description 4
- 150000004681 metal hydrides Chemical class 0.000 description 4
- 239000003921 oil Substances 0.000 description 4
- 229910052763 palladium Inorganic materials 0.000 description 4
- XHXFXVLFKHQFAL-UHFFFAOYSA-N phosphoryl trichloride Chemical compound ClP(Cl)(Cl)=O XHXFXVLFKHQFAL-UHFFFAOYSA-N 0.000 description 4
- 229910052697 platinum Inorganic materials 0.000 description 4
- 239000008107 starch Substances 0.000 description 4
- 125000000464 thioxo group Chemical group S=* 0.000 description 4
- JOXIMZWYDAKGHI-UHFFFAOYSA-N toluene-4-sulfonic acid Chemical compound CC1=CC=C(S(O)(=O)=O)C=C1 JOXIMZWYDAKGHI-UHFFFAOYSA-N 0.000 description 4
- VZCYOOQTPOCHFL-UHFFFAOYSA-N trans-butenedioic acid Natural products OC(=O)C=CC(O)=O VZCYOOQTPOCHFL-UHFFFAOYSA-N 0.000 description 4
- 229910052725 zinc Inorganic materials 0.000 description 4
- 239000011701 zinc Substances 0.000 description 4
- RYHBNJHYFVUHQT-UHFFFAOYSA-N 1,4-Dioxane Chemical compound C1COCCO1 RYHBNJHYFVUHQT-UHFFFAOYSA-N 0.000 description 3
- UZFMOKQJFYMBGY-UHFFFAOYSA-N 4-hydroxy-TEMPO Chemical compound CC1(C)CC(O)CC(C)(C)N1[O] UZFMOKQJFYMBGY-UHFFFAOYSA-N 0.000 description 3
- QGZKDVFQNNGYKY-UHFFFAOYSA-O Ammonium Chemical compound [NH4+] QGZKDVFQNNGYKY-UHFFFAOYSA-O 0.000 description 3
- WVDDGKGOMKODPV-UHFFFAOYSA-N Benzyl alcohol Chemical compound OCC1=CC=CC=C1 WVDDGKGOMKODPV-UHFFFAOYSA-N 0.000 description 3
- CURLTUGMZLYLDI-UHFFFAOYSA-N Carbon dioxide Chemical compound O=C=O CURLTUGMZLYLDI-UHFFFAOYSA-N 0.000 description 3
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 3
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 3
- OTMSDBZUPAUEDD-UHFFFAOYSA-N Ethane Chemical compound CC OTMSDBZUPAUEDD-UHFFFAOYSA-N 0.000 description 3
- VGGSQFUCUMXWEO-UHFFFAOYSA-N Ethene Chemical compound C=C VGGSQFUCUMXWEO-UHFFFAOYSA-N 0.000 description 3
- PXGOKWXKJXAPGV-UHFFFAOYSA-N Fluorine Chemical compound FF PXGOKWXKJXAPGV-UHFFFAOYSA-N 0.000 description 3
- WHXSMMKQMYFTQS-UHFFFAOYSA-N Lithium Chemical compound [Li] WHXSMMKQMYFTQS-UHFFFAOYSA-N 0.000 description 3
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 3
- JUJWROOIHBZHMG-UHFFFAOYSA-N Pyridine Chemical compound C1=CC=NC=C1 JUJWROOIHBZHMG-UHFFFAOYSA-N 0.000 description 3
- 241000700159 Rattus Species 0.000 description 3
- 125000002777 acetyl group Chemical group [H]C([H])([H])C(*)=O 0.000 description 3
- 238000005903 acid hydrolysis reaction Methods 0.000 description 3
- 239000003513 alkali Substances 0.000 description 3
- 150000001408 amides Chemical class 0.000 description 3
- 239000001913 cellulose Substances 0.000 description 3
- 229920002678 cellulose Polymers 0.000 description 3
- 239000007795 chemical reaction product Substances 0.000 description 3
- 238000004587 chromatography analysis Methods 0.000 description 3
- ORTQZVOHEJQUHG-UHFFFAOYSA-L copper(II) chloride Chemical compound Cl[Cu]Cl ORTQZVOHEJQUHG-UHFFFAOYSA-L 0.000 description 3
- 238000003379 elimination reaction Methods 0.000 description 3
- 229910052731 fluorine Inorganic materials 0.000 description 3
- 239000011737 fluorine Substances 0.000 description 3
- 125000002485 formyl group Chemical group [H]C(*)=O 0.000 description 3
- 125000005843 halogen group Chemical group 0.000 description 3
- 238000011065 in-situ storage Methods 0.000 description 3
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Substances [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 3
- 125000000956 methoxy group Chemical group [H]C([H])([H])O* 0.000 description 3
- 230000007935 neutral effect Effects 0.000 description 3
- 229910052759 nickel Inorganic materials 0.000 description 3
- 235000019198 oils Nutrition 0.000 description 3
- 230000003287 optical effect Effects 0.000 description 3
- 150000007524 organic acids Chemical class 0.000 description 3
- 125000001477 organic nitrogen group Chemical group 0.000 description 3
- MUMZUERVLWJKNR-UHFFFAOYSA-N oxoplatinum Chemical compound [Pt]=O MUMZUERVLWJKNR-UHFFFAOYSA-N 0.000 description 3
- 125000001820 oxy group Chemical group [*:1]O[*:2] 0.000 description 3
- 230000000737 periodic effect Effects 0.000 description 3
- 125000000843 phenylene group Chemical group C1(=C(C=CC=C1)*)* 0.000 description 3
- 229910052698 phosphorus Inorganic materials 0.000 description 3
- 239000011574 phosphorus Substances 0.000 description 3
- 229910003446 platinum oxide Inorganic materials 0.000 description 3
- 239000002798 polar solvent Substances 0.000 description 3
- 229920001223 polyethylene glycol Polymers 0.000 description 3
- 239000001267 polyvinylpyrrolidone Substances 0.000 description 3
- 229920000036 polyvinylpyrrolidone Polymers 0.000 description 3
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 description 3
- 229910000027 potassium carbonate Inorganic materials 0.000 description 3
- 239000011541 reaction mixture Substances 0.000 description 3
- 238000007363 ring formation reaction Methods 0.000 description 3
- 239000011780 sodium chloride Substances 0.000 description 3
- BEOOHQFXGBMRKU-UHFFFAOYSA-N sodium cyanoborohydride Chemical compound [Na+].[B-]C#N BEOOHQFXGBMRKU-UHFFFAOYSA-N 0.000 description 3
- 239000007787 solid Substances 0.000 description 3
- 239000000600 sorbitol Substances 0.000 description 3
- 239000003381 stabilizer Substances 0.000 description 3
- 125000000475 sulfinyl group Chemical group [*:2]S([*:1])=O 0.000 description 3
- 150000003460 sulfonic acids Chemical class 0.000 description 3
- 239000000829 suppository Substances 0.000 description 3
- ZIBGPFATKBEMQZ-UHFFFAOYSA-N triethylene glycol Chemical compound OCCOCCOCCO ZIBGPFATKBEMQZ-UHFFFAOYSA-N 0.000 description 3
- 229910052720 vanadium Inorganic materials 0.000 description 3
- NNJPGOLRFBJNIW-HNNXBMFYSA-N (-)-demecolcine Chemical compound C1=C(OC)C(=O)C=C2[C@@H](NC)CCC3=CC(OC)=C(OC)C(OC)=C3C2=C1 NNJPGOLRFBJNIW-HNNXBMFYSA-N 0.000 description 2
- TXUICONDJPYNPY-UHFFFAOYSA-N (1,10,13-trimethyl-3-oxo-4,5,6,7,8,9,11,12,14,15,16,17-dodecahydrocyclopenta[a]phenanthren-17-yl) heptanoate Chemical compound C1CC2CC(=O)C=C(C)C2(C)C2C1C1CCC(OC(=O)CCCCCC)C1(C)CC2 TXUICONDJPYNPY-UHFFFAOYSA-N 0.000 description 2
- UWNADWZGEHDQAB-UHFFFAOYSA-N 2,5-dimethylhexane Chemical group CC(C)CCC(C)C UWNADWZGEHDQAB-UHFFFAOYSA-N 0.000 description 2
- NGNBDVOYPDDBFK-UHFFFAOYSA-N 2-[2,4-di(pentan-2-yl)phenoxy]acetyl chloride Chemical compound CCCC(C)C1=CC=C(OCC(Cl)=O)C(C(C)CCC)=C1 NGNBDVOYPDDBFK-UHFFFAOYSA-N 0.000 description 2
- QOXOZONBQWIKDA-UHFFFAOYSA-N 3-hydroxypropyl Chemical group [CH2]CCO QOXOZONBQWIKDA-UHFFFAOYSA-N 0.000 description 2
- NDPOGPAZKKPOPV-UHFFFAOYSA-N 4-(4-ethylphenyl)piperidine Chemical compound C1=CC(CC)=CC=C1C1CCNCC1 NDPOGPAZKKPOPV-UHFFFAOYSA-N 0.000 description 2
- QNGNSVIICDLXHT-UHFFFAOYSA-N 4-Ethylbenzaldehyde Chemical compound CCC1=CC=C(C=O)C=C1 QNGNSVIICDLXHT-UHFFFAOYSA-N 0.000 description 2
- HCFAJYNVAYBARA-UHFFFAOYSA-N 4-heptanone Chemical compound CCCC(=O)CCC HCFAJYNVAYBARA-UHFFFAOYSA-N 0.000 description 2
- XKRFYHLGVUSROY-UHFFFAOYSA-N Argon Chemical compound [Ar] XKRFYHLGVUSROY-UHFFFAOYSA-N 0.000 description 2
- 239000005711 Benzoic acid Substances 0.000 description 2
- WPYMKLBDIGXBTP-UHFFFAOYSA-N Benzoic acid Natural products OC(=O)C1=CC=CC=C1 WPYMKLBDIGXBTP-UHFFFAOYSA-N 0.000 description 2
- 239000004215 Carbon black (E152) Substances 0.000 description 2
- QOSSAOTZNIDXMA-UHFFFAOYSA-N Dicylcohexylcarbodiimide Chemical compound C1CCCCC1N=C=NC1CCCCC1 QOSSAOTZNIDXMA-UHFFFAOYSA-N 0.000 description 2
- RWSOTUBLDIXVET-UHFFFAOYSA-N Dihydrogen sulfide Chemical class S RWSOTUBLDIXVET-UHFFFAOYSA-N 0.000 description 2
- 239000005977 Ethylene Substances 0.000 description 2
- MHAJPDPJQMAIIY-UHFFFAOYSA-N Hydrogen peroxide Chemical compound OO MHAJPDPJQMAIIY-UHFFFAOYSA-N 0.000 description 2
- 241001233242 Lontra Species 0.000 description 2
- 241001465754 Metazoa Species 0.000 description 2
- LRHPLDYGYMQRHN-UHFFFAOYSA-N N-Butanol Chemical compound CCCCO LRHPLDYGYMQRHN-UHFFFAOYSA-N 0.000 description 2
- OAICVXFJPJFONN-UHFFFAOYSA-N Phosphorus Chemical compound [P] OAICVXFJPJFONN-UHFFFAOYSA-N 0.000 description 2
- 239000002202 Polyethylene glycol Substances 0.000 description 2
- 241000036848 Porzana carolina Species 0.000 description 2
- ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 description 2
- WCUXLLCKKVVCTQ-UHFFFAOYSA-M Potassium chloride Chemical compound [Cl-].[K+] WCUXLLCKKVVCTQ-UHFFFAOYSA-M 0.000 description 2
- CDBYLPFSWZWCQE-UHFFFAOYSA-L Sodium Carbonate Chemical compound [Na+].[Na+].[O-]C([O-])=O CDBYLPFSWZWCQE-UHFFFAOYSA-L 0.000 description 2
- UIIMBOGNXHQVGW-UHFFFAOYSA-M Sodium bicarbonate Chemical compound [Na+].OC([O-])=O UIIMBOGNXHQVGW-UHFFFAOYSA-M 0.000 description 2
- 208000007536 Thrombosis Diseases 0.000 description 2
- 229910021626 Tin(II) chloride Inorganic materials 0.000 description 2
- GWEVSGVZZGPLCZ-UHFFFAOYSA-N Titan oxide Chemical compound O=[Ti]=O GWEVSGVZZGPLCZ-UHFFFAOYSA-N 0.000 description 2
- 241000209140 Triticum Species 0.000 description 2
- 235000021307 Triticum Nutrition 0.000 description 2
- 238000006856 Wolf-Kishner-Huang Minlon reduction reaction Methods 0.000 description 2
- 238000010521 absorption reaction Methods 0.000 description 2
- DHKHKXVYLBGOIT-UHFFFAOYSA-N acetaldehyde Diethyl Acetal Natural products CCOC(C)OCC DHKHKXVYLBGOIT-UHFFFAOYSA-N 0.000 description 2
- 150000001241 acetals Chemical class 0.000 description 2
- 230000002378 acidificating effect Effects 0.000 description 2
- 239000004480 active ingredient Substances 0.000 description 2
- 125000003342 alkenyl group Chemical group 0.000 description 2
- SMZOGRDCAXLAAR-UHFFFAOYSA-N aluminium isopropoxide Chemical compound [Al+3].CC(C)[O-].CC(C)[O-].CC(C)[O-] SMZOGRDCAXLAAR-UHFFFAOYSA-N 0.000 description 2
- 229910000147 aluminium phosphate Inorganic materials 0.000 description 2
- VSCWAEJMTAWNJL-UHFFFAOYSA-K aluminium trichloride Chemical compound Cl[Al](Cl)Cl VSCWAEJMTAWNJL-UHFFFAOYSA-K 0.000 description 2
- 230000002785 anti-thrombosis Effects 0.000 description 2
- 239000007864 aqueous solution Substances 0.000 description 2
- YZXBAPSDXZZRGB-DOFZRALJSA-N arachidonic acid Chemical compound CCCCC\C=C/C\C=C/C\C=C/C\C=C/CCCC(O)=O YZXBAPSDXZZRGB-DOFZRALJSA-N 0.000 description 2
- 125000003118 aryl group Chemical group 0.000 description 2
- QVQLCTNNEUAWMS-UHFFFAOYSA-N barium oxide Chemical compound [Ba]=O QVQLCTNNEUAWMS-UHFFFAOYSA-N 0.000 description 2
- 235000010233 benzoic acid Nutrition 0.000 description 2
- PASDCCFISLVPSO-UHFFFAOYSA-N benzoyl chloride Chemical compound ClC(=O)C1=CC=CC=C1 PASDCCFISLVPSO-UHFFFAOYSA-N 0.000 description 2
- KCXMKQUNVWSEMD-UHFFFAOYSA-N benzyl chloride Chemical compound ClCC1=CC=CC=C1 KCXMKQUNVWSEMD-UHFFFAOYSA-N 0.000 description 2
- 229940073608 benzyl chloride Drugs 0.000 description 2
- WTEOIRVLGSZEPR-UHFFFAOYSA-N boron trifluoride Chemical compound FB(F)F WTEOIRVLGSZEPR-UHFFFAOYSA-N 0.000 description 2
- 229940065285 cadmium compound Drugs 0.000 description 2
- 239000001506 calcium phosphate Substances 0.000 description 2
- 230000003197 catalytic effect Effects 0.000 description 2
- 235000013339 cereals Nutrition 0.000 description 2
- 125000001309 chloro group Chemical group Cl* 0.000 description 2
- 238000000576 coating method Methods 0.000 description 2
- 229940075614 colloidal silicon dioxide Drugs 0.000 description 2
- 239000012230 colorless oil Substances 0.000 description 2
- 238000002425 crystallisation Methods 0.000 description 2
- USIUVYZYUHIAEV-UHFFFAOYSA-N diphenyl ether Chemical compound C=1C=CC=CC=1OC1=CC=CC=C1 USIUVYZYUHIAEV-UHFFFAOYSA-N 0.000 description 2
- 238000004821 distillation Methods 0.000 description 2
- 229940079593 drug Drugs 0.000 description 2
- 230000008030 elimination Effects 0.000 description 2
- 125000001301 ethoxy group Chemical group [H]C([H])([H])C([H])([H])O* 0.000 description 2
- 239000010685 fatty oil Substances 0.000 description 2
- 239000007789 gas Substances 0.000 description 2
- 239000007903 gelatin capsule Substances 0.000 description 2
- 239000012362 glacial acetic acid Substances 0.000 description 2
- 150000002366 halogen compounds Chemical class 0.000 description 2
- 150000002429 hydrazines Chemical class 0.000 description 2
- 125000005597 hydrazone group Chemical group 0.000 description 2
- 150000007857 hydrazones Chemical class 0.000 description 2
- 150000003840 hydrochlorides Chemical class 0.000 description 2
- 208000027866 inflammatory disease Diseases 0.000 description 2
- 230000005764 inhibitory process Effects 0.000 description 2
- 150000002500 ions Chemical class 0.000 description 2
- 229910052742 iron Inorganic materials 0.000 description 2
- 239000008101 lactose Substances 0.000 description 2
- 239000000314 lubricant Substances 0.000 description 2
- 235000019359 magnesium stearate Nutrition 0.000 description 2
- 239000000155 melt Substances 0.000 description 2
- 125000000449 nitro group Chemical group [O-][N+](*)=O 0.000 description 2
- 125000004433 nitrogen atom Chemical group N* 0.000 description 2
- 150000002905 orthoesters Chemical class 0.000 description 2
- 230000003647 oxidation Effects 0.000 description 2
- 238000007254 oxidation reaction Methods 0.000 description 2
- 230000001590 oxidative effect Effects 0.000 description 2
- 239000012188 paraffin wax Substances 0.000 description 2
- 238000007911 parenteral administration Methods 0.000 description 2
- 230000000144 pharmacologic effect Effects 0.000 description 2
- 239000012071 phase Substances 0.000 description 2
- 125000003356 phenylsulfanyl group Chemical group [*]SC1=C([H])C([H])=C([H])C([H])=C1[H] 0.000 description 2
- XUWHAWMETYGRKB-UHFFFAOYSA-N piperidin-2-one Chemical group O=C1CCCCN1 XUWHAWMETYGRKB-UHFFFAOYSA-N 0.000 description 2
- 239000004033 plastic Substances 0.000 description 2
- 229920003023 plastic Polymers 0.000 description 2
- 125000001453 quaternary ammonium group Chemical group 0.000 description 2
- JPJALAQPGMAKDF-UHFFFAOYSA-N selenium dioxide Chemical compound O=[Se]=O JPJALAQPGMAKDF-UHFFFAOYSA-N 0.000 description 2
- 235000012239 silicon dioxide Nutrition 0.000 description 2
- QDRKDTQENPPHOJ-UHFFFAOYSA-N sodium ethoxide Chemical compound [Na+].CC[O-] QDRKDTQENPPHOJ-UHFFFAOYSA-N 0.000 description 2
- 239000001119 stannous chloride Substances 0.000 description 2
- 235000011150 stannous chloride Nutrition 0.000 description 2
- BDHFUVZGWQCTTF-UHFFFAOYSA-N sulfonic acid Chemical compound OS(=O)=O BDHFUVZGWQCTTF-UHFFFAOYSA-N 0.000 description 2
- 125000004963 sulfonylalkyl group Chemical group 0.000 description 2
- 150000003462 sulfoxides Chemical class 0.000 description 2
- 125000003396 thiol group Chemical group [H]S* 0.000 description 2
- FYSNRJHAOHDILO-UHFFFAOYSA-N thionyl chloride Chemical compound ClS(Cl)=O FYSNRJHAOHDILO-UHFFFAOYSA-N 0.000 description 2
- 230000000699 topical effect Effects 0.000 description 2
- 150000003626 triacylglycerols Chemical class 0.000 description 2
- QORWJWZARLRLPR-UHFFFAOYSA-H tricalcium bis(phosphate) Chemical class [Ca+2].[Ca+2].[Ca+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O QORWJWZARLRLPR-UHFFFAOYSA-H 0.000 description 2
- 125000002023 trifluoromethyl group Chemical group FC(F)(F)* 0.000 description 2
- 239000002023 wood Substances 0.000 description 2
- JIAARYAFYJHUJI-UHFFFAOYSA-L zinc dichloride Chemical compound [Cl-].[Cl-].[Zn+2] JIAARYAFYJHUJI-UHFFFAOYSA-L 0.000 description 2
- OGNVQLDIPUXYDH-ZPKKHLQPSA-N (2R,3R,4S)-3-(2-methylpropanoylamino)-4-(4-phenyltriazol-1-yl)-2-[(1R,2R)-1,2,3-trihydroxypropyl]-3,4-dihydro-2H-pyran-6-carboxylic acid Chemical class CC(C)C(=O)N[C@H]1[C@H]([C@H](O)[C@H](O)CO)OC(C(O)=O)=C[C@@H]1N1N=NC(C=2C=CC=CC=2)=C1 OGNVQLDIPUXYDH-ZPKKHLQPSA-N 0.000 description 1
- CSIMNOITWORGRO-UHFFFAOYSA-N (3,4-dichlorophenyl)-[4-(4-ethylphenyl)piperidin-1-yl]methanone Chemical compound C1=CC(CC)=CC=C1C1CCN(C(=O)C=2C=C(Cl)C(Cl)=CC=2)CC1 CSIMNOITWORGRO-UHFFFAOYSA-N 0.000 description 1
- SVTBMSDMJJWYQN-RXMQYKEDSA-N (4r)-2-methylpentane-2,4-diol Chemical compound C[C@@H](O)CC(C)(C)O SVTBMSDMJJWYQN-RXMQYKEDSA-N 0.000 description 1
- AIPJZPPOFWCJRC-UHFFFAOYSA-N 1,2-dichloro-3-(chloromethyl)benzene Chemical compound ClCC1=CC=CC(Cl)=C1Cl AIPJZPPOFWCJRC-UHFFFAOYSA-N 0.000 description 1
- GVGVUNDFQUSHDM-UHFFFAOYSA-N 1-benzyl-2h-pyridine Chemical group C=1C=CC=CC=1CN1CC=CC=C1 GVGVUNDFQUSHDM-UHFFFAOYSA-N 0.000 description 1
- YSFLQVNTBBUKEA-UHFFFAOYSA-N 1-bromo-2,4-dimethylbenzene Chemical group CC1=CC=C(Br)C(C)=C1 YSFLQVNTBBUKEA-UHFFFAOYSA-N 0.000 description 1
- BASMANVIUSSIIM-UHFFFAOYSA-N 1-chloro-2-(chloromethyl)benzene Chemical compound ClCC1=CC=CC=C1Cl BASMANVIUSSIIM-UHFFFAOYSA-N 0.000 description 1
- DDGRAFHHXYIQQR-UHFFFAOYSA-N 1-chloro-3-(chloromethyl)benzene Chemical compound ClCC1=CC=CC(Cl)=C1 DDGRAFHHXYIQQR-UHFFFAOYSA-N 0.000 description 1
- 125000004066 1-hydroxyethyl group Chemical group [H]OC([H])([*])C([H])([H])[H] 0.000 description 1
- LLSKXGRDUPMXLC-UHFFFAOYSA-N 1-phenylpiperidine Chemical class C1CCCCN1C1=CC=CC=C1 LLSKXGRDUPMXLC-UHFFFAOYSA-N 0.000 description 1
- 125000000530 1-propynyl group Chemical group [H]C([H])([H])C#C* 0.000 description 1
- 125000000954 2-hydroxyethyl group Chemical group [H]C([*])([H])C([H])([H])O[H] 0.000 description 1
- FBOPSFFWGHLLTB-UHFFFAOYSA-N 2-methoxy-1,3,2-dioxaphospholane Chemical compound COP1OCCO1 FBOPSFFWGHLLTB-UHFFFAOYSA-N 0.000 description 1
- JYVLIDXNZAXMDK-UHFFFAOYSA-N 2-pentanol Substances CCCC(C)O JYVLIDXNZAXMDK-UHFFFAOYSA-N 0.000 description 1
- 125000003903 2-propenyl group Chemical group [H]C([*])([H])C([H])=C([H])[H] 0.000 description 1
- VTXNOVCTHUBABW-UHFFFAOYSA-N 3,4-dichlorobenzoyl chloride Chemical compound ClC(=O)C1=CC=C(Cl)C(Cl)=C1 VTXNOVCTHUBABW-UHFFFAOYSA-N 0.000 description 1
- ROLMZTIHUMKEAI-UHFFFAOYSA-N 4,5-difluoro-2-hydroxybenzonitrile Chemical compound OC1=CC(F)=C(F)C=C1C#N ROLMZTIHUMKEAI-UHFFFAOYSA-N 0.000 description 1
- WTAVYOSGASBTEM-UHFFFAOYSA-N 4-(3-ethylphenyl)piperidine Chemical compound CCC1=CC=CC(C2CCNCC2)=C1 WTAVYOSGASBTEM-UHFFFAOYSA-N 0.000 description 1
- CSDQQAQKBAQLLE-UHFFFAOYSA-N 4-(4-chlorophenyl)-4,5,6,7-tetrahydrothieno[3,2-c]pyridine Chemical compound C1=CC(Cl)=CC=C1C1C(C=CS2)=C2CCN1 CSDQQAQKBAQLLE-UHFFFAOYSA-N 0.000 description 1
- SXIFAEWFOJETOA-UHFFFAOYSA-N 4-hydroxy-butyl Chemical group [CH2]CCCO SXIFAEWFOJETOA-UHFFFAOYSA-N 0.000 description 1
- 244000215068 Acacia senegal Species 0.000 description 1
- 229920001817 Agar Polymers 0.000 description 1
- NLXLAEXVIDQMFP-UHFFFAOYSA-N Ammonia chloride Chemical class [NH4+].[Cl-] NLXLAEXVIDQMFP-UHFFFAOYSA-N 0.000 description 1
- BOJKULTULYSRAS-OTESTREVSA-N Andrographolide Chemical compound C([C@H]1[C@]2(C)CC[C@@H](O)[C@]([C@H]2CCC1=C)(CO)C)\C=C1/[C@H](O)COC1=O BOJKULTULYSRAS-OTESTREVSA-N 0.000 description 1
- 241000272517 Anseriformes Species 0.000 description 1
- 229910015900 BF3 Inorganic materials 0.000 description 1
- ZOXJGFHDIHLPTG-UHFFFAOYSA-N Boron Chemical compound [B] ZOXJGFHDIHLPTG-UHFFFAOYSA-N 0.000 description 1
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 1
- QPLDLSVMHZLSFG-UHFFFAOYSA-N Copper oxide Chemical compound [Cu]=O QPLDLSVMHZLSFG-UHFFFAOYSA-N 0.000 description 1
- 239000005751 Copper oxide Substances 0.000 description 1
- 229920002307 Dextran Polymers 0.000 description 1
- 101100260565 Dictyostelium discoideum thyA gene Proteins 0.000 description 1
- 241000896693 Disa Species 0.000 description 1
- 101100536354 Drosophila melanogaster tant gene Proteins 0.000 description 1
- LVGKNOAMLMIIKO-UHFFFAOYSA-N Elaidinsaeure-aethylester Natural products CCCCCCCCC=CCCCCCCCC(=O)OCC LVGKNOAMLMIIKO-UHFFFAOYSA-N 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- KRHYYFGTRYWZRS-UHFFFAOYSA-M Fluoride anion Chemical compound [F-] KRHYYFGTRYWZRS-UHFFFAOYSA-M 0.000 description 1
- 241000276484 Gadus ogac Species 0.000 description 1
- 229920000084 Gum arabic Polymers 0.000 description 1
- 241000243251 Hydra Species 0.000 description 1
- CPELXLSAUQHCOX-UHFFFAOYSA-N Hydrogen bromide Chemical class Br CPELXLSAUQHCOX-UHFFFAOYSA-N 0.000 description 1
- AVXURJPOCDRRFD-UHFFFAOYSA-N Hydroxylamine Chemical compound ON AVXURJPOCDRRFD-UHFFFAOYSA-N 0.000 description 1
- 241000407429 Maja Species 0.000 description 1
- 241000699670 Mus sp. Species 0.000 description 1
- 102100026933 Myelin-associated neurite-outgrowth inhibitor Human genes 0.000 description 1
- SECXISVLQFMRJM-UHFFFAOYSA-N N-Methylpyrrolidone Chemical compound CN1CCCC1=O SECXISVLQFMRJM-UHFFFAOYSA-N 0.000 description 1
- 241001670273 Ooia Species 0.000 description 1
- 240000007594 Oryza sativa Species 0.000 description 1
- 235000007164 Oryza sativa Nutrition 0.000 description 1
- 229910019142 PO4 Inorganic materials 0.000 description 1
- 235000008753 Papaver somniferum Nutrition 0.000 description 1
- 239000005662 Paraffin oil Substances 0.000 description 1
- 239000004698 Polyethylene Substances 0.000 description 1
- 241000212342 Sium Species 0.000 description 1
- KEAYESYHFKHZAL-UHFFFAOYSA-N Sodium Chemical compound [Na] KEAYESYHFKHZAL-UHFFFAOYSA-N 0.000 description 1
- 235000021355 Stearic acid Nutrition 0.000 description 1
- QAOWNCQODCNURD-UHFFFAOYSA-L Sulfate Chemical compound [O-]S([O-])(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-L 0.000 description 1
- NINIDFKCEFEMDL-UHFFFAOYSA-N Sulfur Chemical compound [S] NINIDFKCEFEMDL-UHFFFAOYSA-N 0.000 description 1
- 239000005864 Sulphur Substances 0.000 description 1
- 244000269722 Thea sinensis Species 0.000 description 1
- 241001061127 Thione Species 0.000 description 1
- 241000776233 Tisis Species 0.000 description 1
- 240000008042 Zea mays Species 0.000 description 1
- 235000005824 Zea mays ssp. parviglumis Nutrition 0.000 description 1
- 235000002017 Zea mays subsp mays Nutrition 0.000 description 1
- IRFZJPGNMMFURY-UHFFFAOYSA-M [Br-].COC[Mg+] Chemical compound [Br-].COC[Mg+] IRFZJPGNMMFURY-UHFFFAOYSA-M 0.000 description 1
- GJEAMHAFPYZYDE-UHFFFAOYSA-N [C].[S] Chemical compound [C].[S] GJEAMHAFPYZYDE-UHFFFAOYSA-N 0.000 description 1
- 239000000205 acacia gum Substances 0.000 description 1
- 235000010489 acacia gum Nutrition 0.000 description 1
- 150000001242 acetic acid derivatives Chemical class 0.000 description 1
- DPXJVFZANSGRMM-UHFFFAOYSA-N acetic acid;2,3,4,5,6-pentahydroxyhexanal;sodium Chemical compound [Na].CC(O)=O.OCC(O)C(O)C(O)C(O)C=O DPXJVFZANSGRMM-UHFFFAOYSA-N 0.000 description 1
- VGZSUPCWNCWDAN-UHFFFAOYSA-N acetohexamide Chemical compound C1=CC(C(=O)C)=CC=C1S(=O)(=O)NC(=O)NC1CCCCC1 VGZSUPCWNCWDAN-UHFFFAOYSA-N 0.000 description 1
- 238000006640 acetylation reaction Methods 0.000 description 1
- 238000007171 acid catalysis Methods 0.000 description 1
- 125000004423 acyloxy group Chemical group 0.000 description 1
- 239000008272 agar Substances 0.000 description 1
- 239000000783 alginic acid Substances 0.000 description 1
- 235000010443 alginic acid Nutrition 0.000 description 1
- 229920000615 alginic acid Polymers 0.000 description 1
- 229960001126 alginic acid Drugs 0.000 description 1
- 150000004781 alginic acids Chemical class 0.000 description 1
- 150000001336 alkenes Chemical class 0.000 description 1
- 125000003282 alkyl amino group Chemical group 0.000 description 1
- 125000005907 alkyl ester group Chemical group 0.000 description 1
- 150000005215 alkyl ethers Chemical class 0.000 description 1
- 150000004791 alkyl magnesium halides Chemical class 0.000 description 1
- 125000005037 alkyl phenyl group Chemical group 0.000 description 1
- 230000029936 alkylation Effects 0.000 description 1
- 238000005804 alkylation reaction Methods 0.000 description 1
- 125000005530 alkylenedioxy group Chemical group 0.000 description 1
- 125000000304 alkynyl group Chemical group 0.000 description 1
- HSFWRNGVRCDJHI-UHFFFAOYSA-N alpha-acetylene Natural products C#C HSFWRNGVRCDJHI-UHFFFAOYSA-N 0.000 description 1
- 239000004411 aluminium Substances 0.000 description 1
- 230000003110 anti-inflammatory effect Effects 0.000 description 1
- 229910052787 antimony Inorganic materials 0.000 description 1
- WATWJIUSRGPENY-UHFFFAOYSA-N antimony atom Chemical compound [Sb] WATWJIUSRGPENY-UHFFFAOYSA-N 0.000 description 1
- 229960004676 antithrombotic agent Drugs 0.000 description 1
- 239000008346 aqueous phase Substances 0.000 description 1
- 239000007900 aqueous suspension Substances 0.000 description 1
- 229940114079 arachidonic acid Drugs 0.000 description 1
- 235000021342 arachidonic acid Nutrition 0.000 description 1
- 229910052786 argon Inorganic materials 0.000 description 1
- 206010003246 arthritis Diseases 0.000 description 1
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 1
- 239000010953 base metal Substances 0.000 description 1
- 235000015278 beef Nutrition 0.000 description 1
- WPUJEWVVTKLMQI-UHFFFAOYSA-N benzene;ethoxyethane Chemical compound CCOCC.C1=CC=CC=C1 WPUJEWVVTKLMQI-UHFFFAOYSA-N 0.000 description 1
- VEFXTGTZJOWDOF-UHFFFAOYSA-N benzene;hydrate Chemical compound O.C1=CC=CC=C1 VEFXTGTZJOWDOF-UHFFFAOYSA-N 0.000 description 1
- SRSXLGNVWSONIS-UHFFFAOYSA-N benzenesulfonic acid Chemical class OS(=O)(=O)C1=CC=CC=C1 SRSXLGNVWSONIS-UHFFFAOYSA-N 0.000 description 1
- 125000005605 benzo group Chemical group 0.000 description 1
- 150000001558 benzoic acid derivatives Chemical class 0.000 description 1
- 125000003236 benzoyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C(*)=O 0.000 description 1
- 235000019445 benzyl alcohol Nutrition 0.000 description 1
- FKPSBYZGRQJIMO-UHFFFAOYSA-M benzyl(triethyl)azanium;hydroxide Chemical compound [OH-].CC[N+](CC)(CC)CC1=CC=CC=C1 FKPSBYZGRQJIMO-UHFFFAOYSA-M 0.000 description 1
- AWHNUHMUCGRKRA-UHFFFAOYSA-N benzylsulfonylmethylbenzene Chemical compound C=1C=CC=CC=1CS(=O)(=O)CC1=CC=CC=C1 AWHNUHMUCGRKRA-UHFFFAOYSA-N 0.000 description 1
- 235000021028 berry Nutrition 0.000 description 1
- 230000033228 biological regulation Effects 0.000 description 1
- 229910052796 boron Inorganic materials 0.000 description 1
- 229910010277 boron hydride Inorganic materials 0.000 description 1
- 239000012267 brine Substances 0.000 description 1
- 150000001649 bromium compounds Chemical class 0.000 description 1
- 125000001246 bromo group Chemical group Br* 0.000 description 1
- RDHPKYGYEGBMSE-UHFFFAOYSA-N bromoethane Chemical compound CCBr RDHPKYGYEGBMSE-UHFFFAOYSA-N 0.000 description 1
- 125000004063 butyryl group Chemical group O=C([*])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- 239000011575 calcium Substances 0.000 description 1
- 229910052791 calcium Inorganic materials 0.000 description 1
- AXCZMVOFGPJBDE-UHFFFAOYSA-L calcium dihydroxide Chemical compound [OH-].[OH-].[Ca+2] AXCZMVOFGPJBDE-UHFFFAOYSA-L 0.000 description 1
- 239000000920 calcium hydroxide Substances 0.000 description 1
- 229910001861 calcium hydroxide Inorganic materials 0.000 description 1
- 235000011010 calcium phosphates Nutrition 0.000 description 1
- CJZGTCYPCWQAJB-UHFFFAOYSA-L calcium stearate Chemical compound [Ca+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O CJZGTCYPCWQAJB-UHFFFAOYSA-L 0.000 description 1
- 235000013539 calcium stearate Nutrition 0.000 description 1
- 239000008116 calcium stearate Substances 0.000 description 1
- 239000002775 capsule Substances 0.000 description 1
- 125000003917 carbamoyl group Chemical group [H]N([H])C(*)=O 0.000 description 1
- 239000001569 carbon dioxide Substances 0.000 description 1
- 229910002092 carbon dioxide Inorganic materials 0.000 description 1
- QGJOPFRUJISHPQ-NJFSPNSNSA-N carbon disulfide-14c Chemical compound S=[14C]=S QGJOPFRUJISHPQ-NJFSPNSNSA-N 0.000 description 1
- 229950005499 carbon tetrachloride Drugs 0.000 description 1
- 150000004649 carbonic acid derivatives Chemical class 0.000 description 1
- 125000005588 carbonic acid salt group Chemical group 0.000 description 1
- 125000002915 carbonyl group Chemical group [*:2]C([*:1])=O 0.000 description 1
- 239000001768 carboxy methyl cellulose Substances 0.000 description 1
- 125000004181 carboxyalkyl group Chemical group 0.000 description 1
- 150000007942 carboxylates Chemical class 0.000 description 1
- 230000021523 carboxylation Effects 0.000 description 1
- 238000006473 carboxylation reaction Methods 0.000 description 1
- 239000000969 carrier Substances 0.000 description 1
- 238000009903 catalytic hydrogenation reaction Methods 0.000 description 1
- 238000006555 catalytic reaction Methods 0.000 description 1
- 238000012512 characterization method Methods 0.000 description 1
- 235000013351 cheese Nutrition 0.000 description 1
- 150000001805 chlorine compounds Chemical class 0.000 description 1
- 125000004773 chlorofluoromethyl group Chemical group [H]C(F)(Cl)* 0.000 description 1
- 238000003776 cleavage reaction Methods 0.000 description 1
- 239000003245 coal Substances 0.000 description 1
- 239000011248 coating agent Substances 0.000 description 1
- 239000000470 constituent Substances 0.000 description 1
- 150000001879 copper Chemical class 0.000 description 1
- 229910000431 copper oxide Inorganic materials 0.000 description 1
- 235000005822 corn Nutrition 0.000 description 1
- 239000006071 cream Substances 0.000 description 1
- 230000008025 crystallization Effects 0.000 description 1
- 238000006114 decarboxylation reaction Methods 0.000 description 1
- NQNFKQOIDNMNBB-UHFFFAOYSA-L dichloroplatinum;triphenylphosphane Chemical compound Cl[Pt]Cl.C1=CC=CC=C1P(C=1C=CC=CC=1)C1=CC=CC=C1 NQNFKQOIDNMNBB-UHFFFAOYSA-L 0.000 description 1
- 150000005690 diesters Chemical class 0.000 description 1
- 235000014113 dietary fatty acids Nutrition 0.000 description 1
- 125000004177 diethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 description 1
- CCAFPWNGIUBUSD-UHFFFAOYSA-N diethyl sulfoxide Chemical compound CCS(=O)CC CCAFPWNGIUBUSD-UHFFFAOYSA-N 0.000 description 1
- 239000003085 diluting agent Substances 0.000 description 1
- YWEUIGNSBFLMFL-UHFFFAOYSA-N diphosphonate Chemical compound O=P(=O)OP(=O)=O YWEUIGNSBFLMFL-UHFFFAOYSA-N 0.000 description 1
- LXQXGFPPYLKKSD-UHFFFAOYSA-L disodium;2,2-diethylpropanedioate Chemical compound [Na+].[Na+].CCC(CC)(C([O-])=O)C([O-])=O LXQXGFPPYLKKSD-UHFFFAOYSA-L 0.000 description 1
- 238000007323 disproportionation reaction Methods 0.000 description 1
- 239000002552 dosage form Substances 0.000 description 1
- 238000001035 drying Methods 0.000 description 1
- 239000000975 dye Substances 0.000 description 1
- 230000000694 effects Effects 0.000 description 1
- 239000003480 eluent Substances 0.000 description 1
- 239000000839 emulsion Substances 0.000 description 1
- 230000032050 esterification Effects 0.000 description 1
- 238000005886 esterification reaction Methods 0.000 description 1
- PSLIMVZEAPALCD-UHFFFAOYSA-N ethanol;ethoxyethane Chemical compound CCO.CCOCC PSLIMVZEAPALCD-UHFFFAOYSA-N 0.000 description 1
- 239000012259 ether extract Substances 0.000 description 1
- 150000002170 ethers Chemical class 0.000 description 1
- 229940052303 ethers for general anesthesia Drugs 0.000 description 1
- MHZFMMSRIDAQIB-UHFFFAOYSA-N ethyl 3-(4-chlorophenyl)prop-2-enoate Chemical compound CCOC(=O)C=CC1=CC=C(Cl)C=C1 MHZFMMSRIDAQIB-UHFFFAOYSA-N 0.000 description 1
- 235000019439 ethyl acetate Nutrition 0.000 description 1
- LVGKNOAMLMIIKO-QXMHVHEDSA-N ethyl oleate Chemical compound CCCCCCCC\C=C/CCCCCCCC(=O)OCC LVGKNOAMLMIIKO-QXMHVHEDSA-N 0.000 description 1
- 229940093471 ethyl oleate Drugs 0.000 description 1
- BLHLJVCOVBYQQS-UHFFFAOYSA-N ethyllithium Chemical compound [Li]CC BLHLJVCOVBYQQS-UHFFFAOYSA-N 0.000 description 1
- 125000004705 ethylthio group Chemical group C(C)S* 0.000 description 1
- 125000002534 ethynyl group Chemical group [H]C#C* 0.000 description 1
- 230000007717 exclusion Effects 0.000 description 1
- 239000000194 fatty acid Substances 0.000 description 1
- 229930195729 fatty acid Natural products 0.000 description 1
- 239000012467 final product Substances 0.000 description 1
- 235000013305 food Nutrition 0.000 description 1
- 235000010855 food raising agent Nutrition 0.000 description 1
- ULITUPMHIDVLLV-UHFFFAOYSA-N formonitrile;sodium Chemical compound [Na].N#C ULITUPMHIDVLLV-UHFFFAOYSA-N 0.000 description 1
- FATAVLOOLIRUNA-UHFFFAOYSA-N formylmethyl Chemical group [CH2]C=O FATAVLOOLIRUNA-UHFFFAOYSA-N 0.000 description 1
- 238000001640 fractional crystallisation Methods 0.000 description 1
- 235000011389 fruit/vegetable juice Nutrition 0.000 description 1
- VZCYOOQTPOCHFL-OWOJBTEDSA-L fumarate(2-) Chemical class [O-]C(=O)\C=C\C([O-])=O VZCYOOQTPOCHFL-OWOJBTEDSA-L 0.000 description 1
- 239000001530 fumaric acid Substances 0.000 description 1
- 210000004051 gastric juice Anatomy 0.000 description 1
- 239000000499 gel Substances 0.000 description 1
- 150000002334 glycols Chemical class 0.000 description 1
- 229940093915 gynecological organic acid Drugs 0.000 description 1
- 125000004997 halocarbonyl group Chemical group 0.000 description 1
- 229940028332 halog Drugs 0.000 description 1
- 230000002140 halogenating effect Effects 0.000 description 1
- GNOIPBMMFNIUFM-UHFFFAOYSA-N hexamethylphosphoric triamide Chemical compound CN(C)P(=O)(N(C)C)N(C)C GNOIPBMMFNIUFM-UHFFFAOYSA-N 0.000 description 1
- 150000004677 hydrates Chemical class 0.000 description 1
- BHEPBYXIRTUNPN-UHFFFAOYSA-N hydridophosphorus(.) (triplet) Chemical compound [PH] BHEPBYXIRTUNPN-UHFFFAOYSA-N 0.000 description 1
- IXCSERBJSXMMFS-UHFFFAOYSA-N hydrogen chloride Substances Cl.Cl IXCSERBJSXMMFS-UHFFFAOYSA-N 0.000 description 1
- 229910000041 hydrogen chloride Inorganic materials 0.000 description 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-M hydroxide Chemical compound [OH-] XLYOFNOQVPJJNP-UHFFFAOYSA-M 0.000 description 1
- 150000002440 hydroxy compounds Chemical class 0.000 description 1
- 125000004029 hydroxymethyl group Chemical group [H]OC([H])([H])* 0.000 description 1
- 125000001841 imino group Chemical group [H]N=* 0.000 description 1
- 238000000338 in vitro Methods 0.000 description 1
- 230000006698 induction Effects 0.000 description 1
- 230000002757 inflammatory effect Effects 0.000 description 1
- 229910001867 inorganic solvent Inorganic materials 0.000 description 1
- 239000003049 inorganic solvent Substances 0.000 description 1
- 125000002346 iodo group Chemical group I* 0.000 description 1
- HVTICUPFWKNHNG-UHFFFAOYSA-N iodoethane Chemical compound CCI HVTICUPFWKNHNG-UHFFFAOYSA-N 0.000 description 1
- QRXWMOHMRWLFEY-UHFFFAOYSA-N isoniazide Chemical compound NNC(=O)C1=CC=NC=C1 QRXWMOHMRWLFEY-UHFFFAOYSA-N 0.000 description 1
- 125000001449 isopropyl group Chemical group [H]C([H])([H])C([H])(*)C([H])([H])[H] 0.000 description 1
- 239000007791 liquid phase Substances 0.000 description 1
- 239000006193 liquid solution Substances 0.000 description 1
- 239000006210 lotion Substances 0.000 description 1
- 238000012792 lyophilization process Methods 0.000 description 1
- 239000000395 magnesium oxide Substances 0.000 description 1
- CPLXHLVBOLITMK-UHFFFAOYSA-N magnesium oxide Inorganic materials [Mg]=O CPLXHLVBOLITMK-UHFFFAOYSA-N 0.000 description 1
- NXPHGHWWQRMDIA-UHFFFAOYSA-M magnesium;carbanide;bromide Chemical compound [CH3-].[Mg+2].[Br-] NXPHGHWWQRMDIA-UHFFFAOYSA-M 0.000 description 1
- FRIJBUGBVQZNTB-UHFFFAOYSA-M magnesium;ethane;bromide Chemical compound [Mg+2].[Br-].[CH2-]C FRIJBUGBVQZNTB-UHFFFAOYSA-M 0.000 description 1
- AXZKOIWUVFPNLO-UHFFFAOYSA-N magnesium;oxygen(2-) Chemical compound [O-2].[Mg+2] AXZKOIWUVFPNLO-UHFFFAOYSA-N 0.000 description 1
- 150000002736 metal compounds Chemical class 0.000 description 1
- 229910000000 metal hydroxide Inorganic materials 0.000 description 1
- 150000004692 metal hydroxides Chemical class 0.000 description 1
- AFVFQIVMOAPDHO-UHFFFAOYSA-M methanesulfonate group Chemical class CS(=O)(=O)[O-] AFVFQIVMOAPDHO-UHFFFAOYSA-M 0.000 description 1
- NBTOZLQBSIZIKS-UHFFFAOYSA-N methoxide Chemical compound [O-]C NBTOZLQBSIZIKS-UHFFFAOYSA-N 0.000 description 1
- 150000007522 mineralic acids Chemical class 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- APVPOHHVBBYQAV-UHFFFAOYSA-N n-(4-aminophenyl)sulfonyloctadecanamide Chemical compound CCCCCCCCCCCCCCCCCC(=O)NS(=O)(=O)C1=CC=C(N)C=C1 APVPOHHVBBYQAV-UHFFFAOYSA-N 0.000 description 1
- 125000004708 n-butylthio group Chemical group C(CCC)S* 0.000 description 1
- 125000003136 n-heptyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
- 125000001280 n-hexyl group Chemical group C(CCCCC)* 0.000 description 1
- 125000000740 n-pentyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
- 210000005036 nerve Anatomy 0.000 description 1
- NCYVXEGFNDZQCU-UHFFFAOYSA-N nikethamide Chemical compound CCN(CC)C(=O)C1=CC=CN=C1 NCYVXEGFNDZQCU-UHFFFAOYSA-N 0.000 description 1
- 150000002825 nitriles Chemical class 0.000 description 1
- 235000012149 noodles Nutrition 0.000 description 1
- QIQXTHQIDYTFRH-UHFFFAOYSA-N octadecanoic acid Chemical compound CCCCCCCCCCCCCCCCCC(O)=O QIQXTHQIDYTFRH-UHFFFAOYSA-N 0.000 description 1
- OQCDKBAXFALNLD-UHFFFAOYSA-N octadecanoic acid Natural products CCCCCCCC(C)CCCCCCCCC(O)=O OQCDKBAXFALNLD-UHFFFAOYSA-N 0.000 description 1
- 239000002674 ointment Substances 0.000 description 1
- 229940051803 opioid analgesics phenylpiperidine derivative Drugs 0.000 description 1
- 235000005985 organic acids Nutrition 0.000 description 1
- 150000007530 organic bases Chemical class 0.000 description 1
- 150000002894 organic compounds Chemical class 0.000 description 1
- 125000000962 organic group Chemical group 0.000 description 1
- 150000004967 organic peroxy acids Chemical class 0.000 description 1
- 239000003960 organic solvent Substances 0.000 description 1
- 125000005188 oxoalkyl group Chemical group 0.000 description 1
- 229910052760 oxygen Inorganic materials 0.000 description 1
- 239000001301 oxygen Substances 0.000 description 1
- 239000000546 pharmaceutical excipient Substances 0.000 description 1
- DLRJIFUOBPOJNS-UHFFFAOYSA-N phenetole Chemical compound CCOC1=CC=CC=C1 DLRJIFUOBPOJNS-UHFFFAOYSA-N 0.000 description 1
- ISWSIDIOOBJBQZ-UHFFFAOYSA-N phenol group Chemical group C1(=CC=CC=C1)O ISWSIDIOOBJBQZ-UHFFFAOYSA-N 0.000 description 1
- 150000002989 phenols Chemical class 0.000 description 1
- 125000000951 phenoxy group Chemical group [H]C1=C([H])C([H])=C(O*)C([H])=C1[H] 0.000 description 1
- CILDJVVXNMDAGY-UHFFFAOYSA-N phenyl ethenesulfonate Chemical compound C=CS(=O)(=O)OC1=CC=CC=C1 CILDJVVXNMDAGY-UHFFFAOYSA-N 0.000 description 1
- 239000003016 pheromone Substances 0.000 description 1
- NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 description 1
- 239000010452 phosphate Substances 0.000 description 1
- 235000021317 phosphate Nutrition 0.000 description 1
- DLYUQMMRRRQYAE-UHFFFAOYSA-N phosphorus pentoxide Inorganic materials O1P(O2)(=O)OP3(=O)OP1(=O)OP2(=O)O3 DLYUQMMRRRQYAE-UHFFFAOYSA-N 0.000 description 1
- XNGIFLGASWRNHJ-UHFFFAOYSA-L phthalate(2-) Chemical compound [O-]C(=O)C1=CC=CC=C1C([O-])=O XNGIFLGASWRNHJ-UHFFFAOYSA-L 0.000 description 1
- 239000000049 pigment Substances 0.000 description 1
- 239000004014 plasticizer Substances 0.000 description 1
- 150000003058 platinum compounds Chemical class 0.000 description 1
- 229920000573 polyethylene Polymers 0.000 description 1
- 239000001103 potassium chloride Substances 0.000 description 1
- 235000011164 potassium chloride Nutrition 0.000 description 1
- DPLVEEXVKBWGHE-UHFFFAOYSA-N potassium sulfide Chemical compound [S-2].[K+].[K+] DPLVEEXVKBWGHE-UHFFFAOYSA-N 0.000 description 1
- 229920001592 potato starch Polymers 0.000 description 1
- 229940116317 potato starch Drugs 0.000 description 1
- 239000000843 powder Substances 0.000 description 1
- 239000002244 precipitate Substances 0.000 description 1
- 239000003755 preservative agent Substances 0.000 description 1
- 230000002335 preservative effect Effects 0.000 description 1
- 125000001501 propionyl group Chemical group O=C([*])C([H])([H])C([H])([H])[H] 0.000 description 1
- 125000001436 propyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- 125000006239 protecting group Chemical group 0.000 description 1
- 230000001681 protective effect Effects 0.000 description 1
- 238000000746 purification Methods 0.000 description 1
- UMJSCPRVCHMLSP-UHFFFAOYSA-N pyridine Natural products COC1=CC=CN=C1 UMJSCPRVCHMLSP-UHFFFAOYSA-N 0.000 description 1
- 150000003856 quaternary ammonium compounds Chemical class 0.000 description 1
- 238000001953 recrystallisation Methods 0.000 description 1
- 229910052703 rhodium Inorganic materials 0.000 description 1
- 239000010948 rhodium Substances 0.000 description 1
- MHOVAHRLVXNVSD-UHFFFAOYSA-N rhodium atom Chemical compound [Rh] MHOVAHRLVXNVSD-UHFFFAOYSA-N 0.000 description 1
- SONJTKJMTWTJCT-UHFFFAOYSA-K rhodium(iii) chloride Chemical compound [Cl-].[Cl-].[Cl-].[Rh+3] SONJTKJMTWTJCT-UHFFFAOYSA-K 0.000 description 1
- 235000009566 rice Nutrition 0.000 description 1
- 229940100486 rice starch Drugs 0.000 description 1
- 238000007127 saponification reaction Methods 0.000 description 1
- 230000007017 scission Effects 0.000 description 1
- 150000007659 semicarbazones Chemical class 0.000 description 1
- 238000000926 separation method Methods 0.000 description 1
- 239000008159 sesame oil Substances 0.000 description 1
- 235000011803 sesame oil Nutrition 0.000 description 1
- 239000000741 silica gel Substances 0.000 description 1
- 229910002027 silica gel Inorganic materials 0.000 description 1
- RMAQACBXLXPBSY-UHFFFAOYSA-N silicic acid Chemical compound O[Si](O)(O)O RMAQACBXLXPBSY-UHFFFAOYSA-N 0.000 description 1
- 239000000377 silicon dioxide Substances 0.000 description 1
- 150000003378 silver Chemical class 0.000 description 1
- ODZPKZBBUMBTMG-UHFFFAOYSA-N sodium amide Chemical compound [NH2-].[Na+] ODZPKZBBUMBTMG-UHFFFAOYSA-N 0.000 description 1
- 235000017557 sodium bicarbonate Nutrition 0.000 description 1
- 229910000030 sodium bicarbonate Inorganic materials 0.000 description 1
- 229910000029 sodium carbonate Inorganic materials 0.000 description 1
- 235000019812 sodium carboxymethyl cellulose Nutrition 0.000 description 1
- 229920001027 sodium carboxymethylcellulose Polymers 0.000 description 1
- 239000012312 sodium hydride Substances 0.000 description 1
- 229910000104 sodium hydride Inorganic materials 0.000 description 1
- 159000000000 sodium salts Chemical class 0.000 description 1
- HPALAKNZSZLMCH-UHFFFAOYSA-M sodium;chloride;hydrate Chemical compound O.[Na+].[Cl-] HPALAKNZSZLMCH-UHFFFAOYSA-M 0.000 description 1
- 239000007901 soft capsule Substances 0.000 description 1
- 238000003797 solvolysis reaction Methods 0.000 description 1
- 239000004071 soot Substances 0.000 description 1
- 241000894007 species Species 0.000 description 1
- 239000008117 stearic acid Substances 0.000 description 1
- 210000002784 stomach Anatomy 0.000 description 1
- 125000001424 substituent group Chemical group 0.000 description 1
- 125000001273 sulfonato group Chemical group [O-]S(*)(=O)=O 0.000 description 1
- 150000003459 sulfonic acid esters Chemical class 0.000 description 1
- 239000002511 suppository base Substances 0.000 description 1
- 208000011580 syndromic disease Diseases 0.000 description 1
- 150000003892 tartrate salts Chemical class 0.000 description 1
- JRMUNVKIHCOMHV-UHFFFAOYSA-M tetrabutylammonium bromide Chemical compound [Br-].CCCC[N+](CCCC)(CCCC)CCCC JRMUNVKIHCOMHV-UHFFFAOYSA-M 0.000 description 1
- VZGDMQKNWNREIO-UHFFFAOYSA-N tetrachloromethane Chemical compound ClC(Cl)(Cl)Cl VZGDMQKNWNREIO-UHFFFAOYSA-N 0.000 description 1
- 150000003568 thioethers Chemical class 0.000 description 1
- 206010043554 thrombocytopenia Diseases 0.000 description 1
- 230000001732 thrombotic effect Effects 0.000 description 1
- 101150068774 thyX gene Proteins 0.000 description 1
- 239000004408 titanium dioxide Substances 0.000 description 1
- 230000001256 tonic effect Effects 0.000 description 1
- 230000007704 transition Effects 0.000 description 1
- 229940078499 tricalcium phosphate Drugs 0.000 description 1
- 235000019731 tricalcium phosphate Nutrition 0.000 description 1
- 229910000391 tricalcium phosphate Inorganic materials 0.000 description 1
- FAQYAMRNWDIXMY-UHFFFAOYSA-N trichloroborane Chemical compound ClB(Cl)Cl FAQYAMRNWDIXMY-UHFFFAOYSA-N 0.000 description 1
- AVCVDUDESCZFHJ-UHFFFAOYSA-N triphenylphosphane;hydrochloride Chemical compound [Cl-].C1=CC=CC=C1[PH+](C=1C=CC=CC=1)C1=CC=CC=C1 AVCVDUDESCZFHJ-UHFFFAOYSA-N 0.000 description 1
- 239000002966 varnish Substances 0.000 description 1
- 239000000052 vinegar Substances 0.000 description 1
- 235000021419 vinegar Nutrition 0.000 description 1
- 125000000391 vinyl group Chemical group [H]C([*])=C([H])[H] 0.000 description 1
- 229920002554 vinyl polymer Polymers 0.000 description 1
- 238000005406 washing Methods 0.000 description 1
- 239000011592 zinc chloride Substances 0.000 description 1
- 235000005074 zinc chloride Nutrition 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C255/00—Carboxylic acid nitriles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/06—Antigout agents, e.g. antihyperuricemic or uricosuric agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
- C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
- C07D211/08—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms
- C07D211/10—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with radicals containing only carbon and hydrogen atoms attached to ring carbon atoms
- C07D211/12—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with radicals containing only carbon and hydrogen atoms attached to ring carbon atoms with only hydrogen atoms attached to the ring nitrogen atom
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
- C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
- C07D211/08—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms
- C07D211/10—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with radicals containing only carbon and hydrogen atoms attached to ring carbon atoms
- C07D211/14—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with radicals containing only carbon and hydrogen atoms attached to ring carbon atoms with hydrocarbon or substituted hydrocarbon radicals attached to the ring nitrogen atom
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
- C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
- C07D211/08—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms
- C07D211/18—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms
- C07D211/20—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms with hydrocarbon radicals, substituted by singly bound oxygen or sulphur atoms
- C07D211/22—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms with hydrocarbon radicals, substituted by singly bound oxygen or sulphur atoms by oxygen atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
- C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
- C07D211/08—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms
- C07D211/18—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms
- C07D211/30—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms with hydrocarbon radicals, substituted by doubly bound oxygen or sulfur atoms or by two oxygen or sulfur atoms singly bound to the same carbon atom
- C07D211/32—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms with hydrocarbon radicals, substituted by doubly bound oxygen or sulfur atoms or by two oxygen or sulfur atoms singly bound to the same carbon atom by oxygen atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
- C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
- C07D211/36—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D211/40—Oxygen atoms
- C07D211/44—Oxygen atoms attached in position 4
- C07D211/52—Oxygen atoms attached in position 4 having an aryl radical as the second substituent in position 4
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
- C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D211/68—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having one double bond between ring members or between a ring member and a non-ring member
- C07D211/70—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having one double bond between ring members or between a ring member and a non-ring member with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
- C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D211/68—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having one double bond between ring members or between a ring member and a non-ring member
- C07D211/72—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having one double bond between ring members or between a ring member and a non-ring member with hetero atoms or with carbon atoms having three bonds to hetero atoms, with at the most one bond to halogen, directly attached to ring carbon atoms
- C07D211/74—Oxygen atoms
- C07D211/76—Oxygen atoms attached in position 2 or 6
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
- C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D211/68—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having one double bond between ring members or between a ring member and a non-ring member
- C07D211/72—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having one double bond between ring members or between a ring member and a non-ring member with hetero atoms or with carbon atoms having three bonds to hetero atoms, with at the most one bond to halogen, directly attached to ring carbon atoms
- C07D211/78—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Pain & Pain Management (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Rheumatology (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Diabetes (AREA)
- Neurosurgery (AREA)
- Hematology (AREA)
- Physical Education & Sports Medicine (AREA)
- Hydrogenated Pyridines (AREA)
- Plural Heterocyclic Compounds (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Description
Oppfinnelsen vedrører on fremgangsmåte for fremstilling av nye fenylpiperidinderivater, spesielt substituerte, eventuelt enkeltumettet 1-benayl-fenyl-piperidin eied f onael The invention relates to a process for the production of new phenylpiperidine derivatives, especially substituted, optionally monounsaturated 1-benayl-phenyl-piperidine-eid f onael
hvori Kj botyr en i 1-stilling aod eventuelt substituert ben- in which Kj botyr an in 1-position and optionally substituted ben-
zyl substituert, eventuelt enkelt umettet piperldylrest.Ph er en eventuelt substituert fenylrest og B2betyr en eventuelt substituert lavere alkylrest tued forbehold at Ph eventuelt be- zyl substituted, optionally monounsaturated piperldyl residue. Ph is an optionally substituted phenyl residue and B2 means an optionally substituted lower alkyl residue with the proviso that Ph optionally means
tyr substituert 1,2- eller 1,3-fenylen»når E2inneholder i tyr substituted 1,2- or 1,3-phenylene»when E2 contains i
alfa-stilling en hydroks-, hydroksymetyl-, lavere alkaaoyjl-, alpha position a hydroxy-, hydroxymethyl-, lower alkaoyjl-,
2-okso lavere alkanoyl- eller 2-hydroksy lavere alkanoylgruppe 2-oxo lower alkanoyl or 2-hydroxy lower alkanoyl group
oglaod do videre forbehold at Kj or forskjellig fra 4-(l-benssyl) and added the further caveat that Kj is different from 4-(l-benzyl)
^piperidyl og 4-(l-ben2yl)-, 4- [l-(monoalkylben^yl)] - og 4- [1-(monohalogen-bensy 1)] -1, 2»5, 6-tetrahydro-pyridyl når Ph ^piperidyl and 4-(1-ben2yl)-, 4- [1-(monoalkylbenzyl)] - and 4- [1-(monohalo-benzyl)]-1, 2»5, 6-tetrahydro-pyridyl when Ph.D
angir^eventuelt substituert 1,4-fonylen og E2be*yr lavere alkyl denotes optionally substituted 1,4-phenylene and E2be*yr lower alkyl
eller lavere alkanofri eller lavere 1-hydrokey-alkyl ned i det minste 2 C-atomer og deres salter* or lower alkane-free or lower 1-hydroalkyl down to at least 2 C atoms and their salts*
Den 1 l-stilling med eventuelt substituert benzyl substituert»eventuelt umettet piperldylrest er eksempelvis en tilsvarende piporidyl- eller i annen linje t, 2, 5, 6-tetrahydro-pyridylrest. Som substituenter til disse koauaor eksempelvis i The 1 l-position with optionally substituted benzyl substituted" optionally unsaturated piperldyl residue is, for example, a corresponding piperidyl or in another line t, 2, 5, 6-tetrahydro-pyridyl residue. As substitutes for these koauaor, for example i
betraktning laver©alkyl, lavere alkoksy, lavere alkylthio, hydroksy, halogen og/eller trifluonaetyl, hvorved en eller flere consideration of lower alkyl, lower alkoxy, lower alkylthio, hydroxy, halogen and/or trifluonaethyl, whereby one or more
av de nevnte substituenter, spesielt te halogenatotaer, kan være tilstede. of the said substituents, especially halogen atoms, may be present.
Den eventuelt substituerte fenylenrest er eksempelvis The optionally substituted phenylene residue is an example
en eventuelt med lavere alkyl, lavere alkoksy, hydroksy og/eller one optionally with lower alkyl, lower alkoxy, hydroxy and/or
halogen substituert 1,4-eller i annen linje 1,3-fenylearost, halogen substituted 1,4-or in another line 1,3-phenyl ester,
hvorved i substituert f enylenrest kan veer©tilstede en, fortrinnsvis i o-stilling til E^bundet, eller i annen linje åer enn oa aubstituont. whereby in the substituted f phenylene residue one can be present, preferably in o-position to the E^bond, or in a different line than oa aubstituont.
En eventuelt substituert lavere alkylreat er eksempelvis en med okso eller hydroksy substituert lavere alkylrest, fortrinnsvis usubstituert eller med hydroksy eller i annen linje enkelt okso substituert lavere alkyl, dvs, lavere alkyl, hydroksy lavere alkyl, fortrinnsvis alfa-hydroksy lavere alkyl eller okso lavere alkyl, fortrinnsvis lavere alkanoyl. An optionally substituted lower alkyl group is, for example, an oxo- or hydroxy-substituted lower alkyl residue, preferably unsubstituted or with hydroxy or, in another line, simply oxo-substituted lower alkyl, i.e. lower alkyl, hydroxy lower alkyl, preferably alpha-hydroxy lower alkyl or oxo lower alkyl , preferably lower alkanoyl.
Foran- og etterfølgende skal under "lavere" rester og organiske forbindelser fortrinnsvis forstå slike som inneholder til og med 7, fortrinnsvis til og med 4, C-atomer. Before and after "lower" residues and organic compounds should preferably be understood to mean those which contain up to and including 7, preferably up to and including 4, C atoms.
Lavere alkyl er eksempelvis metyl, etyl, propyl, isopro-pyl, n-, iso-, sek.- eller tert.- butyl, videre n-pentyl, n-heksyl eller n-heptyl. Lower alkyl is, for example, methyl, ethyl, propyl, isopropyl, n-, iso-, sec.- or tert.-butyl, further n-pentyl, n-hexyl or n-heptyl.
Lavere alkoksy or eksempelvis metoksy, etoksy, propyl-oksy, isopropyloksy eller n-butyloksy. Lower alkoxy or, for example, methoxy, ethoxy, propyloxy, isopropyloxy or n-butyloxy.
Lavere alkyltio er eksempelvis metyltio, etyltio, pro-pyltlo, isopropyltio eller n-butyltio. Lower alkylthio is, for example, methylthio, ethylthio, propylthio, isopropylthio or n-butylthio.
Hydroksy lavere alkyl er eksempelvis 2-hydrdksyetyl, 2- eller 3-bydroksypropyl, 4-hydroksybutyl eller fortrinnsvis alfa-hydroksy lavere alkyl, som hydroksymetyl, 1-hydroksyetyl, 1-hydroksypropyl eller 1-hydroksybutyl, videre 1-hydroksypentyl, Hydroxy lower alkyl is, for example, 2-hydroxyethyl, 2- or 3-byhydroxypropyl, 4-hydroxybutyl or preferably alpha-hydroxy lower alkyl, such as hydroxymethyl, 1-hydroxyethyl, 1-hydroxypropyl or 1-hydroxybutyl, further 1-hydroxypentyl,
-heksyl eller -heptyl. -hexyl or -heptyl.
Okso lavere alkyl er eksempelvis 2-oksoetyl, 2- eller 3- oksopropyl, 4-oksobutyl fortrinnsvis lavere alkanoyl, formyl, acetyl, propionyl, butyryl, isobutyryl eller vider©kaproyl eller onantyl. Oxo lower alkyl is, for example, 2-oxoethyl, 2- or 3-oxopropyl, 4-oxobutyl, preferably lower alkanoyl, formyl, acetyl, propionyl, butyryl, isobutyryl or, furthermore, caproyl or onantyl.
Halogen er eksempelvis halogen til atomnummer 35, som Halogen is, for example, halogen to atomic number 35, which
klor eller 1 annen linje brom eUer Fluor. chlorine or 1 other line bromine or Fluorine.
Salter av forbindelse med formel I er eksempelvis deres syreaddisjonssalter, fortrinnsvis farmasøytiske anvendbare syré-addisjonssalter, med farmakologiske ubetenkelige minera-, sul-fon- eller karbonsyrer som hydrohalogonidej$ f «eks. hydroklorider eller -bromider, hydrogensulfater, sulfonater, f«eks. benzyl-, Salts of compounds of formula I are, for example, their acid addition salts, preferably pharmaceutical usable acid addition salts, with pharmacologically harmless mineral, sulfonic or carboxylic acids such as hydrohalogenidej$ e.g. hydrochlorides or bromides, hydrogen sulphates, sulphonates, e.g. benzyl,
p-toluol- eller metansulfonater, sulfaminater, f.eks. syklo-heksylsulfaminater, eller karbonsyresalter, f.eks.acetatar, p-toluene or methane sulfonates, sulfaminates, e.g. cyclohexylsulfaminates, or carbonic acid salts, e.g. acetates,
fumarater, maleinater oller tartrater. fumarates, maleinates or tartrates.
Oppfinnelsen vedrører i første linje forbindelse med formel 1, hvori Rj betyr an i l-stilling med en eventuelt med lavere alkyl, lavere alkoksy, hydroksy, halogen og/eller klor-substituort,benzylrest substituert, eventuMt enkelt umettet©iperidylreato$h bQtyr esi eventuelt osrd laver® alkyl, lavere alkoksy, hydroksy og/eller halogen substituert fenylenrest og &2betyr en eventuelt 1 i-stilling eller 1 høyere som 2-stilling med okso eller i l-stilling med hydroksy substituert lavere alkylrest, som legemiddel farmasøytiske preparater Inneholdende disse og de nevnte forbindelser selv med det forbehold at Ej er forskjellig fra i l-stilling med usubstituert benzyl substituert eventuelt i 3,4-stilling enkelt umettet 4-piperidyl når Ph angir eventuelt substituert 1,4-fenylon og 3R2 er lavere alkyl eller lavere alkanoyl med 1 det minste 2 C-atomer* The invention relates in the first line to a compound of formula 1, in which Rj means an in l-position with an optionally lower alkyl, lower alkoxy, hydroxy, halogen and/or chlorine substituent, benzyl residue substituted, optionally monounsaturated optionally osrd lower® alkyl, lower alkoxy, hydroxy and/or halogen substituted phenylene residue and &2means an optionally 1 i-position or 1 higher as 2-position with oxo or in l-position with hydroxy substituted lower alkyl residue, as medicine pharmaceutical preparations containing these and the aforementioned compounds even with the proviso that Ej is different from in the 1-position with unsubstituted benzyl optionally substituted in the 3,4-position monounsaturated 4-piperidyl when Ph denotes optionally substituted 1,4-phenylone and 3R2 is lower alkyl or lower alkanoyl with 1 at least 2 C atoms*
Oppfinnelsen vedrører fortrinnsvis forbindelse med formel X, hvori Hf betyr en i fenyIdelen eventuelt med lavere alkyl med til og med. 4 C-atomer, som metyl, lavere alkoksy med til og med 4 C-atomer, som metoksy, hydroksy, halogen med atomnummer til og med 35, som klor-, hydroksy og/eller trifluormetyl substituert 3- eller 4-(l-benzyl)-piperidyl- henholdsvis 3- eller 4-(l-benzyl-1, 2, 5, 6-tetrahydro)-pyridylrest, Ph angir eventuelt, spesielt i o-stilling til ftj, med lavere alkyl med til og med 4 C-atomer som metyl, lavere alkoksy med til og méd 4 C-atomer som metoksy, hydroksy eller halogen med atomnummer til og med 35t The invention preferably relates to a compound of formula X, in which Hf means a in the phenyl part optionally with lower alkyl with even. 4 C atoms, such as methyl, lower alkoxy with up to and including 4 C atoms, such as methoxy, hydroxy, halogen with atomic number up to and including 35, such as chloro-, hydroxy and/or trifluoromethyl substituted 3- or 4-(l- benzyl)-piperidyl- respectively 3- or 4-(l-benzyl-1, 2, 5, 6-tetrahydro)-pyridyl residue, Ph denotes optionally, especially in the o-position to ftj, with lower alkyl with up to and including 4 C -atoms such as methyl, lower alkoxy with up to and including 4 C atoms such as methoxy, hydroxy or halogen with atomic number up to and including 35t
som klor, substituert 1,4-eller i annen linje 1,3-fenylen, og R2, betyr eventuelt i høyere enn 2-stilllng med hydroksy eller i 1-stllllng eller 1 høyere enn 2-stillingen med okso substituert lavere alkyl med til og med 4 C-atomer, som metyl, etyl, 3-hydroksypropyl, 4-hydroksypropyl, formyl eller acetyl, som legemiddel, farmasøytiske preparater inneholdande disse og de nevnte forbindelser selv, <,;med det forbehold at K1er forskjellig fra usubstituert 4-(i->benayl)-piperidyl og 4-(1 -benzyl-1, 2, 5, 6-tetrahydro-pyridyl eller Ph©r forskjellig fra eventuelt substituert 1,4-fenylen når R2er lavere alkyl eller lavere alkanoyl med i det minste 2 C-atomer* as chlorine, substituted 1,4-or alternatively 1,3-phenylene, and R2, optionally in higher than 2-position with hydroxy or in 1-position or 1 higher than 2-position with oxo substituted lower alkyl with to and with 4 C atoms, such as methyl, ethyl, 3-hydroxypropyl, 4-hydroxypropyl, formyl or acetyl, as medicine, pharmaceutical preparations containing these and the aforementioned compounds themselves, <,; with the proviso that K1 is different from unsubstituted 4- (i->benayl)-piperidyl and 4-(1-benzyl-1, 2, 5, 6-tetrahydro-pyridyl or Ph©r different from optionally substituted 1,4-phenylene when R2 is lower alkyl or lower alkanoyl with in minimum 2 C atoms*
Oppfinnelsen vedrører fortrinnsvis forbindelse med formel I, hvori S|betyr i fenyIdelen med lavere alkoksy med til og med 4 C-atom, som metoksy, og/eller halogen med atomnummer til og med 35#som klor, mono-eller disubstituert 3- eller fortrinnsvis 4-(l-benayl)-piperidyl, Ph betyr 1,4-fenylen og S2 betvr eventuelt i l-stilling eller i høyere enn 2-stillingen med okso eller i høyere enn 2-stillingen med hydroksy monosubstituert lavere alkyl med til og med 4 C-atomer, f«eks. etyl, 3-hydroksypropyl eller acety» og deres farmasøytiske anvendbare syreaddi-sjonssalter.The invention preferably relates to a compound of formula I, in which S| in the phenyl part means lower alkoxy with up to and including 4 C atoms, such as methoxy, and/or halogen with atomic number up to and including 35# such as chlorine, mono- or disubstituted 3- or preferably 4-(1-benayl)-piperidyl, Ph means 1,4-phenylene and S2 is optionally in the l-position or in the higher than the 2-position with oxo or in the higher than the 2-position with hydroxy monosubstituted lower alkyl with to and with 4 C atoms, e.g. ethyl, 3-hydroxypropyl or acetyl" and their pharmaceutically usable acid addition salts.
Oppfinnelsen vedrører i første linje forbindelse med formel I, hvori &|betyr i fenyldelen med lavere alkoksy med til og med 4 C-atomer, som metoksy, mønosubstituert eller sod halogen til og med Atomnummer 35»som klor, disubstituort 4-(l-benisyl)-piperidyl, Ph fremstiller 1,4-fenylon og Rz^©tyr lavere alkyl med til og med 4 C-atom, som etyl, og deres far-masøytiske anvendbare syreaddisjonssalter. The invention relates in the first line to a compound of formula I, wherein &|means in the phenyl part with lower alkoxy with up to and including 4 C-atoms, such as methoxy, mono-substituted or sod halogen up to and including Atomic number 35» as chlorine, di-substituted 4-(l- benisyl)-piperidyl, Ph prepares 1,4-phenylone and Rz represents lower alkyl with up to 4 C atoms, such as ethyl, and their pharmaceutically useful acid addition salts.
Oppfinnelsen vedrører nemlig de i eksemplene angitte forbindelse med formel X 1 fri form eller i form av farmasøy-tiske anvendbare syreaddisjonssalter. Namely, the invention relates to the compounds of formula X 1 specified in the examples in free form or in the form of pharmaceutically usable acid addition salts.
Se nye forbindelser kan fremstilles på i og for seg kjente metoder som eksempelvis, idet man 1 en forbindelse med formel See new compounds can be produced by methods known per se, such as, for example, taking a compound of formula
hvori &Å betyr en i 5-atilling i fenyldelen eventuelt substituert bonsylamino substituert, Inneholdende i l-stilling en utbyttbar rest X oller i 1,2-stilling en evéfttueltytterligere dobbeltbinding, eventuelt enkel umettet a-peatylrest, eller et salt derav, ^«ri*g slutter RA til tilsvarende rest R±og om onskellgi r skiller en erhalt-stereøisomerhlanding i komponentene, overfører erhalt-forbindelse i en annen forbindelse med formelen I og/eller omdanner en erhalt-forbindelao i et salt eller et erhalt-salt 1 en fri forbindelse eller i et annet salt. in which &Å means a 5-acetylation in the phenyl part optionally substituted bonsylamino substituted, Containing in the 1-position an exchangeable residue X or in the 1,2-position an optional additional double bond, optionally single unsaturated a-peatyl residue, or a salt thereof, ^«ri *g joins RA to the corresponding residue R± and if necessary separates an erhalt-stereoisomer mixture into the components, transfers erhalt-compound into another compound of the formula I and/or converts an erhalt-compound into a salt or an erhalt-salt 1 a free compound or in another salt.
Utbyttbare rester er derved eksempelvis eventuelt fores terede eller foredrede hydroksygrupper eller eventuelt substituerte mereapto- eller aminogrupper. Replaceable residues are, for example, optionally esterified or preferred hydroxy groups or optionally substituted mereapto- or amino groups.
iForesterede hydroksygrupper er eksempelvis reaksjonsdyktige foresterede hydroksygrupper, fortrinnsvis med minøral-syrer eller med organiske sulfonsyror foresterede hydroksygrupper, som halogen, f.eks» klor, brom eller jod, fluorsulfonyloksy eller aromatisk eller allfatisk sulfonyloksy, f.eks* metan-, iEsterified hydroxy groups are, for example, esterified hydroxy groups capable of reacting, preferably with mineral acids or hydroxy groups esterified with organic sulfonic acids, such as halogen, e.g. chlorine, bromine or iodine, fluorosulfonyloxy or aromatic or allphatic sulfonyloxy, e.g.* methane-,
etan-, etensulfonyloksy, benzen-, p-toluol- eller p-broobenzen-sulfonyloksy* Som foresterede hydroksygrupper kommer videre i betraktning mod organiske syrer foresterede hydroksygrupper som lavere alkanoyloksy eller eventuelt, f.eks* mod halogen eg/eller nitro, substituert beaaoyloksy* ethane-, ethenesulfonyloxy, benzene-, p-toluene- or p-broobenzenesulfonyloxy* As esterified hydroxy groups, esterified hydroxy groups such as lower alkanoyloxy or optionally, e.g.* against halogen eg/or nitro, substituted beaaoyloxy are also taken into consideration against organic acids *
Foredrede hydroksygrupper er eksempelvis med alifatiske alkoholer©lier mod evontuolt substituerte fenoler foredrede hy- droksygruppor som lavere alkoksy eller eventuelt iaed halogen og/eller nltrosubstituerte fenoksygrupper. Preferred hydroxy groups are, for example, with aliphatic alcohols versus optionally substituted phenols, preferred hydroxy groups such as lower alkoxy or optionally added halogen and/or nitro-substituted phenoxy groups.
Substituerte mercaptogrupper er eksempelvis alifatyl-tiogrupper eller eventuelt substituerte fenyltiogrupper, soia lavere alkyltlo eller eventuelt med halogen og/eller nitro substituerte fenyltio eller benzyltio. Som videresubstituerte merca<p>to<g>rup<p>er kommer i betraktning tilsvarende sulfoniumestary .. som di-lavere alkylsulfonxum eller eventuelt med halogen og/ eller nitrosubstltuert dif eaylsulfoaiura. Substituted mercapto groups are, for example, aliphatylthio groups or optionally substituted phenylthio groups, such as lower alkylthio or optionally halogen and/or nitro substituted phenylthio or benzylthio. As further substituted merca<p>to<g>rup<p>s come into consideration corresponding sulfonium esters .. such as di-lower alkylsulfonxum or optionally with halogen and/or nitro-substituted dif eaylsulfoaiura.
Substituerte aminogrupper er eksempelvis alifatisk og/ eller med eventuelt substituert fenyl eller benzyl substituerte aminogrupper, som mono-eller di-lavere alkylatuino eller eventuelt med lavere alkyl, lavere alkoksy, hydroksy, halogen og/eller trifluormetyl substituerte aniiiao-, benzylamino- eller difenyl-aminogrupper. Som videre substituerte aminogrupper kommer i betraktning tilsvarende kvaternSre ammoniumgrupper, som tri- Substituted amino groups are, for example, aliphatic and/or with optionally substituted phenyl or benzyl substituted amino groups, such as mono- or di-lower alkylatuino or optionally with lower alkyl, lower alkoxy, hydroxy, halogen and/or trifluoromethyl substituted amino-, benzylamino- or diphenyl- amino groups. As further substituted amino groups, corresponding quaternary ammonium groups, such as tri-
lavero ammonium- eller di»lavere alkylamino-oksydgrupperinger* lower ammonium or di»lower alkylamino oxide groups*
Salter av forbindelser med formel II er eksempelvis deres syreaddisjonssalter»fortrinnsvis mineralayreaddisjons-salter som hydrohalogonider, f•eks» hydroklorider, hydrobromi-der «lier hydrogensulfater ay disse* Salts of compounds of formula II are, for example, their acid addition salts, preferably mineral addition salts such as hydrohalides, for example, hydrochlorides, hydrobromides, hydrogen sulfates and the like.
Sykliseringen av resten RÅ utføres på vanlig måte eksempelvis termisk, f.eks. ved opphetning til ca. 50 til 250°C., om nødvendig å nærvær av et kondensasjonsmiddel og/eller vannbindende middel 1 et inert oppløsningsmiddel og/eller under inert ga sg som nitrogen. The cyclization of the RÅ residue is carried out in the usual way, for example thermally, e.g. when heated to approx. 50 to 250°C., if necessary in the presence of a condensing agent and/or water-binding agent 1 an inert solvent and/or under inert gas such as nitrogen.
Som kondensasJonsmidler hvor en utgår fra forbindelser med formel II» hvori X betyr eventuelt foresteret hydroksy eller en eventuelt foresteret mercapto- eller aminogrttppe, kommer spesielt basiske kondensasjonsmidler 1 betraktning som f.eks* hy-drlder»alkoholater eller amider av alkalimetaller, f.eks* na-triumhydrid, alkalimetall-lavere alkanolater som natriuEUBetano-lat eller natrlumetanolat, eller alkalimetallamider som natrium-amid eller litiumdiiaopropylamid, videre kvaternSre ammonlumba-ser som benzyltrletylammoniumhydroksyd, oller også tertier© organiske nitrogenbaser, f«eks* pyridln eller trietylamin* For sykliøering av forbindelsor med formelen II, hvori X eventuelt betyr foretert hydroksy»anvender man eksempelvis syrokondensa-sjonsmidler som mineralsyrer, f*eks. svovelsyre eller føsforayre, ellor sur© loaeutbyttore, og for sykliseringen av forbindelser i hvilket H A oppviser en 1,2-dobbeltbinding anvender csan ekso»-pelvis lve.wls-syrer som bortrifluorid eller sink-klorid. Condensing agents starting from compounds of formula II in which X means an optionally esterified hydroxy or an optionally esterified mercapto- or amino group, especially basic condensation agents come into consideration such as, for example, hydrogen alcoholates or amides of alkali metals, e.g. * sodium hydride, alkali metal lower alkanolates such as sodium eubethanolate or sodium ethanolate, or alkali metal amides such as sodium amide or lithium diiopropylamide, further quaternary ammonium compounds such as benzyl triethylammonium hydroxide, or also tertiary organic nitrogen bases, e.g.* pyridln or triethylamine* For cyclization of connecting acid with the formula II, in which X possibly means etherified hydroxy», for example, acid condensation agents such as mineral acids are used, e.g. sulfuric acid or phosforayre, or sour© loaeutbyttore, and for the cyclization of compounds in which H A exhibits a 1,2-double bond csan exo»-pelvis lve.wls acids such as boron trifluoride or zinc chloride are used.
lignode oppløsnlngsmidier or eksempelvis under reak-sjonsbetisgolsone inerte, organiske fortrinnsvis polar-opplos-ningsmldler som^lavere alkanoler» f.eks. etanol, laver© alkan* syreamider, f.eks. K,N-dimetylforatamid oller M-iaetylpyrrolidon, lavere dialkylsulfoksyder som diraetylsulfoksyd, ved anvendelse av kvaternSre ammoniumbaser som kondenaas JonsEaiddel videre vann-holdige tof ase—systemer, som æetylenklorid-vaim, bens en-vann eller omylalkohol-vann. lignode solvents or, for example, during the reaction betisgol zone inert, organic, preferably polar solvents such as lower alkanols, e.g. ethanol, low© alkane* acid amides, e.g. K,N-dimethylforatamide or M-iaethylpyrrolidone, lower dialkylsulfoxides such as diethylsulfoxide, by using quaternary ammonium bases as condensate JonsEaiddel further water-containing two-phase systems, such as ethylene chloride-vaim, benzene-water or omyl alcohol-water.
Vasrabindende midler er eksempelvis anhydrido ellor , ., lånere anhydridor som disykloheksylkarbodi-imid oller fosfor-pentoksyd. Vas binding agents are, for example, anhydrido or , ., anhydrides such as dicyclohexylcarbodiimide or phosphorus pentoxide.
U tgangsstoffer med formelen II blir fordelaktig fremstilt under reaksjonsbetingelser in situ, eksempelvis idet asm. omsetter on forbindelse med formelen Starting substances with the formula II are advantageously prepared under reaction conditions in situ, for example when asm. converts on connection with the formula
hvori Rj^ betyr en eventuelt enkelt umettet a-peatylrost som oppviser i 1- og 5-stillinger en rest X og i 1,2- og 1,5-stilllnger hver en ytterligere dobbeltbinding, oller et salt derav, med eventuelt i fenyldelen substituert benaylamin eller et salt derav. Be nye forbindelsene kan videre fremstilles idet man substituerer en forbindelse med formelen in which Rj^ means an optionally single unsaturated α-peatyl rust which exhibits in the 1- and 5-positions a residue X and in the 1,2- and 1,5-positions each an additional double bond, or a salt thereof, optionally substituted in the phenyl part benaylamine or a salt thereof. The new compounds can further be prepared by substituting a compound with the formula
hvori R|jbetyr en 1-usubstituert, eventuelt enkelt umettet piperidylrest oller et salt derav, med et middel som ved omsetning har eventuell substituert benaylrest i <_ Ol-stilling, og om ønskelig skiller en erhalt-stereoisomerblanding i komponentene, overfarer erbalt-forbindelsø i en annen forbindelse med formel I in which R|jmeans a 1-unsubstituted, optionally monounsaturated piperidyl residue or a salt thereof, with an agent which, upon reaction, has any substituted benayl residue in the <_ Ol position, and if desired separates an erhalt-stereoisomer mixture into the components, passes erbalt-combination acid in another connection with formula I
og/eller omdanner en orhalt fri forbindelse i ot salt oller oa-danner et erhalt-salt i on fri forbindelse ellor i et annet salt. and/or converts an orhalt free compound into a salt or oa-forms an orhalt salt into a free compound or into another salt.
Kidlot for innføring av don eventuelt substituerte benaylrest or eksempelvis reaksjonsdyktige estere sotafaineralsyre-estore, f.eks. halogen-, fortrinnsvis klor-, brom- eller jodhy-drogonsyre-ostøre, eller organiske3ulfonsyre-©st©re, f«eks. s j ico tau-, etan-, otea-, won^cn-, p-ioIuQl«> ei lor pobrotuben&ensul-i'onsyre-ostere tilsvarende benzylalfcoholor eller ved reduser-eade betingelser tilsvarendebon^-aldelbiydør. Kidlot for the introduction of optionally substituted benayl residues or, for example, reactive esters, sotafineral acid esters, e.g. halogen, preferably chloro, bromo or iodohydrogonic acid esters, or organic sulfonic acid esters, e.g. s j ico tau-, ethane-, otea-, won^cn-, p-ioIuQl«> ei lor pobrotuben&ensul-i'onic acid esters corresponding to benzylalfcholor or under reducing conditions corresponding to bon^-aldelbidoor.
'Xnnxøringoa av d©n eveatuelt substituerte benzyirost finnex'stod ved omsetning ued do ovenfor angitfco nudler pa van-iig mate, oie nødvendig i ot inert oppløsniagsnaiddel, i nærvar av ot kondeasusjonsmiddcl og/oilor ved foraøyet eller nedsatt ' temperatur, i', oka. vod ca. 0° tii ca. 15Ci°C. Xnnxøringoa of the eveatually substituted benzyirost finnex'stood by reaction ued do above specified fco noodles on usual food, oie necessary in ot inert solvent part, in the presence of ot condesaussion middcl and/oilor at pre-eye or reduced 'temperature, i', okay water approx. 0° tii approx. 15Ci°C.
Ved OESotaing mod reaksjonsayktigo ben^yl-ostor©arbeiderEjan i opplosningsuiidier som ovenfor reaksjonodeltagorno er inorto, od nødvendig a nerve*' av oi basisk.©ad ensas joaouiduoi, ved forhøyet ellor ned&att teatera tur, i* «eks. ved ca. 0° til 150°(i., og/ellor uador xsiort j^ass aoa ni feromon.. Lia si ske kon=» densasjonsmidler erOiisoispoivio do organiske baser a out alkuli-motall- oller joititilka.iiiaetailhyurokayder oller -karbonater, 2'.oka. uatriuEjhydro^syd, kaiiuMiydroksyd, kal s-iutiihydr oksyd, kul iuukarbonat ellor^aisiutakapbonnt, oller tørtiere organiske nitrogonbaser, soa yyriuxu ellor triotylaaiJLia. ugaod©. opplos-siiagsuxdier er©køeispQAviiu ketoner soe) lavore di-alkylkoto&å©r, x".eks. aceton, alkoholor, souj lavere"alkaaoler, f.ekso aeSanoi, otanoi eller a&ylalkoaol, eveatuoit h&logoaorte hydrokarboner aom benzen, tolnaol ellor Lte ty lenk lor id, oller JJ,N=disubstitu» orte lavere 'alkansyrea&iider som dxactylloroauid oller iS-metyl-pyrrolidoa.. When OESotaing against reaktionsyktigo ben^yl-ostor©Ejan works in solution suiidies which above reaktionodeltagorno is inorto, od necessary a nerve*' of oi basic.©ad ensas joaouiduoi, at elevated or down&att theatera tur, i* «ex. at approx. 0° to 150°(i., and/or uador xsiort j^ass aoa ni pheromone.. Lia si ske kon=» densation agents areOiisoispoivio do organic bases a out alkuli-motall- oller joititilka.iiiaetailhyurokayder oller -carbonates, 2'. oka. uatriuEjhydro^syd, kaiiuMiydroxide, cal s-iutiihydr oxide, carbon iuucarbonat or^aisiutakapbonnt, or tertiere organic nitrogen bases, soa yyriuxu or triotylaaiJLia. ugaod©. solsiiagsuxdie are©køeispQAviiu ketones soe) lavore di-alkylcoto&å©r, x ".e.g. acetone, alcohols, souj lower"alkaaols, e.g.e.so aeSanoi, otanoi or a&ylalkoaol, eveatuoit h&logoaorte hydrocarbons aom benzene, tolnaol or Lte ty lenk lor id, oller JJ,N=disubstitu» orte lower 'alkanoi a&iides such as dxactylloroauid oller iS-methyl-pyrrolidoa..
Vod oiiisetaiiigea ned bon^aldehydor ved reduserende b©°tingelsor aavexidor saan so&s reduksjonsmiddel for aminoalkyleriag vanlig© uldier som loitiuetalluydrider, . i'.eks. aatriusaborhydrid ell©r iortrlaasvis aati-iuu-cyaaborhydx*idfka&aly tisis. aktivert hydrogen aoa hydrogen i iiarver av on hydraringskataiysator, soai ea palladium-, piatia- oller aikkoikataiysutor, i<*>.eks» platin, eveatuolt på karboa,, platino&syd, paliadiucu pk karboa oller iianey-iiikkol, videre ctaursyre ellor dets salter. Omsetningen i ncsrvtcr av de angitte • roduksjoasEiiidler utreres pa den for diss©vanlige mate, fordelaktig x et overfor reaksjonsdeitagerno inert opp-løsningsciiddeleuauor aøytrale bo tingels or ellor osu nodvoadig-het «jsvaksuro betingelser, ved uatalytiske hydreriager ota nødven» djig cod forhøyet trykk, f.oko. til ca. 10 bar. Som iaorte opp-løoaiagSEidlor nuveacos. i'ortriaasvis alkoholer socs lavore alka-aoior, 'f.oks. uetauol oi Jer etaaol, evontuolt i blanding med vasa. Vod oiiisetaiiigea down bon^aldehydor by reducing be©°tingelsor aavexidor saan so&s reducing agent for aminoalkyleriag common© uldier as loitiueetalluydride, . i'.eg. aatriusaborhydrid or©r iortrlaasvis aati-iuu-cyaaborhydx*idfka&aly tisis. activated hydrogen or hydrogen in iiarver of on hydrogenation catalyst, such as palladium-, piatia- or aikokaitaiysutor, i<*>.eg» platinum, evetuolt on carboa,, platino&syd, palliadiucu pk carboa or iianey-iiikcol, further ctauric acid or its salts. The turnover in ncsrvtcr of the indicated • redukjoasEiiidels is carried out in the usual way, advantageously x an inert solution ciideleuauor aeutral bo tingels or else osu necessariat "weakly acidic conditions, in the case of non-analytical hydrogen reactions ota nevedven" djig cod elevated pressure, f.ok. to approx. 10 bars. As iaorte up-løoaiagSEidlor nuveacos. i'ortriaasvis alcohols socs lavare alka-aoior, 'e.g. uetauol oi Jer etaaol, evontuolt in mixture with vasa.
Ved anvo&doise av lettøotaili&ythridor arboidos* utan fordelaktig ved nøytrale og voa iiatriucicyasiføorhydrid uaxder svake sur© be ting© le or, f.tuis. vod ea.. yH 3 til 6,<q>é<q>s aiaa utforox-katalytisk© hydrorijagcx- fordelaktig i saærvas: av©ri jaineralsyre, i<*>«eks. saltsyre henholdsvis ousottor realtsjøiiøkoEa<p>oxiesiteno med formel III i fora av tilsvarende syreaddisjonssalter, i'.eks.3QS1iiydroklorid.. In the application of lettøotaili&ythridor arbidos* without advantage at neutral and voa iiatriucicyasiføorhydride uaxder weak acid© be ting© le or, f.tuis. vod ea.. yH 3 to 6,<q>é<q>s aiaa utforox-catalytic© hydrorijagcx- advantageous in saærvas: av©ri jaineralic acid, i<*>«ex. hydrochloric acid respectively ousottor realtsjøiiecoEa<p>oxysiteno with formula III in fora of corresponding acid addition salts, i'.ex.3QS1iihydrochloride..
Utgangsatoffor taud foraelen 111 kan fremstilles' på i og for sog kjent© .uetodor» forbindelsen sod foreaolora lii, i hvilket Kg betyr i alfa-stiiliag med okso substituert lavere alkyl, orliai(S©s f.ekø. idet iaaa oasettor sn forbindoiso aad forete len Starting atom for taud foraelen 111 can be prepared' on i and for sog known© .uetodor» compound sod foreaolar lii, in which Kg means in alpha-stiliag with oxo substituted lower alkyl, orliai(S©s f.ekø. idet iaaa oasettor sn forbindoiso aad forete fief
hvori botyr o<q>nitrogonatoiu-beskyttet, f.oke. acylex-t, f.eks. lavere alkanoylort, eventuelt enkelt uaottet plperidylroot, i nærvar av en leuis-eyre, f.oks. alwaiaiuiatriklorid, caed et ro-aksjonsdyktig lavere alkaasyredorivat, f.eko. ors laver©alkairi-kartoonsyreaahydrid oilor -klorid, og a vs pa i tor b©skyttols©sg:rup-ttexi pd vanlig aåto, f.oks. ved syrokatalysort hydrolyse. Vorbindolsor tsod formelen 111, i hvilket i%g betyr for-tuyl, kan fordelaktig erholdes ©ttor vauxilgo f orunaieringsuaotodor, f.eks. ved omsetning av on forbindelse eiod forcieien in which botyr o<q>nitrogonatoiu-protected, f.oke. acylex-t, e.g. lower alkanoyl root, possibly simply unoated plperidyl root, in the presence of a leuis-eyre, e.g. alwaiaiuia trichloride, caed a ro-action capable lower alkaic acid derivative, f.eko. ors laver©alkairi-cartoonic acid aahydride oilor -chloride, and a vs pa in tor b©skytols©sg:rup-ttexi pd usual aåto, e.g. by acid-catalyzed hydrolysis. Vorbindolsor tsod the formula 111, in which i%g means for-tuyl, can advantageously be obtained ©ttor vauxilgo f orunaieringsuaotodor, e.g. by turnover of on connection eiod forcieien
Gied SJ,M«disubstituorte forsnataldor som N-ej© tyl» forman i lid oller diC30tylforaatQid, 1 mæmar av fosforoksyklorid©Iler tcod dimotyl-foxrøataid-ootosulfat.. Forbindoiso ped for<a>élea 121, hvori H2 u©d hydrokoy substituert lavoro alkyl, kan f.eks. orholdes utgående fra tilsvarende forbiixdolso mod formelen III, hvori Hg ør mod okso substituert lavoro alkyl, iuod reduksjon, f.oks. tacd aa« triUEibox^hydrid i ©sx lavoro alLonol. Forbindoiso mod x^orstelen III, hvox-i kt», .©r toratinai-hydroksy-substituert lavore alkyl, kais analog fremstilles ved reduksjon av estoro, sota lavoro alkylester, Gied SJ,M«disubstituorte forsnataldor such as N-ej© tyl»forman in lid oller diC30tylforaatQid, 1 mæmar of phosphorus oxychloride©Iler tcod dimotyl-foxrøataid-ootosulphate.. Forbindoisoped for<a>élea 121, in which H2 u©d hydrocoy substituted lavoro alkyl, can e.g. orhold starting from corresponding forbiixdolso mod formula III, in which Hg is mod oxo substituted lavoro alkyl, iuod reduction, e.g. tacd aa« triUEibox^hydride in ©sx lavoro alLonol. Forbindoiso mod x^orstene III, hvox-i kt», .©r toratinai-hydroxy-substituted lavore alkyl, kais analog is prepared by reduction of estoro, sota lavoro alkyl ester,
•tilsvarande .oiaoga-karbokoy lavore alkylfo&yipiporidin-forblndel-sor kan f.oks» rodusores suod litiuiaalusairiiuathydrid i diotylctor©Iler tstrahydrofuran. i?orbia.dols©taod fonaolen III, hvori I4g or laver©'alkyl, kan eksempelvis orholdes fra forbindelser som inneholder røofc kg ocd hydrousy substituert lavere aiLyl9raod •corresponding .oiaoga-carbokoy lavore alkylfo&yipiporidine-forblndel-sor can for example be rodusores suod litiuiaalusairiiuathydride in diotylctor©Iler tstrahydrofuran. i?orbia.dols©taod phonaolen III, in which I4g or laver©'alkyl, can for example be obtained from compounds containing røofc kg ocd hydrousy substituted lower aiLyl9raod
reduksjon av &2*** lavere'alkyl, fortrinnsvis vod innvirkning av hydrogen i nærvær av oa hydreringskatalyaator, • f.oks. palladium på karbon, fortrinnsvis i on organisk syre sod .oddiksyro. reduction of &2*** lower'alkyl, preferably under the influence of hydrogen in the presence of a hydrogenation catalyst, • e.g. palladium on carbon, preferably in organic acid sod .oddiksyro.
De nyo forbindelser kan taim videre fremstille idet san i on forbindelse med fo rote len The new compounds can then be further prepared in the same way as the original compound
hvori Hq botyr.cn taed hydrogouutbyttbar substituert rest og/ ellor eventuelt dobbeItbinding inneholdende rest , eller ot salt derav, reduserer rosten kctii k-j og oia ønskelig skiller en erhalts storeoisomorbiandin<g>i kolonen ten©, ovorforor esa erhalt-forfoindols© i en annen forbindelse iaed forjueloa X e<g/ eller omdanner en©rhalt fri forbindelse i et salt oller ot erhalt-salt i on fri forbindelse ellor i ot annet salt»in which Hq botyr.cn taed hydrogou-exchangeable substituted residue and/or possibly dobbeIt bond containing residue , or ot salt thereof, reduces the rust kctii k-j and oia desirably separates an erhalt's storeoisomorbiandin<g>in the column ten©, overforor esa erhalt-forfoindols© in another compound iaed forjueloa X e<g/ or converts an ©erhalt free compound into a salt or ot erhalt-salt into a free compound or into another salt»
I2ed hydrogonutbyttbare grupper or eksempelvis reduktiv eaed hydrogehutbyttbare grupper som ovoatuelt funksjonelt osidaai-JiGtio oksføhydroksy- ellor aercaptogruppor ellor organiske oul-fonylgrupper. Funksjonelt omdannede oksogrupper or eksempelvis okso- eller tiongruppor, scnikarbasongrupper eller©vomtuelt i^-stilling med organisk sulfonyi som bonden-, p-toluaol-, p-tarom-benson- ellor uotur.sulf ouyi, substituert© hydrasongruppør* I2ed hydrogen exchangeable groups or for example reductive eaed hydrogen exchangeable groups such as ovoatual functional osidaai-JiGtio oxfohydroxy- or aercaptogruppor or organic oul-fonyl groups. Functionally converted oxo groups or, for example, oxo- or thione groups, scnicarbazone groups or ©vomtual i^ position with organic sulfonyi such as bondene-, p-toluaol-, p-tarom-benzol or uotur.sulf ouyi, substituted© hydrazone group*
Funksjonelt omdannede hydroksygrupper er eksempelvis foredrede oller foresteredo hydroksygrupper, caen oosn funksjonelt omdannedelaorcaptogruppor komiaor spesielt foredrede mor-captogruppor i betraktning. Foredrede hydroksygrupper er eksempelvis lavere alkoksygrupper som aetoksy eller etoksy. For-©storedo hydroksygrupper©r eksempelvis iaod en taineralsyre eller organisk karbon- eller sulfonsyre foresteredo hydroksygrupper. Organiske karbonsyrer er f.oks. eventuelt substituert©bejisol-syrer, alkan-, fortrinnsvis laver©alkan karbonsyrer9f.eks. benzo- eller eddiksyro. Organiske stjlfonsyrer er f.oks. b©ns©n°, p-toluol-, p-broiabenseen-, taétan-, etan- eller otensulfonsyre. Ktineralsyrer er fortrinnsvis halogenhydrogeasyrer»f.eks. klor-, brom- eilor jodhydrogenayre. Foredredo taercaptogruppor er eksempelvis lavoro alkylox^te eller lavere alkonylerte cjercapto-grupper sora aetyltio, otyltio oller etylentio. Functionally converted hydroxy groups are, for example, preferred or esterified hydroxy groups, as well as functionally converted or capto groups or particularly preferred parent capto groups in consideration. Preferred hydroxy groups are, for example, lower alkoxy groups such as aethoxy or ethoxy. For-©stored hydroxy groups© are for example iaod a taineral acid or organic carbonic or sulphonic acid esteredo hydroxy groups. Organic carboxylic acids are e.g. optionally substituted bejisol acids, alkane, preferably lower alkane carboxylic acids, e.g. benzo or acetic acid. Organic sulfonic acids are e.g. b©ns©n°, p-toluene-, p-broiabenzene-, taétano-, ethane- or othenesulfonic acid. Ctineral acids are preferably halogen hydrogeic acids» e.g. chloro-, bromo-eilor iodohydrogenayre. Preferred tercapto groups are, for example, lower alkyloxy or lower alkonylated tercapto groups such as ethylthio, octylthio or ethylenethio.
Eventuelt funkajonelt oadannode oksogrupper befinner sog spesielt i alfa-stilling til nitrogenatonet, evontuelt foresterede hydroksygrupper og foredrede aercaptogrnapper or spesielt bund ot til bonayliek C-atøtaor. Foredrede hydroksygrupper befinner seg spesielt på C-atotaot til en C-J-J-dobbøltbinding. Eventuelt ytterligere dobbelt bindinger kan vatre ori©ntort såvel esj- sod også endo-syklisk. Optionally functionally added oxo groups are also especially in the alpha position to the nitrogen atom, optionally esterified hydroxy groups and preferred aercaptogrnaps are especially bound to the bonylic C atom. Preferred hydroxy groups are located especially on the C atom of a C-J-J double bond. Any additional double bonds can be oriented both ecso- and endo-cyclically.
Deri reduktive overforing av & q i Ll^utfort på vanlig saåto «ed oasotning med et©gnet reduksjonsmiddel. There reductive conversion of &q in Ll^outfort in the usual way «ed oasotization with a suitable reducing agent.
Sea reduksjonsiaiddel kosmaor spesielt i betraktning! Naseerende, eksempelvis freastilt vod innvirkning av en forbindelsefeed labilt hydrogen pa ete tallet, f. eks. en protonsyr©sota en halogenhydrogensyre eller lavere alkasikarbonsyre, på jern oller eventuelt aiaalgort sink, magnesium eller aluiainiua eller taed vann på, fortrinnsvis ataalgert aluniniura, magnesium eller natrium, f.oks. hatriuiaaiualgae, ellor eksempelvis fremstilt ved hydrogeneringskatalysator soa en nikkol-©Iler©del-laetallkatalysator, f.oks. vod Ikmoy- oller eventuelt på kjemisk eller på©n bsrebundet foro, f.oks. som oksyd, foreliggende platin, sop platin på karbon eller,poa platihokeyd oller ved homogene odeliaétallkatalysatoror sota trifenylfosfin-platin-klorid eller trifenyiiosfin-rhodiuiaklorid, katalytisk aktivert hydrogen, vider©lav-verdigo overgangsraetallforblndelser sos tinn-II-©Iler krom-II-salter, f.oks. tinn-II-klorid, eller hy-drider soa kalsiuohydrid oller borhydrid-tetrahydrofurankocsplek-set eller dilettjaotallhydrider som litiuaaiuffiiniurahydrid, ovon-tuolt i blanding taed aluciniuaklorid, natriuc3-bis-(2-E5otoksy-etokey) -aluciniucaiydrid oller natriuta-tris-(2-diE30tylat3ino-etoksy)-aluc3inlui2hydrid, aatriutnborhydrid ellor natriuctcyanbor-hydrld. Sea reduction aiddel kosmaor especially in consideration! Nasating, for example exposed to the influence of a compound feed labile hydrogen on the number, e.g. a protonic acid©sota a halogenhydrogen acid or lower alkasicarbonic acid, on iron or possibly aiaalgorted zinc, magnesium or aluminum or taed water on, preferably ataalgered aluniniura, magnesium or sodium, e.g. hatriuiaaiualgae, or for example produced by hydrogenation catalyst soa a nickel-©Iler©del-laetal catalyst, e.g. vod Ikmoy-oller possibly on chemical or on©n bsrebonded foro, e.g. as oxide, present platinum, sop platinum on carbon or, poa platyhokeyd or by homogeneous odeliaétal catalystsor sota triphenylphosphine-platinum-chloride or triphenyiiosphine-rhodiuiachloride, catalytically activated hydrogen, further © low-valued transition raetal compounds sos tin-II-©Iler chromium-II- salts, e.g. tin-II chloride, or hydrides such as calcium hydride or borohydride-tetrahydrofurancox complex or dilettiotal hydrides such as lithiuaaiulfiniurahydride, ovone-tuolt in a mixture with aluciniua chloride, natriuc3-bis-(2-E5otoxy-ethokey)-aluciniucaihydrid or natriuta-tris-( 2-diethylamino-ethoxy)-alucylaminohydride, atriutinoborohydride or sodium cyanoborohydride.
Omsetningen kan utfores på en oåte som for den aktuelle omsetning er funnet egnot i literaturon. The turnover can be carried out on a basis which for the turnover in question has been found to be acceptable in the literature.
Eventuelt forestorede eller forodred©, til en benayl-isk karbonatora bundeto hydroksygrupper, ketoniske oksygrupper og/eller grupper Rq sota inneholder i det minste en dobbeltbind» ing, kan ved vanlige omsetninger»f.eks. soia angitt ovenfor, reduseres med katalytisk aktivt hydrogen, eksempelvis taed ot hydrogen i narver av palladiuta på karbon, oa nødvendig i et inert oppløsningstaiddol soa ot lavere alkanol, on lavere alkaasyre oller en alifatisk eter, f«eks* i etanol, eddiksyr©©Hør dioksan, og/eller vod forhøyet teeperatur. Optionally enlarged or substituted, hydroxy groups, ketonic oxy groups and/or groups Rq sota contain at least one double bond, bound to a benayl carbonator, can by ordinary reactions, e.g. as stated above, is reduced with catalytically active hydrogen, for example hydrogen in grains of palladium on carbon, oa necessary in an inert solution such as a lower alkanol, a lower alkanol or an aliphatic ether, e.g.* in ethanol, acetic acid©© Hear dioxane, and/or vod elevated tea temperature.
Hester Rcsom inneholder ketoniske oksygrupper»sulfonylgrupper og/eller foredrede tiereaptogruppør, kan vidoro reduseres ved vanlig omsetning»f.eks, sota ovenfor froeastilt, nas-cerendo hydrogen»eksempelvis etter fresagangsiaåten av Clecaconsst, fortrinnsvis med sink og saltsyre. Horses Rc containing ketonic oxygroups»sulfonyl groups and/or preferred thieraptogroups can be reduced by ordinary reaction»eg, sota above froeastilt, nas-cerendo hydrogen»for example after fresagangsiaat of Clecaconsst, preferably with zinc and hydrochloric acid.
Hester Uq som inneholder halogen bundet til C-atooet i en C-N-dobbe It binding med foredret hydroksy gruppe og sota inneholder oinst en, ytterligere dobbeItbinding og/eller lactaoiske, henholdsvis ataidiske oksogrupper, kan eksempelvis vod vanlig omsetning reduseres med et egnet dilett&etollhydrid som et av do nevnte, on nodvendig i et inert oppløsningsoiddel og/eller ved forhøyet teiaperatur, f.oks. kokepunkt temperatur, utgående fra halogénforbindelser ekseiapolvis med natriuuborhydrid i vann, alkoholer som etanol, eller etylenglykomoiaeryieter, eller aminer sota pyr i din, triotyiamin, med natriuta-bis-(2-iaetoksyotoksy)- alu-miniurahydrid i aromatiske ellor aralfatiske hydrokarboner sota beiisol eller toluol, eller taed natriuGJ-tris-(ditaotylatainoetoksy)-alutniniuiahydrid, eller utgående fra lactotaer ellor auidcr eksempelvis méd litlumalutainiurnhydrid 1 en alifatisk oter, f.eks. i dietyletor, tetrahydrofuran eller dioksan, om nødvondig ved kokepunkt temperatur. Hester Uq which contains a halogen bound to the C atom in a C-N double bond with a preferred hydroxy group and the soot contains at least one, additional double bond and/or lactaoic, respectively ataidic oxo groups, can for example be reduced by normal reaction with a suitable dilettol hydride as a of the aforementioned, is necessary in an inert solution part and/or at elevated temperature, e.g. boiling point temperature, starting from halogen compounds exeiapolwise with sodium borohydride in water, alcohols such as ethanol, or ethylene glycomoyaeryether, or amines sota pyr in din, triothiamine, with natriuta-bis-(2-iaethoxyotoxy)- aluminum miniurahydride in aromatic or aralphatic hydrocarbons sota beiisol or toluene, or taed natriuGJ-tris-(ditaotylatainoethoxy)-alutniniuiahydride, or starting from lactotaer or auidcr for example with low-malutainiurnhydride 1 an aliphatic oter, e.g. in diethyl ether, tetrahydrofuran or dioxane, if necessary at boiling temperature.
Substituerte hydraaonogrupper, f.oks. (p-toluolsulfo^ nyl)-hydrasono, sont inneholdos i res tor Kg kan sop angitt erstattes taed hydrogen ved vanlig omsetning taed©t diletttaetallhydrid, f.eks. taed natriuatcyanborhydrid i heksametylfosforsyre-triamid, oat nødvendig ved forhøyet temperatur. Semikarbasono-eller usubstituerto hydrasonogruppar soa inneholdes i rester Rq kan eksempelvis reduseros ved vanlig otasetning mod on sterk base, eksempelvis otter fremgangsmåte fra uol£f-Kishnor,. taed ot alkali-alkoholat, f.eks. ned natriucuaetanolat, om nødvendig vod for-høyet trykk og/eller ved forhøyet temperatur ellor etter modifi-kasjoner fra Huang-Minlon taed et alkalimotallhydroksyd, f .eks. kaliumhydroksyd, i ct inert, høytkokende opp løsnings taiddel, f. eks. i di- ellor trietylenglykol oller dietylenglykoltaonoBietyleter. Substituted hydraano groups, e.g. (p-toluenesulfo^nyl)-hydrazone, sont contained in res tor Kg can sop indicated be replaced by taed hydrogen by ordinary reaction taed©t dilettaetal hydride, e.g. taed sodium cyanoborohydride in hexamethylphosphoric acid triamide, oat necessary at elevated temperature. Semicarbazone or unsubstituted hydrazone groups that are contained in residues Rq can, for example, be reduced by ordinary addition against a strong base, for example by the method from Uolf-Kishnor. taed ot alkali alcoholate, e.g. down sodium ethanolate, if necessary under elevated pressure and/or at elevated temperature or after modifications from Huang-Minlon taed an alkali metal hydroxide, e.g. potassium hydroxide, i ct inert, high-boiling part of solution, e.g. in di- or triethylene glycol or diethylene glycol taonoBiethyl ether.
I en forotrukket utførolsesform ved foreliggende fremgangsmåte utga taan eksempelvis fra en forbindelse taed formelen IV, hvori resten Hq betyr en rest lij, taed minst en til nitroges-atotaet bundet karbonylgruppe, eksempelvis on i 1-stilling etod eventuelt substituert benaoyl substituert plperldyl- oller 2- piperidonrest oller eia i l-etilllug taed eventuelt substituert bonsyl substituert 2-piperIdoiarest, og reduserer oksogruppen(o) vod oasetning med et ognot diletttaetallhydrid, f.eks. moti- li-titaaaluiainiuobydrid i en oter, f.oks. i diotyleter oller totra-hydrofuraa, oa nødvendig ved fornøyet tempera tur, f. eks. ved kokepunkttoiispora tur. In a preferred embodiment of the present method, the reaction starts, for example, from a compound of the formula IV, in which the residue Hq means a residue lij, at least one carbonyl group bound to the nitrogen atom, for example on in the 1-position etod optionally substituted benaoyl substituted plperldyl or 2 - piperidone residue or else in 1-ethyl alcohol with optionally substituted bonsyl substituted 2-piperidone residue, and reduces the oxo group(o) without addition with an ognot dilettaethyl hydride, e.g. moti- li-titaaaluiainiuobydrid in an otter, e.g. in diethyl ether or totra-hydrofuraa, oa necessary at a suitable temperature, e.g. at boiling point toiispora turn.
Ved en armom foretrukket utførolsesf©ret utgår man fra on forbindelse ned formelen IV, hvori &c botyr en eventuelt i fenyldelen av beasayirøetea substituert Kf-bønaylpyridiniutarost s og reduserer tainst to av dobbeltbindlngene i gyridiniutarosten til enkoltbindingor. Dersom man anvender som reduksjonsmiddel hydrogen i nervar av en platin-©Iler riiodiuokatalysator, f.eks. piatin på karbon, pla tin oksyd, oller trifenyifosf in-fihoditsia-kloridkotaploksot, ellor litiuiaaluuiiniuahydrid i en eter, eoe dietyleter©Iler tetrahydrofuran, erholder laan fortrinnsvis forbindelser taed foraelen 1, hvor H-j inneholder en aettet piporidylrest. In a particularly preferred embodiment, one starts from a compound of the formula IV, in which &c botyr an optionally substituted Kf-bønaylpyridinium ester s in the phenyl part of the beasayyl ester and reduces at least two of the double bonds in the gyridinium ester to single carbon bonds. If hydrogen is used as a reducing agent in the form of a platinum-©Iler riiodiocatalyst, e.g. piatin on carbon, platinum oxide, or triphenyphosphin-fihodicia-chloride kotaploxote, or litiuiaaluuiniuahydride in an ether, eoe diethylether©Iler tetrahydrofuran, laan preferably obtains compounds taed forael 1, where H-j contains an aetated piperidyl residue.
Derimot erholder aan ved anvendelse av svakvirkende di°lottiaøtallhydrider, f.oks. natriuaborhydrid i on lavoro alkonol som etanol, fortrinnsvis forbinde Is or seed foraelen I, hvori R|inneholder en 1, 2, 5»6-tetrahydropyridyirosfc. In contrast, aan is obtained by using weakly acting di°lottiaetal hydrides, e.g. sodium borohydride in on lavoro alkanol such as ethanol, preferably connecting Is or seed formula I, in which R|contains a 1, 2, 5»6-tetrahydropyridyirosfc.
Likeledes kan karboksygruppen ooeq eventuelt kan for©lig°ge i saltform, f.eks. natriuosalt, kopporsalt oller assaoniuosalt, orstattes taed hydrogen. Ikirboksygruppen er fortrinnsvis bundet til C-atornet til hvilket rosten -PhKg er bundet i roston Hc, Ombyttningen av denne med hydrogon utføros fortrinnsvis vod dém' karboksyl or ing, oksoapolvis ved opj> varta ing til ca. 100 til 250°CWota nødvendig i et høytkokendo oppløsningstoiddol, f.ok3« i etylen-glykol, ditaetyiforiaaoiu, etylenglykolEJonoeotyloter oller difenyl-etor. Likewise, the carboxyl group ooeq can optionally be present in salt form, e.g. Natriuosalt, copper salt or assaoniuosalt, or replaced by hydrogen. The carboxyl group is preferably bound to the C atom to which the rust -PhKg is bound in the ruston Hc. The exchange of this with hydrogen is preferably carried out vod dém' carboxylation, oxoapolwise by increasing to approx. 100 to 250° CWota necessary in a high-boiling endo solution toiddol, f.ok3« in ethylene glycol, ditaetyforiaaoiu, ethylene glycol EJonoeotylots or diphenyl ether.
Utgangsstoffeno aed foraelen IV er kjente ellor kaia fremstilles ettor i og for seg kjente metoder. The starting materials aed forael IV are known or can be prepared by methods known in and of themselves.
Forbindelser med formolon IV, hvori &c botyr en til don taed en lavere alkylfenylrost -PMi2forbundet C-a totn taed hydroksy-substituerte, eventuelt i fenyldelen substituert 1~bensylpiperi-dylrost, kan f.oks. fremstilles ved oasetning av on tilsvarende N-bcasylpiperidon betl en ved innvirkning av ©ra lavere alkylha-logenbensen med vtsagnesium orholdolig lavere alkylfenylEaagne» ølucihaiogonid, eksempelvis mod foriseleai i^-Ph-i-SgDr, fortrinnsvis i®n eter som dietyleter ellor tetrahydrofuran. Analogt kan også utgangs st of fot fretastillos 1 hvilko Bg ia&eholdør okso-oller hydroksy, idet aaa utgår fra okso- oller lavore hydroksy-alkylhalogenbenson, i hvilke okso- henholdsvis hydroksygruppen er beskyttet, f.eks. okso er acotalisort, og avspalter beokyt-telsesgruppen etter gjennomføringen av omsetningene. Compounds with formolon IV, in which &c butyr one to don taed a lower alkylphenyl rust -PMi2 connected C-a totn taed hydroxy-substituted, optionally in the phenyl part substituted 1~benzylpiperidyl rust, can e.g. is prepared by the addition of the corresponding N-bacylpiperidone but by the action of a lower alkylhalobenzene with hydrogen, or relatively lower alkylphenylEaagne» alcoholichalogonide, for example against foriseleai i^-Ph-i-SgDr, preferably in an ether such as diethyl ether or tetrahydrofuran. Analogously, the starting st or foot can also be prepared 1 which Bg contains oxo-or hydroxy, as aaa starts from oxo-or lower hydroxy-alkylhalobenzone, in which the oxo or hydroxy group is protected, e.g. okso is acotalisort, and spins off the management group after the completion of the transactions.
Forbindelser mod foraolen IV, hvori Uq betyr on taod foresteret eller foredret hydroksy substituert, eventuelt .1 fenyldelen substituert 1-bensylpiperidylrest, kan oksetapelvis erholdes fra tilsvarende, f.eks. sosa ovenfor Herholdelige hy-droksyforbindelser, idet taaa foresterer ©llér foredbnarirjhydrok-sygruppen på vanlig tadto, f.oks. med©t halogonoringBEtiddel sest tionylklorid eller fosfortribroaid, og overforer i halogen oller i et lavere alkanoyloksy^ tBød ot lavere alkankarbonsyroan-hydrid sota acotylklorid, oller vod otasotniag til ot lavere alkoksy med et lavere alkanolat som nati-iutaetaaolat. Compounds against the foraol IV, in which Uq means on taod esterified or preferably hydroxy substituted, possibly .1 the phenyl part substituted by 1-benzylpiperidyl residue, can be obtained from corresponding, e.g. sosa above Retainable hydroxy compounds, in that taaa esterifies ©llér foredbnarirj hydroxy group in ordinary tadto, e.g. with the halogonoring part ses thionyl chloride or phosphorus tribroide, and transfers in halogen or in a lower alkanoyloxy^ tBöd ot lower alkane carbonic acid anhydride sota acotyl chloride, or vod otasotniag to ot lower alkoxy with a lower alkanolate such as nati-iutaetaaolate.
Forbindelser taed fortaelou IV, i hvilke resten Hcinneholder en foredret morcaptogruppo, kan eksetapélvis erholdes idet taan©tasetter en tilsvarende, f .eks. sora ovenfor angitt er-holdelig, halogenf orbindelso taed et lavero alkalitaetallalkyl-tioiat på vanlig aåte. Compounds described IV, in which the residue H contains a preferred morcapto group, can be obtained exemplarily by adding a corresponding one, e.g. sora stated above is-holdable, halogen f compound so taed a lower alkalinity tall alkyl thioate on a regular basis.
Forbindelser taed fortaelen IV, i hvilke resten tic Inneholder en aulfonylgruppo, er eksempelvis tilgjengelig vod vanlig oksydasjon av tilsvarende tioeter, fortrinnsvis taed en organisk porsyre sota SB-klor-perbeasønsyre. Den aed sulfonyl substituerte forbindelse taed formelen IV taed resten -Ph-Rg bundet til C-atotaet kan videre erholdes idet taan kondenserer på vanlig tflåt*bensylsulfon taed dolsfcruktur K2-Ph-CH2-S02- csed tilsvarende 1,3-dihalogen-, sota 1,5-dibrom-W-bensyI-pontan henholdsvis Compounds according to preface IV, in which the residue tic contains an aulfonyl group, are for example available by ordinary oxidation of corresponding thioethers, preferably using an organic poric acid such as SB-chloro-perbeasonic acid. The aed sulfonyl substituted compound taed formula IV taed the residue -Ph-Rg bound to the C atom can further be obtained by condensing taan on ordinary tflat*benzylsulfone taed dolsfkruktur K2-Ph-CH2-SO2- csed corresponding to 1,3-dihalo-, sota 1,5-dibromo-N-benzyl-pontane respectively
-penten. - pretty.
På analog taåte kan også orholdeo forbindelse aed formelen IV, i hvilke resten Uq inneholder en karboksygruppe bundet til C-atotaot til hvilket også er bundet resten -PhRg, idet man på vanlig aåte kondenserer fonyloddiksyro-ostor inneholdende dei» strukturen I^-Ph-Ciu^-COG- taod tilsvarondo l,5-dihalogen-I>J-b©n2!yi-pentan henholdsvis -pentoa. In an analogous way, a compound of the formula IV can also be considered, in which the residue Uq contains a carboxy group bound to the C-atom to which the residue -PhRg is also bound, as one condenses in the usual way the phenolic dioxyroster containing the structure I^-Ph- Ciu^-COG- taod corresponds to 1,5-dihalo-I>J-b©n2!yi-pentane and -pentoa respectively.
Forbindelser aed formelen I¥, hvori Eg botyr on eventuelt i fenyldelen substituert l-benzyl-2-piperldonrest, kan eksempelvis fremstilles idet taaa på vanlig taåt©syklissrer til svarende 5-ben2<y>lataino-(lLj-<f>enyl)-valoriansyro oller et reaktivt som on ester oller et anhydrid derav. På analogEtåtø kan aan også fremstilIo forbindelser mod foretelon IV i hvilken betyr en eventuelt substituert l-benayl»2,6-dioksopiperidylrost. Ber-ved utgår taan fra en tilsvarende kg-fonylglutarsyr© eller et reaktivt derivat, f«eks. et diester eller anhydrid, og omsetter på vanlig filåte mod et tilsvarende bonzylamin. Compounds of the formula I¥, in which Eg butyrone is optionally substituted in the phenyl part with a 1-benzyl-2-piperledone residue, can for example be prepared by using the usual taå©cycliser to correspond to 5-ben2<y>lataino-(1Lj-<f>enyl) -valoric acid or a reactive such as an ester or an anhydride thereof. On analogue Etåtø aan can also prepare compounds against forethelone IV in which means an optionally substituted 1-benayl»2,6-dioxopiperidyl rust. Ber-wood starts from a corresponding kg-phenylglutaric acid © or a reactive derivative, e.g. a diester or anhydride, and reacts in the usual way towards a corresponding bonzylamine.
Forbindelser taed formelen IV, i hvilken Rcinneholder en funksjonell omdannet okso, kan eksempelvis erholdes idet moa i tilsvarende oksoforbindelser omdanner okso-gruppen(e) funksjonelt på vanlig måte, f*eks. ved omsetning med seaikarbasid eller eventuelt overfører substituert hydra2in i aoaikarbasono, henholdsvis hydrosono. Analogt kan iaan overføre oksoforbindelser med formelen IV ved alfcylering, f.oks. cod lavere trialkyl-oksoniutasalter, i tilsvarende ouol- eller laetitaetor. Usubati-tuerte hydrazonoforbindolsor mod foraolen IV kan derved fremstilles fordelaktig in situ, idet man foretar omsetningen taed hydrasin ved forhøyet temperatur, f.eke. ved ca. 100 til 250°C, om nødvendig i et høytkokonde opp løsningsmiddel sota di- eller trietylønglykol©lier dietylenglykoliaonomøtyletor, og i nærver av en base, f.eks. et metallalkoliolat sota natriutstaetanolat, ellor et alkalimetallhydroksyd, f «øks. ka ilurahydr oksyd. Compounds of the formula IV, in which R contains a functional converted oxo, can for example be obtained as moa in corresponding oxo compounds functionally converts the oxo group(s) in the usual way, e.g. by reaction with seaicarbazide or optionally transfers substituted hydra2in in aoaicarbasono, respectively hydrosono. Analogously, iaan can transfer oxo compounds with the formula IV by alphacylation, e.g. cod lower trialkyl oxonium salts, in corresponding ouol- or laetitaetor. Usubatiated hydrazonophorbindolsor against the foraol IV can thereby be advantageously prepared in situ, by carrying out the reaction with hydrazine at an elevated temperature, e.g. at approx. 100 to 250°C, if necessary in a highly concentrated solvent sota di- or triethyleneglycol©lier diethyleneglycolianomoethylether, and in the presence of a base, e.g. a metal alkoliolate sota natriustaethanolate, or an alkali metal hydroxide, e.g. ca ilurahydroxide.
Forbindelser taed formelen IV, i hvilken resten Rq inneholder en i l-stilling eventuelt substituert benssoylrøst, kan eksempelvis fremstilles idet man på vanlig toåte otasetter en forbindelse taed fortaol l& £ - Ph-&2(IVa)»i hvilken Rq\ or usubstituert i l-stilling, fortrinnsvis en forbindelse taed formelen Hg-Ph-R2(il)»hvori Jig betyr en i l-stilling usubstituert, eventuelt enkelt umettet piperidylrest, taed©t bemsoylerings-taiddel, f.oks. bonzoylklorid, om nødvendig i nærvær av et basisk kondensas jonsatlddel, f. eks. na tron lut eller en organisk nltrogenbase, f.eks. pyridin eller trietylatnin. På analog tsåte kan oksoforbindelser taed fortaelen IV erholdes,, hvori Rq betyr eheventuelt substituert N-benzylpyridinrest, idet æaa kvater-niserer en tilsvarende Mg-fehylpyridin med et reaktivt derivat, f.eks. bromidet av en tilsvarendo bensylalkohoi. Compounds of the formula IV, in which the residue Rq contains an optionally substituted benzoyl group in the l position, can for example be prepared by substituting a compound of the formula l& £ - Ph-&2(IVa)»in which Rq\ is unsubstituted in l -position, preferably a compound of the formula Hg-Ph-R2(il)" in which Ig means an unsubstituted in the l-position, optionally monounsaturated piperidyl residue, taed©t bemsoylation part, e.g. benzoyl chloride, if necessary in the presence of a basic condensation ion salt, e.g. sodium hydroxide or an organic nitrogen base, e.g. pyridine or triethylamine. In an analogous way, oxo compounds according to IV can be obtained, in which Rq means an optionally substituted N-benzylpyridine residue, with æaa quaternizing a corresponding Mg-phenylpyridine with a reactive derivative, e.g. the bromide of a corresponding benzyl alcohol.
De nyo forbindelser i hvilko Kj betyr©n i l-stilling med eventuelt substituert benzyl substituort eakolt umettet piperidylrest, kan videre frotostillos idet taan i on tilsvarende forbindelse med formelen The new compounds in which Kj means ©n in the l-position with an optionally substituted benzyl substituted alcohol unsaturated piperidyl residue, can further be frotostilled as the taan in a corresponding compound with the formula
hvori Sjjbetyr©n i l-stilling med eventuelt substituert beaayl og ved en alfa, bota-eliminering tilgjengelig rest substituert piperidylrost, oller ot salt derav, eliminerer denne til samsen med et beta-ståondo hydrogenatom, og om ønskelig separerer en erhalts Stereo-blanding i komponentene, overfører den erhalte forbindelse i en annen forbindelse aed formelen I og/oller oa-danner en erhalt fri forbindelse i ot salt ellor ot orhalt-salt i den frie forbindelse ellor i et annet salt» in which the Sjjbetyr©n in the l-position with optionally substituted beaayl and by an alpha, bota-elimination available residue substituted piperidyl rust, or ot salt thereof, eliminates this to the same with a beta-standing hydrogen atom, and if desired separates an erhalt Stereo mixture in the components, transfers the obtained compound into another compound of the formula I and/or oa-forms an obtained free compound in a salt or an orhalt salt in the free compound or in another salt"
Koster sos til sammen med et i beta-stilling stående hydrogenatom lar seg avspalte er eksempelvis eventuelle fores toredo hydroksygrupper, eventuelt foredrede ellor foroøtoredeEaoreapt©grupper, sulfonlutagrupper, sulfinylgrupper, sulfonylgrupper og aamoniuEigrupper. Forøstoredo hydroksy eller morcapto ér eksempelvis mod en mineralsyro soa on halogenhydrogonsyr©, f.oks* mod brom- eller klorhydrogen, forestere^ hydroksy eller med en organisk syre som en lavore alkankarbonsyro, f.oks. eddiksyro ellor aed xantogenoyre, foresteret hydroksy ellor morcapto. Foredret morcapto er okaeKpelvis lavero alkyltio, ooia aetyltio ©Iler etyltio,©Iler©vontuolt substituert fenyItlo, f.eks. fe<° nyl- p-aøtylf®nyl« ellor p-broiafenyItio. Sulfinyl- og sulfonyl» grupper or©kseiapelvis av do ovenfor angitte foredrede oerc&pto» gruppor avledede sulfinyl- henholdsvis sulfonylgrupper, f»eks» metan-, etan-, bensen-, p-tbluol-aulfteyl* Eiaahøldsvla sialfonyi»Sulf oniuiagrupper or eksempelvis laver© dialkylsulfoniiatagrupper so<q>diaetylsulfoniuta. Ammoniumgruppor or okseeipelvis laver© di°alkyl- eller trialkylss<p>raoniuugrupper, soa dietylaEataonium eller triotylaEjaoniucs oller lavore dialkylacsinoksidgrupperinger, som diotylaialnoksidgrupper. Costs sos together with a hydrogen atom standing in the beta position can be split off are, for example, any pre-redo hydroxy groups, possibly preferred or pre-redoated Eaoreapt© groups, sulfonyl groups, sulfinyl groups, sulfonyl groups and ammonium groups. For example, ester redo hydroxy or morcapto is against a mineral acid soa on halogenhydrogen acid©, e.g.* against bromine or hydrogen chloride, esters^ hydroxy or with an organic acid such as a lower alkane carboxylic acid, e.g. acetic acid or aed xantogenoyre, esterified hydroxy or morcapto. Preferred morcapto is sometimes lower alkylthio, ooia aethylthio ©Iler ethylthio, ©Iler©vontuolt substituted phenylItlo, e.g. fe<° nyl- p-aøtylf®nyl« or p-broiafenyItio. Sulfinyl and sulfonyl groups or, in particular, of the above-mentioned preferred organic groups, derived sulfinyl or sulfonyl groups, e.g. methane, ethane, benzene, p-tbluol-aulfteyl © dialkylsulfoniiata groups so<q>diaethylsulfoniuta. Ammonium groups are usually lower di°alkyl- or trialkylss<p>raoniuu groups, soa diethylaEataonium or triotylaEjaoniucs or lower dialkylacsinoxide groupings, such as diotylaialinoxide groups.
Elimineringen utføroa på vanlig måte og om nødvendig 1 ilsrvcr av katalytiske og/ellor avøpaltningøprodukt«bind©ade nidior, ved forhøyet temperatur, f.oks. ved cae 50 til 200°C ved f.ekSo deatlllativ spesielt asotrop-destillativ .fjernelse av r©°= aksjonsprodukter, og/eller under inort-gass soa nitrogen, for=> trinnovis i et laort opploeningømiddjfeU Katalytisk©Eiidier©r eliko sora lettet©limineriiragon av ekoeapolvio vann, avov©lhy>= drogoa, orgaaioke oyrer, ammoniakk og o©kundar© aminer 0 pro pr©= tonsyrer, f»oka. minera1syrer, fortrinnsvis klorhydrogonsyre, svovelsyro©Hor alkalimetallh<y>dro<g>ensulfator, fosforsyro, p-toluolsulfonsyro eller ioneutbyttere, eller svak©nauklofile baser, f.eks, køliumhydroksyd, soa lettor elimineringen!av mineralsyrer. Avspaltuingeprodukt-bindendo midler or eksempelvis vannbindende midler som disyklobeksylkarbodiimid, eller svovel-, hydrogen- eller mercaptabladende midler som tungiaetallsaltor, f.eks. koppor, sink oller sølvsalter, vider©aaiaoai&kk- henholdsvis aminbindendo midler som mineralsyror. The elimination is carried out in the usual way and, if necessary, 1 ilsrvcr of catalytic and/or avøpaltningøproduct«bind©ade nidior, at an elevated temperature, e.g. at cae 50 to 200°C by e.g.Deatllative especially azotrope-distillative .removal of r©°= action products, and/or under inert-gas soa nitrogen, for=> stepwise in a laort oploeningømiddjfeU Catalytic©Eiidier©r eliko sora eased©limineriiragon of ekoeapolvio water, avov©lhy>= drogoa, orgaaioke oyrer, ammonia and o©kundar© amines 0 pro pr©= tonic acids, f»oka. mineral acids, preferably chlorohydrogonic acid, sulfuric acid ©Hor alkali metal hy<y>dro<g>ensulfator, phosphoric acid, p-toluenesulfonic acid or ion exchangers, or weak ©nauclophilic bases, e.g., collium hydroxide, so lettor the elimination!of mineral acids. Cleavage product-binding agents or, for example, water-binding agents such as dicyclohexylcarbodiimide, or sulphur, hydrogen or mercapta-leaving agents such as tungiaetal salt, e.g. copper, zinc or silver salts, further©aaiaoai&kk- respectively amine binding agents such as mineral acids.
Utgangsstoffene med formelen V or kjente eller kan The starting substances with the formula V were known or can
fremstilles på i og for seg kjent måte. produced in a manner known per se.
Forbindelser med formelen V, hvori il^ inneholder hydroksy oller inercapto til det med rosten -PhlR^forbundet C»ato%kan eksempelvis erholdes idet man omsetter en tilsvarende i-bea-syl-piperidon henholdsvis 1-bonsyl-plporidin-tion med et eventuelt til en okso- ellor hydroksygruppe intertaedior boskyttot ll^ > fenylmagnosiumhalogenid, f.eks. med formelen R2-S<>>h-MgBr. Compounds with the formula V, in which il^ contains hydroxy or inercapto to the C»ato% connected to the rust -PhlR^ can be obtained, for example, by reacting a corresponding i-beasyl-piperidone or 1-bonsyl-plporidine-thione with an optional to an oxo-ellor hydroxy group intertaedior boskyttot ll^ > phenylmagnesium halide, e.g. with the formula R2-S<>>h-MgBr.
£)e nyo forbindelser kan vidcro fremstilles idet man i en forbindelse med formelen £)e new compounds can be vidcro prepared by using a compound with the formula
hvori R-tø betyr en 1 en rest R^ overførbar gruppo,©Iler et.salt dorav, overføror HE i fl2og om ønskelig skiller on erhalt stereoisomerblanding i komponentene, overfører den erhalte forbindelse i on annen forbindelse med formelen X og/eller omdanner©a erhalt fri forbindelse i et salt eller et erhalt-salt i en fri for* bindelse eller i et annet salt. in which R-tø means a 1 a residue R^ transferable group,©Iler et.salt thereof, transferor HE in fl2and if desired separates the obtained stereoisomer mixture into the components, transfers the obtained compound into another compound with the formula X and/or converts© a free compound obtained in a salt or a salt obtained in a free compound or in another salt.
I rester li2overførbare gruppor er eksempelvis forskjellige fra Sg og reduktiv og/eller solvolytisk i R2overførbare grupper, eksempelvis umettod© og/eller funksjonelt omdannede okso og/eller funksjonelt omdannede hydroksy substituerte lavere alifatiske rester. In residues li2 transferable groups are, for example, different from Sg and reductively and/or solvolytically in R2 transferable groups, for example unsaturated and/or functionally converted oxo and/or functionally converted hydroxy substituted lower aliphatic residues.
Funksjonelt omdannede oksogrupper or eksempelvis tiokso, oventuelt substituerte irainogrupper eller acetaliserte henholdsvis tioacetailserto oksogrupper, videre hydratisert© oksogrupper og estere av de sammew Functionally converted oxo groups or, for example, thioxo, above-twin substituted iraino groups or acetalized or thioacetylserto oxo groups, further hydrated © oxo groups and esters of the same
Som substituera ter for imiaio kocmer okeocspelvio i betraktning eventuelt substituert feayl, lavere alkyl ellor vider©hydroksy©Hor mod lavore 2-sulfoaylaikyl,. ooa lavoro 2<=besiaen° sulfonylalkyl ©Her 2-(p-toluolsulfonyl)-alkyl, og substituert aiaino. Acotalisert©oksogrupper er eksempelvis aed ot laver© alkoaol, som metanol oller otanol,©Iler ot laver©alkandiol,3om etylen- oller propylenglykol, acotalisert© oksogrupper. Analogt forståes vod tioacotaliserte oksogrupper eksempelvis mod©t lavere alkantiol, sosa metyl- eller etylmorcaipitan, ©Her en lavere alkandltiol, som 1,2-dimercaptoetaa eller 1,3«,tliai©r<» captopropan, tioacetaliserto oksogrupper» Ester©med hydrati» sorto oksogrupper or eksempelvis slik©med en caiaør&løyr© soaa©n halogesihydrogensyré, f.oks. klorhydrogoasyro. As substitutes for imiaio kocmer okeocspelvio in consideration of optionally substituted feayl, lower alkyl or further©hydroxy©Hor mod lavore 2-sulfoaylaikyl,. ooa lavoro 2<=besiaen° sulfonylalkyl ©Here 2-(p-toluenesulfonyl)-alkyl, and substituted aiaino. Acotalized ©oxo groups are, for example, aed ot laver© alcohol, such as methanol or ethanol, ©Iler ot laver©alkandiol,3 or ethylene or propylene glycol, acotalized© oxo groups. Analogously, vod thioacetalized oxo groups are understood, for example, against lower alkanethiol, sosa methyl or ethylmorcaipitan, ©Here a lower alkandlthiol, such as 1,2-dimercaptoetaa or 1,3«,tliai©r<» captopropane, thioacetalizedto oxo groups» Ester©with hydrati » sorto oxo groups or, for example, such©with a caiaør&løyr© soaa©n halogenohydrogen acid, e.g. chlorhydrogoacido.
Funksjonelt omdannede hydroksygrupper er eksompolvis foredrodø©Iler foresterode hydroksygrupper. Forødr©;*.:' hydroksy er eksempelvis lavere alkoksy som metoksy oller etoksy©Hor eventuelt substituert fenoksy. Foresteret hydroksy er'eksem-. pelvl8mod©n minoraløyro, som en halogon-hydrogensyr©, fores terot hydroksy, f»eks. klor oller brom, mod on organisk sulfonsyre, som en lavere alkan- oller en eventuelt substituert bensensulfonsyr© foresteret hydroksy, f.eks. metan-,©tan-, p-toluol-, p-brombenzen- oller iaesitylensulfonyloksy,©Iler med en karbonsyre, som en lavere alkaaayro©Iler eventuelt substituert bønzeasyre, eller eventuelt partielt foresteret ellor<*>amidiert karbonsyre foresteret hydroksy, soa lavere alkaaoyl-oksy, f.eks. acetoksy, bensoyloksy, lavere alkoksy», f.eks. metoksykarbonyloksy oller korbamyloksy. Functionally converted hydroxy groups are predominantly esterified hydroxy groups. Substituted hydroxy is, for example, lower alkoxy such as methoxy or ethoxy or optionally substituted phenoxy. Esterified hydroxy er'exem-. pelvl8mod©n minoraløyro, as a halohydrogen acid©, fores terot hydroxy, e.g. chlorine or bromine, mod on organic sulphonic acid, as a lower alkane or an optionally substituted benzene sulphonic acid © esterified hydroxy, e.g. Methane-, methane-, p-toluene-, p-bromobenzene- or acetylenesulfonyloxy, ©Iler with a carboxylic acid, such as a lower alkaayro©Ir optionally substituted benzoic acid, or optionally partially esterified or or<*>amidated carboxylic acid esterified hydroxy, soa lower alkaoyloxy, e.g. acetoxy, benzoyloxy, lower alkoxy', e.g. methoxycarbonyloxy or corbamyloxy.
Som grupper ur-, kommor spesielt 1 betraktning. As groups ur-, chamber especially 1 consideration.
Laver©alkenyl, som vinyl, allyl oller metallyi, lavere alkiayl, som etinyl©Iler 1-propinyl, eventuelt foresteret ©Her aahyd-ridisort karboksy-, karboksy lavore alkyl- og karboksy lavere alkeaylgruppor, som tilsvarende laver© alitoksykarbonyl,©iler halogenkarboayl inneholdende rester, foresteret eller foredret lavere hydroksyalkyl(en)ylrestor, som lavor©alkanoyloksy-oller eventuelt bensoyloksykarbonyIrester, lavore alfa-ellør omega- halogenalkylrester, omega-sulfonyloksy-, f.eks. omega-(p-toluolsulfonyloksy)-lavero alkylrester, eller lavore alkyl-etor av lavero alkyl-onoler, videre tioksfpalkylr©st©r eller geminal© lavere dialkoksy- eller alkylendiokøy-alkylrostor. Lower alkenyl, such as vinyl, allyl or metally, lower alkyl, such as ethynyl or 1-propynyl, optionally esterified Here aahyd-ridisort carboxy-, carboxy lower alkyl and carboxy lower alkeayl groups, which correspondingly lower© alytoxycarbonyl, ©yl halocarboyl containing residues, esterified or preferably lower hydroxyalkyl(en)yl residues, such as lavor©alkanoyloxy-or possibly benzoyloxycarbonylIresters, lavaro alpha-or omega-haloalkyl residues, omega-sulfonyloxy-, e.g. omega-(p-toluenesulfonyloxy)-lower alkyl residues, or lower alkyl ethers of lower alkyl onols, further thioxfpalkyl residues or geminal© lower dialkoxy or alkylenedioxy alkyl groups.
Den reduktiv© overføring i ESj. utfores ottor i og for seg kjent©metoder,©ksempolvis ved katalytiske hydrerisag eller omsetning med lettmetall- ellor dilettmotallhydridor0 Sålodoa kan man reduser©lavere alkenyl, lavere alkinyl eksempelvis ved innvirkning av katalytisk aktivert hydrogen, som hydrogen i .V. nærvær av on hydreriagskatalysator, fortrinnsvis©n nikkel-, platin oller rhodiumkatalysator, f .eks. Ran oy-nikk© 1, pla tisa eller platinoksyd på karbon eller ot platlnklorld- oller rhodi-umklorid-trifenylfosfinkomploks, til lavere alkyl. Derved arbeider man på vanlig måte fortrinnsvis 1 ot inert opplosnings-middel, som en lavere alkanol, f.eks. metanol eller en lavero alkankarbossyre, f.eks. eddiksyre, om nødvendig ved forhøyet trykk, f.oks. opptil ca. 25 bar, fortrinnsvis i et lukket kar. Analogt kan man også redusere halogenkarbonyi eller halogenkar-bonyl lavor© alk(en)yl til lavero hydroksyalky1. The reductive © transfer in ESj. is carried out in and of itself known©methods,©for example by catalytic hydrogenation or reaction with a light metal or dilettmetal hydridor0 In this way, one can reduce©lower alkenyl, lower alkynyl for example by the influence of catalytically activated hydrogen, such as hydrogen in .V. presence of a hydride catalyst, preferably a nickel, platinum or rhodium catalyst, e.g. Ran oy-nick© 1, pla tisa or platinum oxide on carbon or ot platlnchlorldol- or rhodium-um chloride-triphenylphosphine complex, to lower alkyl. Thereby, one usually works with preferably 1 ot inert solvent, such as a lower alkanol, e.g. methanol or a lower alkanecarboxylic acid, e.g. acetic acid, if necessary at elevated pressure, e.g. up to approx. 25 bar, preferably in a closed vessel. Analogously, one can also reduce halocarbonyi or halocarbonyl lower© alk(en)yl to lower hydroxyalkyl1.
Lavere hydra a onalfcy1 K£kan videre på vanlig måt©vod basebehandling reduseres, f.oks. til frem<g>an<g>småten av tfolff-Kishner, med©t alka lim© tal lalkoholat, f.oks. med natriutoaiota-nolat, om nødvendig under forhøyet trykk ved ca. 100 til 250°C, eller etter Huang-Minlon med et alkalimetallhydrøksyd, f.oks. med kaliumhydroksyd, i et inert, høytkokende oppløsningsmiddel, f.oks. di- oi-io./..Oiiglykol, til lavere alkyl Ii2. Lower hydra a onalfcy1 K£can further be reduced in the usual way©vod base treatment, e.g. to the method of tfolff-Kishner, med©t alka lim© tal lalkoholat, e.g. with natriutoaiota nolate, if necessary under elevated pressure at approx. 100 to 250°C, or according to Huang-Minlon with an alkali metal hydroxide, e.g. with potassium hydroxide, in an inert, high-boiling solvent, e.g. di- oi-io./..Oiiglycol, to lower alkyl Ii2.
Videre kan oan eksempelvis redusere eventuelt foredrotio Furthermore, oan can, for example, reduce any foredrotio
.oller anlayaricliserto karboksy- eller karboksy- lavore alkylgruppor vod omsetning med lettmetall- eller dilettmetallhydridor til okso- eller lavere hydroksyalkyl. For reduksjonen til lavere oksoalkyl anvender man fortrinnsvis lavere aikyllitiumalu-mlniumhydrider, som dlisobutyl- eller triisobutyllitlumaluminl-umhydrid, hvorved man for reduksjonen til lavero hydroksyalkyl fortrinnsvis anvender lltiumalumlniumhydrid i en eter, som dletyleter eller tetrahydrofuran. Ved den nevnte reaksjonen arbeider man fortrinnsvis under iaert-gass, f.eks. under nitrogen oller argon, om nødvendig ved kjøling eller oppvarmning, f.eks. ved ca. - 20 til ♦ S0°C. På analog måte kan man også primer© halogen henholdsvis sulfonyloksy inneholdende halogen-henholdsvis lavere sulfonylalkylgrupper reduser© til laver© alkyl mod en karbonsyre eller den partielt forostoredo oller .oller analyariclyserto carboxy- or carboxyl-lower alkyl group by reaction with light metal or dilite metal hydride to oxo- or lower hydroxyalkyl. For the reduction to lower oxoalkyl, lower alkyl lithium aluminum hydrides are preferably used, such as diisobutyl or triisobutyl lithium aluminum hydride, whereby for the reduction to lower hydroxyalkyl, lithium aluminum hydride is preferably used in an ether, such as diethyl ether or tetrahydrofuran. In the aforementioned reaction, one preferably works under inert gas, e.g. under nitrogen or argon, if necessary during cooling or heating, e.g. at approx. - 20 to ♦ S0°C. In an analogous way, one can also prime© halogen or sulfonyloxy containing halogen-respectively lower sulfonylalkyl groups reduce© to lower© alkyl against a carboxylic acid or the partially enlarged redo
amidierte karbonsyre forcsteredeV, lavere hydroksyalkylgrupper \til lavere hydroksyalkyl.'Analogt kan man også som angitt redusere substituert lavere hydrasonalkyl til laver©alkyl, eksempelvis med natriumborhydrid i^hoksafosforsyretriamid. amidated carboxylic acid esterifiedV, lower hydroxyalkyl groups \to lower hydroxyalkyl. Analogously, as indicated, substituted lower hydrazone alkyl can also be reduced to lower alkyl, for example with sodium borohydride and xoxaphosphoric acid triamide.
Likeledes som reduksjon er å forstå den reduktiv©lavere alkylering av eventuelt forostered© ©Her anhydridloort©karboksy- eller karboksy lavero alkylgruppor K-^aed laver©al-kyisaetallforbindelser til okso- ellor hydroksy lavere alkyl-grupper Kg. Lavero alkylmotaleforbindelser or eksempelvis©like, sosa taotallradikal en gruppe aed foraol -W<1>, -H<I3:>-Hal ©Iler 1^/ 2, hvori 14^" botyr et metallatom fra gnappea I, r-3 Xi- betyr ot cio» tallatom fra gruppen II i det periodiske system og Hal betyr halogen, sota klor, brota eller jod. Foretrukne taetallradikalor av den nevnte art©r slike aed formel -Li, -23gHal>= og -Gci/2. Similarly, reduction is to be understood as the reductive ©lower alkylation of possibly esterified© ©Here anhydridloort©carboxy- or carboxy lowero alkyl group por K-^aed lower©al-kyisaetal compounds to oxo-or hydroxy lower alkyl groups Kg. Lower alkyl metal compounds are, for example, the same, such as a total radical with a group aed foraol -W<1>, -H<I3:>-Hal ©Iler 1^/ 2, in which 14^" is a metal atom from group I, r-3 Xi- means ot cio» tall atom from group II in the periodic table and Hal means halogen, sota chlorine, brota or iodine. Preferred taetal radicals of the mentioned species are such aed formula -Li, -23gHal>= and -Gci/2.
Eventuelt funksjonelt omdannede karbokaygruppor foro-ligger eksempelvis i saltform, som oksemp©! 1 form av alkali-motallsalt, f.eks. som natrlumsalt,©Iler sop anhydridisorto karbokaygruppor, fortrinnsvis aakydridioort mod on halogen-hydrogenøyr© som fluor-, klor-, brom- eller jod0som foreator-ede karboka<y>gru<p>por, som lavoro alkoksykarbonyi, ellor©vontuolt substituert bensoyloksykarboayl eller disubstituerte karbamyl«=> grupper, som lavere N,N-dialkylkarbamyl eller l-lmidasolin-karbonyl. Omsetningen med eventuelt funksjonelt omdannede karbonsyrer mod formelen VX med don nevnte lavere alkylmetallfor-bindels© utført på vanlig mdto. fortrinnsvis i et iaort oppløs» ningsmiddel som en eter, f.oks. i dietyleter ©Hor totrahydro-furan, et hydrokarbon, f.eks. bonson,©iler blandinger av disa©, dersom erforderligt ved avkjøling eller under lett oppvartning, f.eks. ved ca. -fcJO til ca. 100°C, f.eks. vod koketemperatur, og/ ellor under iaertgass, f.eks. under nitrogen. Derved©rholdes i avhengighet av anvendt©utgangestoffor og roaksjomsbetingolsor on ten ketoner (Kg ej okso laver©alkyl) oller tor tiøre alkoholer (Hg hydroksy laver© alkyl) mod form©I©n I. Sålod©s©rholdes '.t?o<? anvendelse -av reaktive lavere alkylsjagn©siuEshalog©nid©r©Iler lavore litiumalkyler, og vod normal eller forhoyet temperatur, f.eks. vod ca. 0°C til ca. 100°C, hovedsaklig© forbindelser med formelen I, hvori Sg & r lavere hydroksyalkyl, og vod nedsatt temperatur, f.©ks. ved -80 til 0°C,©Iler ved anv©nd©ls©av mindre reaktive lavere alkylmetailforbindelser, f«eks. laver© alkylkadmiuraforbindelsor, under normale temporaturbetingelser fortrinnsvis forbindelser med formelen 1, hvori &«->er okoo lavero alkyl. Få analog måte kaa oksoforbindoloo mod formelen I, i hviHkon Rg er lavore alkyl, ©rholdoe idot oa» omsetter em for«= biadols© aed formelen VI, hvori R~ er halogen- eller auIfonyl-oksy laver© alkyl, med en av de nevnt©lavere alkylmotallfor-blndelser, spesielt et lavore litinmalkyl. Possibly functionally converted carbokai groups are available, for example, in salt form, such as beef samp©! 1 form of alkali metal salt, e.g. such as sodium salt, ©Iler sop anhydridisorto carbokaygruppor, preferably aakydridioort mod on halogen hydrogenear© such as fluorine, chlorine, bromo- or iodo0as foreator-ed carboca<y>gru<p>por, as lavoro alkoxycarbonyyi, or©vontuolt substituted benzoyloxycarboyl or disubstituted carbamyl groups, such as lower N,N-dialkylcarbamyl or 1-imidazoline carbonyl. The reaction with possibly functionally converted carboxylic acids towards the formula VX with the above-mentioned lower alkyl metal compound© is carried out in the usual mdto. preferably in an inorganic solvent such as an ether, e.g. in diethyl ether ©Hor totrahydro-furan, a hydrocarbon, e.g. bonson,©iler mixtures of disa©, if required during cooling or during light waiting, e.g. at approx. -fcJO to approx. 100°C, e.g. above boiling temperature, and/or under mineral gas, e.g. under nitrogen. Depending on the starting material used and the reaction conditions, ketones are obtained (Kg not oxo lower alkyl) or higher alcohols (Hg hydroxy lower alkyl) against form I. o<? application - of reactive lower alkyl shagn©siuEshalog©nid©r©Iler lower lithium alkyls, and vod normal or elevated temperature, e.g. water approx. 0°C to approx. 100°C, mainly © compounds with the formula I, in which Sg & r lower hydroxyalkyl, and vod reduced temperature, e.g. at -80 to 0°C, ©Iler by use of less reactive lower alkyl metal compounds, e.g. lower alkyl cadmium compounds, under normal temperature conditions preferably compounds of the formula 1, in which &«-> is okoo lower alkyl. Obtain an analogous way of oxophorbindoloo against the formula I, in which Rg is lower alkyl, ©rholdoe idot oa» converts em for«= biadols© aed the formula VI, in which R~ is halogen- or auIfonyl-oxy lower© alkyl, with one of the mentioned © lower alkyl motal compounds, especially a lower litim alkyl.
Ved solvolyse kan man oksompelvis i det minst©overfer©en funksjonelt omdannet okso»©g/ellor hydroksygruppe isamahold-©ndo rest Kg i©n okso- oller©n hydroksygruppe inneholdende rest Eg. Eksempelvis kan man i forbindols©med formelen VI, hvori lig inneholder tiokso, eventuelt substituert ioino, gemi-nale ellor til en dobbeltbinding bundne foredredo hydroksygrupper, hydrolisere til forbindolsor mod formelen I, hvori kg betyr okso lavere alkyl, ellor forbindelse mod formelen VI, hvori inneholder foresteret hydroksy, til forbindelser mød formelon I, hvori £2e^r lavere hydroksyalkyl. Hydrolysen utføres på vanlig måte, eksempelvis i nærvær av et basisk oller surt hydroly-s ©middel, om nødvendig i nssrvtsr av ot opp løsningsmiddel og/oller vod forhøyet temperatur, f.eks» ved ca. 20 til I50°C. By solvolysis, one can, for example, transfer at least a functionally converted oxo»©g/or hydroxy group containing a residue Kg into an oxo-or ©a hydroxy group containing residue Eg. For example, compounds of the formula VI, in which lig contains thioxo, possibly substituted ioino, geminal or preferred hydroxy groups bound to a double bond, can be hydrolyzed to compounds of the formula I, in which kg means oxo lower alkyl, or a compound of the formula VI, in which the ester contains hydroxy, to compounds similar to formelon I, in which £2e^r lower hydroxyalkyl. The hydrolysis is carried out in the usual way, for example in the presence of a basic or acidic hydrolysis agent, if necessary in the presence of a solvent and/or at an elevated temperature, e.g. at approx. 20 to 150°C.
Basisk© kondensasjonsmidler©r eksoiapelvls alkalimotall-, ammonium-©Iler kloralkalimetallhydroksyder ©Hor tilsvarende karbonater, f.eks. natrium-, kalium- oller kalsiunhydroksyd, ammoniakk ©Hor kalium- eller natriurakarbonat• Sure hydrolys©-midler or oksempelvis protonsyrer som mineralsyrer, f.eks. salfc-eller svovelsyre, sulfonsyror, f.oks. p-toluolsulfonsyre, eller karbonsyrer, som eddiksyr©. Inerto oppløsningsoidler er eksempelvis med vannblandbare oppløsningsmidlør som laver© alkanolor, f.oks. metanol eller otanol, ketoner, f.oks. acoton, amider, f.eks. dimetylformaiaid eller N-metylpyrrolidon, oller sulfoksydeq f.eks. dimotylsulfoksyd. Ved hydrolyse av laver© tioksoalkyl arbeider man videre om nødvendig i ærvær av en tuaga©tallfor» bindelse, f.eks. kofferoksyd, eller ot oksydasjonsoiddol, f.oks. hydrogenperoksyd ellor organisk©persyrer. Basic© condensing agents©r exoiapelvls alkali metal-, ammonium-©Iler chloralkali metal hydroxides ©Hor corresponding carbonates, e.g. sodium, potassium or calcium hydroxide, ammonia ©Hor potassium or sodium carbonate• Acid hydrolysis© agents or for example protonic acids such as mineral acids, e.g. sulfuric or sulfuric acid, sulphonic acids, e.g. p-toluenesulfonic acid, or carboxylic acids, such as acetic acid©. Inert solvents are, for example, with water-miscible solvents that reduce alkanol, e.g. methanol or ethanol, ketones, e.g. acotone, amides, e.g. dimethylformaiide or N-methylpyrrolidone, or sulfoxide, e.g. dimotyl sulfoxide. In the case of hydrolysis of lower thioxoalkyl, further work is carried out if necessary in the presence of a tuaga©tallfor» bond, e.g. copper oxide, or ot oxidationoiddol, e.g. hydrogen peroxide or organic peracids.
Iled©n karbonsyre forostorot laver©, hydroksyalkylrest il- f, kan vidoro ved omsotning med en lavore alkohol, som en laver©alkanol, fortrinnsvis metanol, i nærvar av en minoralsyre, f.oks. klorhydrogensyre, ellor ot alka linieta 1 lalk oho lat, som natrium» metanolat, overføres aminolytisk ellor ved omsetning med ammoni» akk eller ot organisk amin, til et lavere hydroksyalkyl. Iled©n carboxylic acid forostorot laver©, hydroxyalkyl residue il-f, can be vidoro by reaction with a lower©alcohol, such as a lower©alkanol, preferably methanol, in the presence of a minoral acid, e.g. hydrochloric acid, or ot alka linieta 1 lalk oho lat, such as sodium» methanolate, is transferred aminolytically or by reaction with ammonia» ack or ot organic amine, to a lower hydroxyalkyl.
Utgangastoffene med formelen IV kan fremstilles på i og for seg kjent© metoder. The starting materials with the formula IV can be prepared by methods known per se.
Således kan man eksempelvis fremstille forbindelse eed formelen VI, i hvilken inneholder en funksjonelt omdannet okso- og/eller hydrøksygruppo, idet mani©a forbindols© mod formelen Kg-Ph-E^ (XII), hvori betyr ©a 1-usubefcituert, ero-tuelt enkelt umettet piperidylrest, overfører gruppen H2ved overføring av okso med fosforpoatasulfid ellor alumiaiumtriaul-fid 1 tiokso, overfører ved omsetning med ammoniakk oller ot organisk amin, hydroksylamla eller eventuelt substituert hydrazin i en eventuelt substituert iminogruppe, overfører mod et ortoester i acetalisort henholdsvis med ot lavore alkaatiol i tioacetalisert okso inneholdende £1^og/øller hydroksy ved fores tering i foresteret hydroksy inneholdende og deretter, for eksempel vod omsetning med et eventuelt substituert bonsyl-bromid Overfører resten R^, i en ønsket rest £ij« Thus, for example, a compound of the formula VI can be prepared, which contains a functionally converted oxo- and/or hydroxy group, as mani©a is connected to the formula Kg-Ph-E^ (XII), in which ©a means 1-unsubstituted, ero -tual single unsaturated piperidyl residue, transfers the group H2 by transfer of oxo with phosphorous potassium sulphide or aluminum triaulfide 1 thioxo, transfers by reaction with ammonia or organic amine, hydroxylamine or optionally substituted hydrazine in an optionally substituted imino group, transfers towards an orthoester in acetal type respectively with ot lavare alkathiol in thioacetalized oxo containing £1^ and/or hydroxy by esterification in the esterified hydroxy containing and then, for example vod reaction with an optionally substituted bonsyl bromide Transfers the residue R^, in a desired residue £ij«
Forbindelse med formelen VI, hvori inneholder©a acetalisort henholdsvis tioacetalisert eller i enoletorform foreliggende oksogruppe, kan man eksempelvis vider©fremstille, idet man acetaliserer©a tilsvaroade halogen-fenylokso lavere alkan, f.oks. med formelen halogen-SPh-Rg (Via) ved omsetning med en ortoester, henholdsvis tioacotaliserer ved omsetning med et merkaptaa oller dimerkaptaa eller på vanlig måt©onolfor-otorer, overfører produktet, f.oks. mod halogen-Ph-E-g (VIb), mod magnesium i Grignard-forbindelsen, f.eks. med formolea halogen-Mg-Ph-Rj; (VIc), omsetter denne med©a eventuelt substituert 1-beasal-halogen-piperidin og opparbeider basisk. Av dls-s© kan©rholdes ved omsetning mod svovolhydrogon tilsvarende forbindelser med formelen VI, i hvilken Bjg inneholder tiokso. A compound with the formula VI, in which the acetal type contains, respectively, a thioacetalized or an oxo group present in enoletor form, can for example be further prepared by acetalizing the corresponding halogen-phenyloxo lower alkane, e.g. with the formula halogen-SPh-Rg (Via) by reaction with an orthoester, respectively thioacatalyzer by reaction with a mercaptaa or dimercaptaa or in the usual way©onolfor-otors, transfers the product, e.g. against halogen-Ph-E-g (VIb), against magnesium in the Grignard compound, e.g. with formolea halogen-Mg-Ph-Rj; (VIc), reacts this with optionally substituted 1-beasal-halo-piperidine and works up basic. From dls-s© can be obtained by reaction against hydrogen sulphide corresponding compounds with the formula VI, in which Bjg contains thioxo.
Forbindelse med formelen VI, i hvilken R-^betyr karboksy henholdsvis lavere karboksyalky1, kan vider© fremstilles idet man overfører en halogenbeiiEonsyre henholdsvis halogoafo-ayl- lavore alkansyre, i syrokloridet og omsetter mod amiaoiso-butanol henholdsvis 2,2-dimetylaziridia til tilsvarende 2- (ha-logoafeayl)- henholdsvis 2- (halogeafenyl lavere alk<y>l)-**,4-henholdsvis ->r5-dimetyl-oksazolyl-(2) eller overfører©t tilsvarende nitril under syrekatalyse med hjelp av 4-amiao-2-motyl-pentan-2-ol eller 2-metyl-pentan-2,4-diol i tilsvarende 2-(ha-logenfenyl)- henholdsvis 2- (halogen-feny1 laver©alkyl)-4, ht6-trimetyl-5,é-dihydro-oksazinyl, overfører roaksjonsproduktot med magnesium i tilsvarende Grlgaard-forbiadelse, omsetter dotta med et tilsvarende l-bonzylpiperldylhalogonid honholdsvic l-bensylpiperidoa, avspalter vann ved sistnevnt©tilfelle fra reaksjonsproduktet, fjerner do aktuello beskyttelaoagrupper vod syr ©behandling- bg oet nødvendig fores torer©rholtend© øyrer©iler omdanner et aahydrid, f.,oks. med,tioaylklorld, i syrokloridot• Compounds of the formula VI, in which R-^means carboxy or lower carboxyalkyl, can also be prepared by transferring a halobeiionic acid or haloafo-yllavore alkanoic acid into the acid chloride and reacting with amioiso-butanol or 2,2-dimethylaziridia to the corresponding 2 - (ha-logoafeayl)- respectively 2- (halogenaphenyl lower alk<y>l)-**,4-respectively ->r5-dimethyl-oxazolyl-(2) or transfers the corresponding nitrile under acid catalysis with the help of 4- amino-2-mothyl-pentan-2-ol or 2-methyl-pentan-2,4-diol in corresponding 2-(halo-phenyl)- or 2-(halo-phenyl-lower©alkyl)-4,ht6-trimethyl -5,é-dihydro-oxazinyl, transfers the reaction product with magnesium in the corresponding Grlgaard reaction, reacts the product with a corresponding l-benzoylpiperdylhalogenide honholdsvic l-benzylpiperidoa, cleaves off water in the latter case from the reaction product, then removes the current protecting groups with acid treatment- bg oet necessary fores tor©rholtend© øyrer©iler converter an aahydride, f., ox. with,thioayl chloride, in acid chloride•
Forbindelse med formelen VI, i hvilken Etg betyr©n substituert©ventuolt foresteret ©Her anhydridi3ørt karboksy, inneholdende i 2«stilling til nevnte hydroksy eller i 2,3-stilling umettot rest, kaa videre fremstilles idet man alkanoylerer oventuolt enkelt umettet 1-acetyl-fenylpiporidén i piperidyl-delen med et lavere alkaaoylhalogenld i amrvær av aluainiumtri-klorid i fenyldelen, oppbygger roston H£i den sålede©©rholt© lavere alkanoyl-(l-acylpiporidyl)-f©noa på vanlig måte, f.oks. ved omsetning med ea lavoro alkaakai-boasyro-oster i nærvær av et alkallmctalialkoholat, med oa alfa-halogen lavere alkaasyrø-ester og slak eller med et lavcx^e alkaakarboasyreaahydrid i amrvmr av ot tilsvarende olkalimotallkarboksylat, ellor vod hjelp av©a fosforylidoneddiksyre-oster, som trifeaylfosforylidea-eddiksyreetyl-ester, avspalter 1-acylreaten hydrolytisk 1-bea-sylerer reaksjonsproduktet på vanlig måte, f.oks. ved omsetning med eventuelt substituert beasylbromid i nervar av trietylamia, om ønskelig hydroliserer funksjonelt omdannet karboksy og/oller halogeaerer karboksy, f.eks. med tioaylklorld. Compound with the formula VI, in which Etg means a substituted optionally esterified here anhydride carboxy, containing in the 2" position to said hydroxy or in the 2,3 position an unsaturated residue, can be further prepared by alkanoylating the above-mentioned monounsaturated 1-acetyl -phenylpiperidene in the piperidyl part with a lower alkanoyl halide in the presence of aluminum trichloride in the phenyl part, builds up rostone H£in the so-called lower alkanoyl-(1-acylpiporidyl)-phenol in the usual way, e.g. by reaction with ea lavoro alkakai-boasyro-osters in the presence of an alkallmctali alcoholate, with oa alpha-halogen lower alkaasyro-ester and slack or with a lowcx^e alkakacarboasyreaaahydride in amrvmr of ot corresponding olkalimottal carboxylate, or else with the help of©a phosphorylidoneacetic acid osters , such as trifeaylphosphorylide acetic acid ethyl ester, cleaves the 1-acylreate hydrolytically 1-bea-sylates the reaction product in the usual way, e.g. by reaction with optionally substituted beacyl bromide in the form of triethylamia, if desired hydrolyzes functionally converted carboxy and/or halogenates carboxy, e.g. with thioacyl chloride.
På analog måt©kan utgåeado fra 1-acyl-plporidyl-bea-zaldehyder henholdsvis l«acylpiperidyl- lavoro alkanalor, som or tilgjeagelig ved formyloring, f.oks. ved hjelp av dimøtyl-formamid og fosforoksyklorid, tilsvareade l-acylpip©ridyl-ben-zener og oveatuelt kjedeforlengelse med metoksymetylen-trifoayl-fosforaa, kaa erholdes forbindelser med formelen VI, i hvilken Jig inneholder ©a okso- ellor forostørot karboksygruppe og©a dertil beta-ståeade hydroksygruppe oller oa konjugert dobbolt-binding, ved omsetning med laver© alkanaler ©Iler laver© alkaasyre-ester i acrvar av ea sterk base©om©a laver© alkalimetall-alkanolat. Analogt kan man i iiærvo:r av et metall, f.oks. slak, omsette©t alfa-halogen lavere alkaasyre-oster hvorved erholdes tilsvareado 2-hydroksy lavere alkaasyro-ester. Analogously, 1-acyl-plporidyl-bea-zaldehydes and 1-acylpiperidyl-lavoro alkanalor can be obtained, for example, by formyl ringing. by means of dimethylformamide and phosphorus oxychloride, corresponding l-acylpiperidyl-benzenes and unusual chain extension with methoxymethylene-trifoyl-phosphoraa, compounds of the formula VI can be obtained, in which Ig contains ©a oxo- or phosphorous carboxy group and ©a in addition, a beta-standing hydroxy group or a conjugated double bond, by reaction with lower alkanals or lower alkalic acid esters in acrvar of a strong base or lower alkali metal alkanolate. Analogously, one can in iiärvo:r of a metal, e.g. slack, converted to alpha-halogen lower alka acid esters whereby the corresponding 2-hydroxy lower alka acid esters are obtained.
Forbindelse mod formelen VI, i hvilken k©tyr laver©alkeayl ellor lavore alkiayl, kaa videre fromstillos idot man overfører tilsvarende halogeafoayl— laver© alken henholdsvis lavore alkia i en asotallforbiadels©, f.eks. vød omsetning m©dmagnesium i'tilsvarende kaiogeneagaooiuiEf orbindalso, kondens©-» Compounds of formula VI, in which the lower alkyl or lower alkyal ketyr can be further removed from the corresponding halogeafoayl—lower alkene or lower alkyl in an azotall forbiadels, e.g. wet turnover m©dmagnesium i'corresponding to kaiogeneagaooiuiEf orbindalso, condensation©-»
rer doane pd vanlig måte aed en eventuelt substituert 1-bemsyl-halogenpiporidin, henholdsvis l-bcazylpiperidoa og i sistnevnte tilfelle•avspalter vann. rer the doane in the usual way with an optionally substituted 1-bemsyl-halopiperidine, respectively l-bacylpiperidoa and in the latter case•cleaves off water.
Forbindelse aed formelen VI, i hvilken Mr, inneholder haløgea kan©ksotsjpslvis fremstilles ved vas&lig halogen- henholdsvis' halogoahydrøgeaanleiriag til tilsvarende forbindelse med form©loa VI, som inaoholdor en umettet rost u^o Compounds of the formula VI, in which Mr, contains halogea can be optionally prepared by liquid halogen or halohydrogea addition to the corresponding compound of the formula VI, which inaoholdor an unsaturated rust u^o
£>© for fremstillingen av utgangsforbind®lson© mod for-moion VI anvoadfc® lavor©alkylaetallforbiadolsor blir fortrinnsvis fremstilt la^qltu» idet man omaetter en tilsvareado halogen-, f.oks. klor-, jod°ellor fortrinnsvis lavere bromalkon, for°£>© for the preparation of the starting compound®lson© mod for-moion VI anvoadfc® low©alkylaetalforbiadolsor is preferably prepared la^qltu» by omatting a corresponding halogen-, e.g. chlorine, iodo°or preferably lower bromoalcone, for°
trihnovis i on eter, f.eks. i diøtyleter©Hor t©trahydrofasran,Eod lifciuoj oilor fortriaaoviø ma<g>aesiura. Andro lavere alkyle©~tallforbiadolsor kaa oriAoldeø ira don sa erholto halo<g>oa«=, for» trinasvis brociaagiaos innafor bind© Is er, ved obsq timing aed©t tilsvarende aotallhalogoald, f.eka. med kadmitataklorids kopporklorid oller øiak<=klorid. trihnovis in on ether, e.g. in diethylether©Hor t©trahydrofasran,Eod lifciuoj oilor fortriaaoviø ma<g>aesiura. Andro lower alkyl©~tallforbiadolsor kaa oriAoldeø ira don sa erholto halo<g>oa«=, for» trinasvis brociaagiaos inside bond© Is is, at obsq timing aed©t corresponding aotallhalogoald, f.eka. with cadmium chloride, copper chloride, or copper chloride.
D©nye forbiadolsor kari vidoro fremstilles idot raaa på oia blanding av forbindelser taed don goneroll©formelen* ■ D©new forbiadolsor kari vidoro is prepared idot raaa on oia mixture of compounds taed don goneroll©the formula* ■
hvori- on av rostoaao il®q 11^ botyr on roat ii, og d©a ana©n022rest rig, og iij_ botyr©n oventuolt reaksjonsdyktig foreo-terøt hy~drokoygrupp©©Hor osi til aabokarboaatoaot ©trokkond© toiadoloo, lar innvirk© ot egaot surt jjidMol og gjønnouforor oa cnskolig ©a©lier floro av aovato tilloggsoperasjoner. Rootoa & i©r for trinnovis'©a forøotorot hydroksy9 sp©=> øiolt halogen mod atommatrasor 17 og høyer Op son klor. Som bun<= dot rost 2s.jj_ til lavoro alkanoyl i.^kocmor vider© eyror med formelen U^-OH forosterot hydrokcy i botraktaingo jiSgaodo sure midlor or eksempelvis caiaoralayrer som fluorhydrøgeasyro©iler Gvoatuolt i aahydridform foroliggoado oksygenøyror av fosfor ollar svovol, f.oks. fosforsyro, -difos-forsyr®, polyfoøforsyror oilor fooforpoafcaoksyd oilor avov©!-»©yro, fortrinnsvis Letslø-øyror, ooib halogeaider av olemoatea© fra hovodgruippoa £' T£9 I' V og V og øidegruppoia©II og i dot periodiske aystea av olououtøno soa bor, aIrøniaiunD gallium^ . txmi9 antimon og ja>ra0 f.okø. vod oidoa av jo^a-triklorid, sink- whereion of rostoaao il®q 11^ botyr on roat ii, and d©a ana©n022rest rig, and iij_ botyr©n abovetuolt reactive foreo-terote hy~drokoygrupp©©Hor osi to aabokarboaaatoot ©trokkond© toiadoloo, lets influence © ot egaot surt jjidMol and gjønnouforor oa cnskolig ©a©lier floro of aovato access operations. Rootoa & i©r for trinnovis'©a forøotorot hydroxy9 sp©=> øiolt halogen mod atomic matrasor 17 and raises Op son chlorine. As bun<= dot rost 2s.jj_ to lavoro alkanoyl i.^kocmor vider© eyror with the formula U^-OH forosterot hydroxykcy in botraktaingo jiSgaodo acid midlor or for example caiaoralayres such as fluorhydrogeacidiro©iler Gvoatuolt in aahydride form foroliggoado oxygenearor of phosphorus ollar sulvol, f .Axe. phosphoric acid, -diphos-forsyr®, polyphoøphosphoric acid oilor fooforpoafcaoxyd oilor avov©!-»©yro, preferably Letsløøyror, ooib halogeaids of olemoatea© from hovodgruippoa £' T£9 I' V and V and øidegrupoia©II and in dot periodic aystea of olououtøno soa boron, aIrøniaiunD gallium^ . txmi9 antimony and ja>ra0 f.okø. vod oidoa of jo^a trichloride, zinc-
klorid, tinnklorid og aatimoapentaklorid fortrinnsvis børtri-klorid og- fluorid og aluminiumtriklorid og -bromid, vidor©kompleks©metallsyror, som totrafluorbor- eller•heksakloraati-monsyro. chloride, stannous chloride and aatimopentachloride, preferably boron trichloride and fluoride and aluminum trichloride and bromide, vidor©complex©metallic acids, such as totrafluoroboronic or •hexachloroathiomonic acid.
Gmsotaingea utfores på vanlig måte, eksempelvis .i ©t inert oppløsaingsmiddol som svovelkarbon, nitrobenaen, tøtra-klormetaa, dietyleter, totroliydrofuran ©Hor ved©t overskudd av utgangsstoffot mod formelen Vill, ved normalt, moderat for-høyet©Iler senket temperatur, f.oks. ved ca. -30 til ca. iOO^C, fortrinnsvis under utelukkelso av fuktighet og/ellor under b©°skyttelsesgass, f.oks. under nitrogen. Gmsotaingea is carried out in the usual way, for example in an inert solvent such as carbon disulfide, nitrobene, tetrachloromethane, diethyl ether, tetrahydrofuran ©Hor with an excess of starting material against the formula Vill, at normal, moderately elevated ©Iler lowered temperature, f .Axe. at approx. -30 to approx. iOO^C, preferably under exclusion of moisture and/or under protective gas, e.g. under nitrogen.
I en foretrukket utførelsoeform av foreliggende fremgangsmåte lar man oksempelvis på en blanding av forbindelser med formler-VIX og VIII, hvori UQbotyr en rest 11^. og & 0 - Xj_ botyr on lavoro aikanoyIhalogenid, f.oks. -klorid, ©Hor lavero alkansyreanhydrid, innvirke aluminiumtriklorld, hvorved maia for^ trinasvis arboider i kokende svovolkarbon. In a preferred embodiment of the present method, a mixture of compounds with formulas VIX and VIII is allowed, for example, in which UQ is a residue 11^. and & 0 - Xj_ botyr on lavoro aikanoyIhalogenide, e.g. -chloride, ©Hor lavero alkanoic anhydride, affect aluminum trichlorld, whereby maia for^ trinasvis arboids in boiling sulfur carbon.
De nye forbindelser kan videre fremstilles idet man kondenserer forbindelser mod formler The new compounds can further be prepared by condensing compounds against formulas
hvori en av restene kQog U Q betyr en rest 21 ^ og den caaen©a rost Ug og oa av restene X* > og Xo betyr et metallradikal og doa andre halogen eller ea til ea lavore alkylr©st buad©t okso eller til ea laver©aikanoyIrost l^ bundet i oaltform forelig-geado forodrot©Hor foresteret hydroksy, og om ønskelig skil°ler ea erhalt storeo-blandiag i komponentene, overfører døn ør° halte forbindelse i en annen forbindelse med formoloa I og/oller omdaaaor oa erhalt fri forbindelse i et salt©Iler ot erhalt-salt i en fri forbiadelse ©Her til©t annet salt. Metallradikalor er eksempelvis grupper med formelea-M1,-M1<1>©Hor -M<I3>"/2, hvori betyr ot metallatom fra gruppen I, U^~betyr©t metallatom fra gruppon II i det periodiske system av elementene og Hal betyr halogen, som klor, brom eller jod. Bruka©møtallradikalor av aevat© art ©r slik© mod formelen in which one of the residues kQ and U Q means a residue 21 ^ and the caaen©a rost Ug and oa of the residues X* > and Xo means a metal radical and doa other halogen or ea to ea lowore alkylr©st buad©t oxo or to ea laver ©aikanoyIrost l^ bound in any form available-geado forodrot©Hor the esterified hydroxy, and if desired separates ea obtained storeo-mixlandiag in the components, transfers the die ør° contained compound in another connection with formoloa I and/or omdaaaor oa obtained free compound in a salt ©Iler ot erhalt-salt in a free forbiade ©Here to©t other salt. Metal radicals are, for example, groups with the formula -M1,-M1<1>©Hor -M<I3>"/2, where ot means a metal atom from group I, U^~means a metal atom from group II in the periodic system of the elements and Hal means halogen, such as chlorine, bromine or iodine. Use metal radicals of any type such as against the formula
-Li, MgKal- og -Cd/2. -Li, MgKal- and -Cd/2.
Foredret hydroksy er eksempelvis laver© alkok©y0 For» os teret hydroksy er f.oks. med ea syre med foraøloa U0 => UH forosterot hydrokay. I saltform foreliggende hydroksy©r eksempelvis i en alkalimetalIsaItform, f.oks. sosa siatrlusisalt* foreliggende hydroksy, halogen,©r fortrinnsvis fluor, klor, Preferred hydroxy is, for example, lower alcohol. Preferred hydroxy is e.g. with ea acid with foraøloa U0 => UH forosterot hydrokay. In salt form, hydroxy©s present, for example, in an alkali metal form, e.g. sosa siatrlusisalt* present hydroxy, halogen,©r preferably fluorine, chlorine,
brom©ll©r jod. brom©ll©r iodine.
Omsetningen med forbindelser med formloae XX og X utfores på vanlig aåte, fortrinnsvis i et ln©rt opp løsningsmiddel, som en et©r, f.eks. i dietyløter oller tetrahydrofuran, ot hydrokarbon, f «øks. benzen eller blandinger av disse, ost. nødvendig under avkjøling ©Hor lett oppvarming, f.eks» vod ca. -30 til The reaction with compounds of the formulae XX and X is carried out in the usual way, preferably in a diluted solvent, such as an ether, e.g. in diethyl ether or tetrahydrofuran, or hydrocarbon, e.g. benzene or mixtures thereof, cheese. necessary during cooling ©Hor light heating, e.g.» vod approx. -30 more
ca. 100°C, f»©ks. koketemporatur, og/ellor under inertgass, about. 100°C, e.g. boiling temperature, and/or under inert gas,
f.eks. under nitrogen. Porotrukao utførelsesformer av denno fremgangsmåt© or spøsielt omsetningen med kadmiumforbindolaør (IX) med syreklorider (X) i bensen-diotyleter til forbindelser taed formelen 1, hvori Ug©r 1-okso lavere alkyl, omsetning av halogonmagnosiumforbiaidolaer (lii) med laver© alkanoner (x) til forbindelser mod formoloh2, hvori E^er 1-hydroksy lavore alkyl, og omsetningen av litium- eller halogoataagaøeluEJforbindøl-sor (X) med forbindolsor med formelen IX, hvori RQor on rost SUj, og ' Vii^ or halogen. e.g. under nitrogen. Particular embodiments of this process are, in particular, the reaction of cadmium compounds (IX) with acid chlorides (X) in benzene diethyl ether to give compounds of the formula 1, wherein U is 1-oxo lower alkyl, reaction of halomagnesium forbiaidoles (lii) with lower alkanones ( x) to compounds against formoloh2, in which E^ is 1-hydroxy lavore alkyl, and the reaction of lithium or halogenoataagaøeluEJcombindolsor-sor (X) with compindolsor with the formula IX, in which RQor on rost SUj, and ' Vii^ or halogen.
Utgangsstoffor med formlene IX og X er kjente eller Starting materials of formulas IX and X are known or
kan, dersom nye, fremstilles ottor i' og for sog kjent©metoder, can, if new, be produced using and for so well known©methods,
Be sota utgangsstof f er anvendeligo motallorgaaisko forbindelser, f.oks. med formelen IX, hvori R betyr en laver© alkylrest R2og X^ metallradikalet, blir fortrinnsvis fremstilt in situ»idet man omsotter en tilsvarende halogen-, f.eks. klor-, jod- oller spesielt bromforbindelser, fortrinnsvis i©a©ter, f.oks. i dletyleter eller tetrahydrofuran, mod litium ellor spesielt magnesium. Andre motallorganisk©forbindelser kan orholdes fra d©således orholte halogen; i-fortrinnsvis brommaga©-siumforbindølser ved omsetning taod et tilsvarende oetallhalog©-aid, f.eks. kadmiumklorid, kopperklorid©Hør siak-klorid. Halogenforbiadelser som derved skal aaveados, kaa f.eks» fremstilles idet man halogeaerer ea 1-acylpiperidyl-bensoa oller lis-bonaon på vaalig auto, f.oks» med brom henholdsvis klor i nor-vor avjera ellor med M-klorsucciaimid, Z^^^^^^^^~ ZJ liserendo ot erhalt l-aeylpiporidyl-halog©ab©nsoa og deretter 1-boasyiøror, f.eks. med tllsvaread©boaaylbromid. Bventuolt substituert l-boaaylhalogøapiporldiaforbiadois©r kas» aaalogt froo» stilles ved l-boazyleriag av tilsvarende l-taoubstitu©rt feayl-' piporidia henholdsvis feayl-tetrahydropyridia. Be sota starting material f are applicable oligo-anti-organic compounds, e.g. with the formula IX, in which R denotes a lower alkyl radical R2 and X^ the metal radical, is preferably produced in situ by reacting a corresponding halogen, e.g. chlorine, iodine or especially bromine compounds, preferably ethers, e.g. in dlethyl ether or tetrahydrofuran, against lithium or especially magnesium. Other counter-organic© compounds can be obtained from d©thus orholt halogen; i-preferably bromine-magazine compounds by reaction with a corresponding non-metalhalogen, e.g. cadmium chloride, copper chloride©Hear siac chloride. Halogen compounds which are thereby to be aveaded can, for example, be prepared by halogenating or 1-acylpiperidyl-benzoa or lis-bonaone in a suitable solvent, e.g. with bromine or chlorine in nor-vor avjera or with M-chlorosucciamide, Z^ ^^^^^^^~ ZJ liserendo ot erhalt l-aeylpiporidyl-halog©ab©nsoa and then 1-boasyiøror, e.g. with tllsvaread©boaayl bromide. Beventually substituted l-boaylhalogøapiporldiaforbiadois©r cas» aaalogt froo» is set by l-boazyleriag of corresponding l-taoubstitu©n feayl-' piporidia respectively feayl-tetrahydropyridia.
Erholdelige forbindelser med formelen I i henhold til oppfinnelsen kan på i og for ;seg kjent måte omdannes<:>i andre forbindelser med formelen I. Obtainable compounds with the formula I according to the invention can be converted into other compounds with the formula I in a manner known per se.
Så kan man eksempelvis i forbindelser med formél I redusere eri rest Rg inneholdende okso til tilsvarende rest B.^ inneholdende hydroksy. Derved anvender man som reduksjonsmiddel eksempelvis et dilettmetallhydrid, som et alkalimétallbor-hydrid eller alkalimetallaluminiumhydrid, f.eks. natriumborhydrid, natriumcyånhydrid eller JijBiumaluminiumhydrid, fortrinnsvis i et inert oppløsningsmiddel, om nødvendig under kjøling Then, for example, in compounds with formula I, you can reduce your residue Rg containing oxo to the corresponding residue B.^ containing hydroxy. Thereby, a dilate metal hydride, such as an alkali metal boron hydride or alkali metal aluminum hydride, is used as a reducing agent, e.g. sodium borohydride, sodium cyanohydride or JijBiumaluminium hydride, preferably in an inert solvent, if necessary under cooling
eller, oppvarming, f.eks. ved ca. 0°.til 120°C, og/eller under: inert gass som nitrogen. Foretrukket er spesielt reduksjon med natriumborhydrid i et inert, polart oppløsningsmiddel som et lavere alkanol, f.éks. i metanol, etanol eller butanol, eller i dimetylformamid, henholdsvis i, eventuelt vannholdigt, blandinger av disse eller med litiumalutniniumhydrid i en eter som dietyleter, dioksån eller tetrahydrofuran. Reduksjonen av oksb-gruppen til hydroksy kan videre utføres ved omsetning med et or, heating, e.g. at approx. 0° to 120°C, and/or below: inert gas such as nitrogen. Particularly preferred is reduction with sodium borohydride in an inert, polar solvent such as a lower alkanol, e.g. in methanol, ethanol or butanol, or in dimethylformamide, respectively in, optionally aqueous, mixtures of these or with lithium aluminum hydride in an ether such as diethyl ether, dioxane or tetrahydrofuran. The reduction of the oxb group to hydroxy can further be carried out by reaction with et
keton som aceton, i nærvær av et aluminiumalkaholat, f.eks. med aluminiumisopropylat, spesielt etter fremgangsmåten av Meerwein-Pbnndorf-Verley. IIT I ketone such as acetone, in the presence of an aluminum alkoxide, e.g. with aluminum isopropylate, especially according to the method of Meerwein-Pbnndorf-Verley. IIT I
Okso kan imidlertid også alkyleres reduktiv, eksempelvis ved omsetning med.et lavere alkylalkalimetall- eller alkyljordalkali-metallforbindelse, som et lavere alkyllitium, f.eks. metyl- eller etyllitium, eller et lavere alkylmagnesiumhalogenid, f.eks. However, oxo can also be reductively alkylated, for example by reaction with a lower alkyl alkali metal or alkyl alkaline earth metal compound, such as a lower alkyl lithium, e.g. methyl or ethyllithium, or a lower alkylmagnesium halide, e.g.
metylmagriesiumbromid eller etylmagnesiumbromid,.fortrinnsvis i en eter som dietyleter. methyl magnesium bromide or ethyl magnesium bromide, preferably in an ether such as diethyl ether.
Videre kan man i en rest R£ som inneholder okso eller hydroksy, erstatte okso eller hydroksy med et hydrogen. Okso kan eksempelvis erstattes med et hydrogen ved ..reduksjon, eksempelvis ved overføring med et eventuelt med 2-sulfonyletyl, som 2-benzen-, 2-(p-toluol)-, 2-metan- eller 2-mesitylensulfonyl-etyl, substituert hydrazin i eventuelt substituert hydrazon. ' Som reduksjonsmiddel for 2-sulfonyletylhydrazongrupper anvender Furthermore, in a residue R£ which contains oxo or hydroxy, oxo or hydroxy can be replaced by a hydrogen. Oxo can, for example, be replaced by a hydrogen by ..reduction, for example by transfer with an optionally with 2-sulfonylethyl, such as 2-benzene-, 2-(p-toluene)-, 2-methane- or 2-mesitylenesulfonyl-ethyl, substituted hydrazine in optionally substituted hydrazone. ' As a reducing agent for 2-sulfonylethylhydrazone groups use
man fortrinnsvis et léttmetallhydrid som natriumcyanborhydrid i et inert, polart oppløsningsmiddel, f.eks. i heksametylenfos-forsyretriamid. Den reduktive utbyttning av usubstituert. hydrazon mot hydrogen utføres fortrinnsvis ved base '> redusert disproporsjonering, eksempelvis ved omsetning med et alkali- preferably a light metal hydride such as sodium cyanoborohydride in an inert, polar solvent, e.g. in hexamethylenephosphoric acid triamide. The reductive yield of unsubstituted. hydrazone to hydrogen is preferably carried out by base '> reduced disproportionation, for example by reaction with an alkali
tie talla Ikoholat sou iiatriurauetario la fc, om nødvendig under for-høyet trykk, f.eks. opp til 10 bar, oller ved innvirkning av tie talla Ikoholat sou iiatriurauetario la fc, if necessary under too-high pressure, e.g. up to 10 bar, or when affected by
et alka1imetalIhydroksyd, f.eks. kaliumhydrokøyd, i et inert høytkokende oppløsningsmiddel, f.eks. i di» oller triøtylon-glykol eller dietylenglykolmonomotyleter, om nødvendig under oppvarming, f.eks. ved ca. I0O til 250°C. Ketøniske oksogrup-por kan videre erstattes mod ot hydrogen mod nasciorende hydro^^, gen som f.eks. fremstilles ved innvirkning av en protonsyre som salt- eller eddlksyre, og uedle metaller som sink, jern oller aluminium eller ved innvirkning av vann på fortrisinsviø amal-gert aluminium, oller ved innvirkning av natrium på alkoholer som metanol,vlan kan også anvende lavverdige metallforblndel-sor som tinn-XI- ©Hor krota-II-saitor, f.eks. tinn-II-klorid. Hydroksy kan erstattes med hydrogen, eksempelvis ved innvirkning av katalytisk aktivert hydrogen, som hydrogen i narver av en hydroringskatalysator, f.eks. iianoy-nikkoi oll©r ©n platin-forbindols©som platinoksyd oller platin på karbon oller på bariumoksyd, fortrinnsvis i©t surt oppløsningsmiddel som en lavere alkansyre, f.eks. i eddiksyre. an alkali metal hydroxide, e.g. potassium hydroxide, in an inert high-boiling solvent, e.g. in di»oller triethylene glycol or diethylene glycol monomothyl ether, if necessary under heating, e.g. at approx. 100 to 250°C. Ketonic oxogroups can also be substituted for hydrogen against nascent hydrogen^^, which e.g. produced by the action of a protonic acid such as hydrochloric or acetic acid, and base metals such as zinc, iron or aluminum or by the action of water on fortrisine amalgamated aluminium, or by the action of sodium on alcohols such as methanol, vlan can also use low-value metal compounds sor as tin-XI- ©Hor krota-II-saitor, e.g. stannous chloride. Hydroxy can be replaced by hydrogen, for example by the effect of catalytically activated hydrogen, such as hydrogen in the grains of a hydrogenation catalyst, e.g. iiano-nikkoi or a platinum compound such as platinum oxide or platinum on carbon or barium oxide, preferably in an acidic solvent such as a lower alkanoic acid, e.g. in acetic acid.
I forbindelse med formelen I kan i rosten ii2innføres oksydativ hydroksy eller okso og/oller hydroksy kan overføres i okso. Innføringen av hydroksy, spesielt i wJ.-stilling utfø-.res eksempelvis vod luftoksydasjon eller innføringen av halo-gon utføres spesielt ved omsetning med N-bromøuccinimid, og etterfølgende hydrolyse. Den oksydative innføring av okso likeledes fortrinnsvis i 'l-stilling utfores eksempelvis ved omsetning med selendioksyd. I resten Si,, kan videre hydroksy ok-syderes til oksy, eksempelvis ved omsetning med©t keton som aceton, i nærvær av et aluminiumalkoholat, som aiumlniumiso-propylat, fortrinnsvis etter fremgangsmåten av Opponauer. In connection with formula I, oxidative hydroxy or oxo can be introduced into the rust ii2 and/or hydroxy can be transferred into oxo. The introduction of hydroxy, especially in the wJ position, is carried out, for example, by air oxidation or the introduction of halogen is carried out in particular by reaction with N-bromouccinimide, and subsequent hydrolysis. The oxidative introduction of oxo is likewise preferably carried out in the 'l-position, for example by reaction with selenium dioxide. In the residue Si,, hydroxy can further be oxidized to oxy, for example by reaction with a ketone such as acetone, in the presence of an aluminum alcoholate, such as aluminum isopropylate, preferably according to the method of Opponauer.
Vidor©kan man okso lavere alkylrester iig i'erIong© på vanlig måte, fortrinnsvis ved omsetning med en metall-©Iler fosforforbindeise av ot lavere dlalkyl- eller fenyletyleter, f.eks. metoksymetylmagnesiumbromid ellor med metoksyfosforan, Furthermore, lower alkyl residues can also be removed in the usual way, preferably by reaction with a metal or phosphorus compound of lower dlalkyl or phenylethyl ether, e.g. methoxymethylmagnesium bromide or with methoxyphosphorane,
og etterfølgende hydrolyse av den erholte©noleter. and subsequent hydrolysis of the erholte©nol ether.
Videre kan man i forbindelse mod formelen 1, hvori K± botyr©n med eventuelt substituert benzyl 1-substituert, enkelt umettet piporidylrest, reduserer dens dobbeltblading, eksempelvis ved omsetning mod katalytisk aktivert hydrogen, i", oies. med h<y>dro<g>ena i amrvmr av en nikkøl-, pla tin» eller rho» diumkatalysator, f.eks» Liaaey-nikkøl, platiaoksyd eller kom» plokset av platin- ellor rhodlumklorid og trif ©aylf os f in, oller ved'hjelp av et dilottmetallbydrid, f.oks. ued aatriumborhydrid eller aed litiuiaalumiaiumhydrid. Furthermore, in connection with formula 1, in which K± butyr©ne with optionally substituted benzyl 1-substituted, singly unsaturated piperidyl residue, its double leafing can be reduced, for example by reaction with catalytically activated hydrogen, i", oies. with h<y>dro <g>ena in the amrvmr of a nickel-coal, platinum» or rho» dium catalyst, for example» Liaaey-nickel», platia oxide or com» ploxet of platin- or rhodium chloride and tri©aylf os f in, oller with the help of a dilotte metal hydride, for example with sodium borohydride or with lithium aluminum hydride.
E2o nye forbiudelsor kan©tter valg av utgangsstof f or E2o new forbiudelsor can © choice of starting material for or
og fremstillingsmåtor foreligge i form av ot av do mulig© ioo^øeror,©Iler som blandiagor av disse, f.eke»©ttor aatalløt av asymmetrisk© karbonatomer som ren© optisk© ioomeror, som aati» poder eller som isomorblandingor som racociatør, difestereoisoioor» blandinger ©Hor racernatblandinger. . Erhalt© isomerblaadinger som diasterooisomorblandingor og raceiaatblandingør kan på grunn av fysikaHøko-kjemisko og©n«=. skaper av bestanddelen© på kjent aåte skyldes i rono isooeror, dlastorooisomeror ellor raceaator, eksosapoivio ved kromatografi og/eller fraksjonert krystallisasjon. • Erhalte raeematør lar s©g • videre otter, kjonto fremgangs» måt©r. skille i optiske antipodor, oksempelvis ved omkrystalllse-rlag fra et optisk aktivt oppløsningsmiddel, m©d hjolp av saikro-organismer, oller vod. omsetning av ot .sluttprodukt med©t aod racetalskt basesait dannende optiske aktiv©syx-ør og atskillelse av d©på denne måton orhalto salter, f.oks. på grunn av forskjel» Hg oppløslighet, i diastereomoror, fra hvilke antipoden©' vod innvirkning av et egnet middel frigjøres. Fortrinnsvis isolerer man don mest virksomme av antipoden©• and methods of preparation exist in the form of ot of the possible © ioo^isomers, ©Iler as a mixture of these, eke»©ttor aatallöt of asymmetric© carbon atoms as pure© optical© isomers, as aati» poder or as isomeric mixtures as a racociator, diferstereoisoioor» mixtures ©Hor racenat mixtures. . Erhalt© isomers such as diastereoisomer mixtures and racemate mixtures can be obtained due to physics, high-chemistry and ©n«=. creation of the constituent© in a known way is due in rono isoeroor, dlastorooisomeror or raceaator, exosapoivio by chromatography and/or fractional crystallization. • Retaining the raeemateur allows you to • further otter, kynto progress" methods. separate into optical antipoders, for example by recrystallization from an optically active solvent, with the help of saccro-organisms, or water. reaction of the final product with aod racetal bases forming optical actives and separation of them in this way orhalto salts, e.g. due to difference» Hg solubility, in diastereomers, from which the antipod©' vod action of a suitable agent is released. Preferably, one isolates the most effective of the antipodes©•
lirhalte fri© forbindelser mod formelen I kan på i og for seg kjont måt© overføres i salter, bloat annet vød fo©haad°ling med tilsvarende syre, vanligvis i nervar av et oppløsnings» ellor fortynningsmiddol. Lir-containing free compounds of the formula I can in and of themselves be transferred into salts, except for wet treatment with a corresponding acid, usually in the form of a solvent or diluent.
lirhalte salter kan på i og for©eg kjent måto omdanaes i fri© forbindelser, f.oks. ved behandling mod & n base soa et alkalimøtallhydroksyd. Acid-containing salts can be converted into free compounds, e.g. by treatment mod & n base soa an alkali metal hydroxide.
Forbindelsene innbefattet deres salter kan orholdes i form av deres hydrater oller innbefattet aavondt oppløsningsaid» dol ved krystalliseringon. The compounds, including their salts, can be obtained in the form of their hydrates, or in the form of solvent, by crystallisation.
På grunn av d©xisbto slektskapsforhold taellom ay©for» blndolsør i fri form og i form av dør©® salter skal hensiktsmes-sig ovenfor og nedenfor forståes a©d fri© forbiadolsor ©Hor deres salter også ovoatuolle salter, heaholdsvis fri forbind.© Is er. Due to d©xisbto kinship relationship taellom ay©for» blndolsør in free form and in the form of door©® salts shall be appropriate-above and below understood as a©d free© forbiadolsor ©Hor their salts also ovoatuolle salts, heahold free connection. © Ice is.
Oppfiimoleea vedroror* også slik© utforingsf©roer av fremgangsmåton hvor eian utifir fra©n soa mollomprødiakt erhalt forbindelse soia oppnåes ved, hvilket* som helst trinn vod fremgangsmåten og hvor en utforer manglendo trinn ©Hor hvor masi utgår fra©t utgangsstoff i foria av et salt og/e II or raceeat, henholdsvis anvender antipoder oller spesielt danner slik© under reaksjonsbeting©Iser. The invention also relates to methods of carrying out a process where a compound is obtained from a soa mollomprodiak, which is obtained at any step of the method and where a missing step is carried out where the masi starts from the starting material in the first part of a salt and/e II or raceeat, respectively use antipodes or especially form such© under reaction conditions©Icer.
Ved fremgangsmåten i henhold til foreliggende oppfinnelse blir fortrinnsvis anvendt sliko utgangsstof f ©r©oia føror til do foran beskrevne verdifulle forbindelser. My©utgangs-stoffer og freugangsaåter for deres fremstilling er likeledes on gjenstand ved foreliggende oppfinnols©. In the method according to the present invention, the starting material is preferably used as a precursor to the valuable compounds described above. My© starting materials and methods for their production are likewise an object of the present invention.
I denno forbindelse skal spesielt aovmsa de som utgangsstoffor angitt©forbindelse aed formelen VII, i hviikon R0 botyr on rest K^., dvs. forbindelse med formelen IZj-Ph-H (la), i hvilken°£^ ^ar doaa foran angitte betydelse. Disse vis©r samme farmakologiske egenskapor i sammenlignbar aktivitetstyrko som forbindelse mod formelen 1 i henhold tii oppfinnelsen. Oppfinnelsen vedrører derfor likeledes forbindelse med formelen Ia og deres anvendelige salter, fremgangsmåte til dores fremstilling, samt deres anvendelse og farmasøytiske preparater som inneholder disse. In this connection, the compound of the formula VII, in which R0 is substituted with the residue K^., i.e. the compound with the formula IZj-Ph-H (la), in which °£^ ^ar doaa above significance. These show the same pharmacological properties in comparable potency as the compound of formula 1 according to the invention. The invention therefore also relates to compounds of the formula Ia and their applicable salts, methods for the preparation of dores, as well as their use and pharmaceutical preparations containing these.
Oppfinnelsen vedrører derfor spesielt sliko forbind©!» ser med formelen Ia, i hvilken il^og Ph har den angitt© betydelse for foretrukne forbind©!sesgruppor, nemlig -rv;- l-(o-klor-bonayl)-3-fenyl-piperidin og dores farmasøytisk© anvendelig© salter som dets hydroklorid. The invention therefore particularly relates to such compounds!» shows with the formula Ia, in which il^ and Ph has the indicated meaning for preferred compound groups, namely -rv;- 1-(o-chloro-bonayl)-3-phenyl-piperidine and its pharmaceutically usable salts as its hydrochloride.
Forbindelse med formelen I kan fremstilles på I og for seg kjont måte, eksempelvis ved don foran angitt© fremgangsmåten for forbindelse med formelen I, idet man istoden for rosten utgår fra hydrogenismholdendo forbindelser mod formeløn II, Ila, III, IV, V, VII og VIII, henholdsvis IX og X, hvorved UQbetyr hydrogen og RQhenholdsvis H0betyr en rest K^.<0>A compound with the formula I can be prepared in a unique way, for example by the above-mentioned method for a compound with the formula I, starting from hydrogenism containing compounds of the formula II, IIa, III, IV, V, VII and VIII, respectively IX and X, whereby UQ means hydrogen and RQrespectively H0means a residue K^.<0>
Forbindelser mod formelen I og deres farmasøytisk© anvendelig©salter har verdifulle farmakologisk© egenskaper. Så har diss©eksempelvis utprogot antitrombotisk virkning. Denno kan eksempelvis dokumenteres på nicor på grunn av hemming av trombocytopeni otter induksjon av ABS? 1 dos©på ca. 100 til 300 mg/kg p.o. likoledes på grunn av Arthias-røakajonon, so Brit. J. Pharmacology 57, s.%4l (197&)»i dosor pa ca. 30 til 300 sne/ hg p• o*på teminer 'på grunn av deres hcmiaels©av den av Arachidoasyro induserte luageemboii i dose på ca. 100 til 300 tag/kg p.o. oller in vitro på gixum av deres prostaglondiasynte-se-hemsielse av Arachidonsyro ved ensjimer utvunnet oksens ocsd-blæro i kona en tras jons området på ca. 0,1 til 1 sig/liter. Por-Forbindelse med formelen I or videre anti-inflammatorisk virksom, hvilket f.oks. lar seg påvis© på rottor på grunn av Kaolia-Pfotenoedems og Adjuvaas-Arthritis i dose på ca. 10 til 100 mg/ kg p.o. Di ny© forbindelser er videre antioeoptiv virksom, noe som lar seg påvise ved f ©nyl-p-benzochiaoa-rjritingsyndroms på mue i dose på ca. 1 til 10 mg/kg p.o. og eddiksyre-xsjritiagsya-droms på rotter i doser på ca. 1 til 10 mg/kg p.o. Bo or, ©ade-liguuricosurisk virksomme, no© som lar seg påvise på grunn a<y>feaolrod-klarering på rotter i dosor på ca. 30 til 100 mg/kg p»o. Compounds of formula I and their pharmaceutically acceptable salts have valuable pharmacological properties. For example, diss© has pronounced antithrombotic effects. Can this, for example, be documented on Nicor due to inhibition of thrombocytopenia after induction of ABS? 1 dose of approx. 100 to 300 mg/kg p.o. likewise on account of Arthias røakajonon, so Brit. J. Pharmacology 57, p.%4l (197&)»in doses of approx. 30 to 300 sne/ hg p• o*on teminers 'due to their hcmiaels©of the Arachidoasyro induced luageemboii in a dose of approx. 100 to 300 tags/kg p.o. ollers in vitro on the gixum of their prostaglondiasynthe-se inhibition of Arachidonic acid by enzymes extracted the ox's ocsd bladder in the kona en tras ions area of approx. 0.1 to 1 sig/liter. Por-Compound with the formula I is further anti-inflammatory, which e.g. can be detected © on rats due to Kaolia-Pfotenoedems and Adjuvaas-Arthritis in a dose of approx. 10 to 100 mg/kg p.o. These new compounds are also antioeptively active, which can be demonstrated in f©nyl-p-benzochiaoa-writing syndromes in mice in a dose of approx. 1 to 10 mg/kg p.o. and acetic acid-xsjritiagsya-droms on rats in doses of approx. 1 to 10 mg/kg p.o. Bo or, ©ade-liguuricosurically active, no© which can be detected due to a<y>feaolrod clearance on rats in doses of approx. 30 to 100 mg/kg p»o.
Forbindelse med formelen I er følgelig utmerket©gnet til behandling av trombotisk© sykdommer, vider© botønnelsessyk-dommor, spesielt med inflammatorlsk© komponenter og kaa anvendes som aktiv i-»stoff i nati trombotisk©og/eller an ti inf lamtaa to-rlske legemidler henholdsvis som antiaoceptiv og/eller uricds-urika. Foreliggende oppfinnelse vedrører derfor også farmasøy-tiske preparater hvilket inneholder ea av forbindelsen©aed formelen X hoaholdsvis 111, i henhold til oppfinnelsen©Iler et farmasøytisk anvendelig salt derav. Farmasøytiske proparater i henhold til oppfinnelsen vedrører sliko som or bestemt til topisk eller lokal så vel som eateral, som oralt eller rektalt, så vel som paront©ral administrering og for inhalering av varm-blodige dyr og som inneholder farmakologiske aktiv-stoffør alen© eller sammen med et farmasøytisk anvendelig bar©materiale. Doseringen av aktiv-stoffet avhenger av arten av varmblodig© dyr, alder og individuell tilstand så vel som måton av administre-ringen. Compounds of the formula I are therefore excellently suitable for the treatment of thrombotic diseases, also inflammatory diseases, especially with inflammatory components and can be used as an active ingredient in nati thrombotic and/or inflammatory diseases drugs respectively as anti-aoceptive and/or uricds-urica. The present invention therefore also relates to pharmaceutical preparations which contain ea of the compound of the formula X respectively 111, according to the invention and a pharmaceutically usable salt thereof. Pharmaceutical preparations according to the invention relate to those intended for topical or local as well as etheral, as oral or rectal, as well as parenteral administration and for inhalation of warm-blooded animals and which contain pharmacologically active substances or together with a pharmaceutically usable bar© material. The dosage of the active substance depends on the type of warm-blooded animal, age and individual condition as well as the method of administration.
De aye farmasøytiske preparater inneholdes f.eks. fra ca. 10$ til ca. 95W fortrinnsvis ca. 2©£ til ca. 90$ aktiv-stoff. Farmasøytiske preparater i henhold til oppfinnelsen or f.oks. slike i doseriagsoahetsformor, som droger, tabletter, kapsler oller suppositorier, videre ampuller. The aye pharmaceutical preparations contain e.g. from approx. 10$ to approx. 95W preferably approx. 2©£ to approx. 90$ active substance. Pharmaceutical preparations according to the invention or e.g. such in dosage forms, such as drugs, tablets, capsules or suppositories, further ampoules.
De farmasøytisk©proparater i henhold til oppfinnelsen blir fremstilt på i og for3eg kjent måte, f.oks. ved konvoa- sjonoli bland©»»grasaaler-, dragler-, oppløsninga-©Iler lyofi-liseringsfrecsigangsiaåtee The pharmaceutical preparations according to the invention are prepared in a manner known in the art, e.g. by convective oil mixture ©»»grasaaler, dragler, solution-©Iler lyophilization process
Så kan roan erholde farmasøytiske prepara tor for oral'.,,,//anvendelse idet man kombinerer aktiv-stoffør aed©t fast bær©-material©,©a ornalt-blanding, henholdsvis granulat, kaa forarbeides dersom©askolig oller påkrevet ott©r tilsetning av egnede hjelpestoffer til tabletter eller dragé-kjeraer. 2Sgn©d© borestoffer er spesielt fullstoffor som sukker, f.oks. lactose, saccaroso, maanit eller sorbit, collulosoproparator og/ollor kalsiumfosfater, f.eks. trikalsiumfosfat ellorkalsiumbydrogen-fosfat, videre bindemiddel som stivolsesklister f.eks. av mais-, hvete-, .ris- eller potetstiveisosklister, golatia, tragaat, motylcelluloso og/eller polyvinylpyrrolidon, og/eller, dersom ønsket, sproagaldler som de ovenfor angitte stivelser, yid©r©karhoksymetylstivelse, tverrfornottet polyvinylpyrrolidon, agar»alginsyro©ll©r©t salt derav, som aatriumalginoå. Hjelpemidler er i første linje fløtrogulerings- og smøremidlør, f.oks. kie-solsyre, talk, stearinsyr©eller salter derav som magnesium-, eller kalsiumstearat, og/ellor polyetylenglykol• Dragé-kjeraer blir forsynt med ogaede, eventuelt magesaft-r©sistoato overtrokk, hvorved maa blant annet anvender konsentrerte sukker oppløøaingor, hvilke inneholder eventuelt arabisk gummi, talkum, polyvinylpyrrolidon, polyetylenglykol og/ollor titan-dioksyd, lakkoppløsaiagør 1 egnede organiske oppløsaiagsmidler©lier oppløsaiagsblaadinger oilor, for fremstilling av mage-saf t -ros is tent© overtrekk, oppløsainger av©gaod©colluloseprø-parater som acotylcellulose^talat eller hydroksypropylaetyi-cellulose-ftalat. Tablotteao eller drag<S-ov©rtrekkea© kaa tilsettes fargestoffer ellør pigmoater, f.oks. for indoatlfisoring eller for aagivelse av forskjellige doser av aati-stoff©ae. Pharmaceutical preparations for oral use can then be obtained by combining the active substance with the solid berry material, or an oral mixture, respectively granules, which can be processed if necessary or required. Addition of suitable excipients to tablets or dragé containers. 2Sgn©d© boring substances are especially whole substances such as sugar, e.g. lactose, saccharoso, maanite or sorbitol, collulosoproparator and/ollor calcium phosphates, e.g. tricalcium phosphate or calcium bydrogen phosphate, further binder such as starch paste, e.g. of corn, wheat, rice or potato starch isosclists, golatia, tragaate, motyl cellulose and/or polyvinylpyrrolidone, and/or, if desired, sproagalder such as the above stated starches, yid©r©caroxymethyl starch, cross-linked polyvinylpyrrolidone, agar»alginic acid© ll©r©t salt thereof, as aatrium alginoå. Auxiliaries are primarily float regulation and lubrication agents, e.g. silicic acid, talc, stearic acid© or salts thereof such as magnesium or calcium stearate, and/or polyethylene glycol• Dragé containers are supplied with a coated, possibly gastric juice-resistant coating, whereby, among other things, concentrated sugar dissolving agents must be used, which contain possibly gum arabic, talc, polyvinylpyrrolidone, polyethylene glycol and/or titanium dioxide, varnish solvents 1 suitable organic solvents©lier solvent sheets oilor, for the production of stomach juice t -ros ice tant© coatings, solutions of©good©collose preparations such as acotyl cellulose ^phthalate or hydroxypropylethyl cellulose phthalate. Tablotteao or drag<S-over©rtrekkea© kaa be added dyes or pigments, e.g. for indolation or for the administration of different doses of aati-stoff©ae.
Anvendbare farmasøytiske preparater er vider©stikk— kapsler av gelatin så vol som myke, lukkede kapsler av gelatin og ot mykniagsmiddel som glyceria©Iler sorbitol. Stikk-kap-slene kaa inneholde aktiv-stoffet i form av et granulat, f.oks. i blandinger mod fullstoffor som lactose, blademidler som stivelse og/eller glidemidlor som talkum©Iler magnesium©tearat, og eventuelt stabilisatorer. I myk©kapsler er aktiv-stoffet fortrinnsvis oppløst eller suspendert i©gned©veskor som fet© oljer, parafinolje ellor væskcforsalgo polyetyloilfglykoler, Pharmaceutical preparations that can be used are also gelatin capsules such as soft, closed gelatin capsules and plasticizers such as glyceryl sorbitol. The suppositories may contain the active substance in the form of a granule, e.g. in mixtures against solids such as lactose, leavening agents such as starch and/or lubricants such as talcum©Iler magnesium©tearate, and optionally stabilizers. In soft capsules, the active substance is preferably dissolved or suspended in a liquid such as fatty oils, paraffin oil or liquid solutions or polyethyl oil glycols,
hvorved likeledes stabilisatorer lean var© tilføyet. Som rek-talanvondølig» farmasøytisk© preparater kommer f.eks. supposl-torler i betraktning, hvilke består av en kombinasjon av aktiv-stof f ene mød en suppositoriegrunnmasse. Som3uppositoriogruna-masse egner seg f.eks. naturlige eller syntetiske triglyceridea parafin-hydrokarboner, polyet<y>len<g>l<y>koler ellor høyere alkanoler. Videre kan også anvendes gelatia-re&talkapelor som iano-. holder en kombinasjon av aktiv-stoffer mod oa grunnmasse; som grunnmasse kan f.eks. anvondes flytende triglycorider, polyety-lenglykoler eller parafiahydrokarboaer. whereby also stabilizers lean were© added. As rectal-painless" pharmaceutical© preparations come e.g. suppositories in consideration, which consist of a combination of active substance f one with a suppository base mass. Som3suppositoriogruna mass is suitable, e.g. natural or synthetic triglyceridea paraffin hydrocarbons, polyethylene<y>len<g>l<y>cols or higher alkanols. Furthermore, gelatia-re&talkapelor can also be used as iano-. holds a combination of active substances against, among other things, the base mass; as base material can e.g. liquid triglycerides, polyethylene glycols or paraffin hydrocarbons are used.
■ For pareatoral administrering egaor sog i førsto linje vandig oppløsning av et aktiv-stoff i vanaløsolig form, f.eks. vaxmoppløselig salt, videre suspensjoner av aktiv-stoffer som tilsvarende oljeaktige iajeksjoassuspensjoner, hvorved maa anvender ©gned© liofile oppløsaingsmidler eller bærev£2Skør som fete oljer, f.eks. sesamoljeoeller syntetiske f©ttsyre-estero, f.eks.©tyloleat©Iler triglycerider, eller vandige iajeksjoas-suspeasjoner som inneholder viskosltetsforhø|cende stoffer, f.eks. natriumkarboksymetylcellulos©, sorbit og/eller dekstran og ■ For parenteral administration, the first-line solution is an aqueous solution of an active substance in normally insoluble form, e.g. wax-soluble salt, further suspensions of active substances such as corresponding oily iaexjoas suspensions, whereby lyophilic solvents or carriers such as fatty oils must be used, e.g. sesame oil or synthetic fatty acid esters, e.g. ethyl oleate and triglycerides, or aqueous aqueous suspensions containing viscosity-increasing substances, e.g. sodium carboxymethylcellulose©, sorbitol and/or dextran and
eventuelt også stabilisatorer. possibly also stabilizers.
Farmasøytiske preparater for topisk og lokal anvendelse or f.eks. for behandling av hud- lotioner og kremer som inneholder en flytende eller halvfast olje-i-vana- eller vaan-l-olje-emulsjoa og salvor som fortrinnsvis inneholder et konserverings-middel Pharmaceutical preparations for topical and local application or e.g. for the treatment of skin lotions and creams containing a liquid or semi-solid oil-in-vana- or vaan-l-oil emulsion and salves which preferably contain a preservative
Oppfinnelsen vedrører dessuten anvendelse av de ny© foi» bind©Iser med formelen I og deres salter som legemiddel, spesielt som aatitrombotika, fortrinnsvis i form av farmasøytiske preparater. The invention also relates to the use of the new binders of the formula I and their salts as medicine, especially as antithrombotics, preferably in the form of pharmaceutical preparations.
Be etterfølgende eksempler illustrerer doa ovonforbe-skrevne oppfinnelse; de skal imidlertid på ingen måte begrense deas omfang. Temperaturer blir angitt i celsiusgrader. The following examples illustrate the above-described invention; however, they shall in no way limit dea's scope. Temperatures are indicated in degrees Celsius.
Eksempel 1 Example 1
8 g 4- (p-etyleafenyl)-piporidia, 7,3 g 3,4- diklorbeazylklorid og 16 g vaaafritt kaliumkarboaat suspenderes under omrøring I 300 ml etanol og oppvarmes 5 timer ved omrøring ved tllbakeløp. ilan lar avkjølo noe, avfUtrerer fra uoppløst og inadamper filtratet ved forminsket trykk til tørrhet. Residiot tilsottos 200 ml og uttrekkes to ganger ood hvor 250 sal diøtyl-et©r. Etøreksiraktoae blir" oammenfort, vasket mod 100 al 2a-natriutalut og deretter med 100 ml mettot kokesaltoppløsning, tørket over riatriumsulfat og iandampot, hvorved reoidiot danner rått l-(3,4-diklorbea:ayl)-4-(p-etylf©nyl)-pip©ridin. Dette blir oppløst i 100 ml©tanol og oppløsningen blir syret med ©tanolisk saltsyre (2m) til pK » 1. Bett© utfølte l-(3,4-dikIorb©nsyl)-4-(p«.©tylf©jiyl)-piperidin-hydroklorid blir avsaget, vasket med diotylotor og tørket. Bet smoltor ved 253-257°. 8 g of 4-(p-ethyleaphenyl)-piperidia, 7.3 g of 3,4-dichlorobeazyl chloride and 16 g of anhydrous potassium carbonate are suspended with stirring in 300 ml of ethanol and heated for 5 hours with stirring at reflux. allow to cool somewhat, filter off undissolved and evaporate the filtrate at reduced pressure to dryness. The residue is added to 200 ml and extracted twice with 250 ml of diethyl ether. The ether extracts are combined, washed with 100 ml of 2a-sodium salt and then with 100 ml of saturated sodium chloride solution, dried over sodium sulfate and iandampot, whereby the reiodioate forms crude 1-(3,4-dichlorobea:yl)-4-(p-ethylphenyl) )-pip©ridine. This is dissolved in 100 ml©tanol and the solution is acidified with ©ethanolic hydrochloric acid (2m) to pK » 1. Bett© felt l-(3,4-dicIorb©nsyl)-4-(p« .©tylph©jiyl)-piperidine hydrochloride is sawn off, washed with diothylotor and dried.Bet smoltor at 253-257°.
Utgaagsmaterialet kan f.eks. fremstill©© som følgende» En oppløsning av 12,0 g alfa-g>-(-4-piperJ.dyl)-feayl] -©tanol i 120 ml ls-eddik tilsettes 1,2 g palladium (5^«*ig på karbon) og hydrert ved 40-50° inntil opptak av 1 ekvivalent hydrogen vod normalt trykk. ^ Deretter avfUtrerer maxi katalysatoren og Inadamper filtratet i vakuum til tørrhet. Dot i r©si-diot gjenlevende råe 4-(4-otylf©nyl)-pip©ridin kan vider© rensas vod behandling mod aktiv-kull og tilsluttende overføring i hydrokloridet. Smeltepunktet av hydrokloridot er 198-202° (fra otanol-etor). The output material can e.g. prepare©© as follows» A solution of 12.0 g of alpha-g>-(-4-piperJ.dyl)-feayl]-©tanol in 120 ml of ls-acetic acid is added 1.2 g of palladium (5^«*ig on carbon) and hydrated at 40-50° until absorption of 1 equivalent of hydrogen vod normal pressure. ^ Then filter off the maxi catalyst and evaporate the filtrate in vacuum to dryness. The crude 4-(4-otylf©nyl)-piperidine remaining in the solution can be further purified by treatment with activated carbon and subsequent transfer into the hydrochloride. The melting point of the hydrochloride is 198-202° (from ethanol-ether).
Lksemnel 2 Example 2
På analog måte som beskrevet i eksempel 1 erholdes v©d In an analogous way as described in example 1, v©d is obtained
omsetning av 4-(p-otylfoayl)-piporidin reaction of 4-(p-otylphoyl)-piperidine
med 2,4-diklorbeazylklorid l-(2,4-diklorboaisyl)-4-(p-etyifoayl)-piperidia-hydroklorid mod smelt©punkt 230°, with 2,4-dichlorobeazyl chloride 1-(2,4-dichlorobeazyl)-4-(p-ethylfoayl)-piperidia hydrochloride against melting point 230°,
med o-klorbeazylklorid l-(o-klorboazyl)-4-(p-etylf©ayl)=> piperidin-hydroklorid med smeltepunkt 195-196°»with o-chlorobeazyl chloride l-(o-chloroboazyl)-4-(p-ethylphenyl)=> piperidine hydrochloride with melting point 195-196°»
med p-klorbenssylklorld l-(p-klorbeaayl)-4-(p-©tylf©ayl)-piperidia-hydroklorid med smeltepunkt 263-265°, with p-chlorobenzylchlorold 1-(p-chlorobeaayl)-4-(p-©tylph©ayl)-piperidia hydrochloride with melting point 263-265°,
med m-klorbenzylklorid l-(sa-klorbensyl)-4-(p-etylfoayl)-piperidia-hydroklorid mod smeltepunkt 23O<0>, og med m-motoksybeaaylklorid l»(m-m©toksybenayl)-4-(p-©tyl-fenyl)-piperidin-hydroklorid med smeltepunkt 157-158°. with m-chlorobenzyl chloride 1-(sa-chlorobenzyl)-4-(p-ethylfoyl)-piperidia hydrochloride m.p. -phenyl)-piperidine hydrochloride with melting point 157-158°.
Eksempel 3 Example 3
ca g 4-(p»acctyIf©nyl)-pip©rIdin blir på analog måt©, som beskrevet i©ksompol 1 omsatt med o-kiorbo&sylklorid til l-^-klorbeasylJ-^-Cp-acetylfeaylJ-piperidin mod smeitøpunkt 96-97°. ca g of 4-(p»actyIf©nyl)-piperidine is analogously©, as described in ©exompol 1 reacted with o-corbo&syl chloride to 1-^-chlorobeasylJ-^-Cp-acetylfeaylJ-piperidine towards melting point 96- 97°.
iiksoragel k iiksoragel k
Ved omsetning av 5 g 4- [p-(l-hydrokByQtyl)-fGnyl)-piperidin med o-klorbcnsylklorid på den i' eksempel 1 bøskxovn©måt© erholdes l-(o-klorbensyl)-4-[p-(l-hydroksyetyl )-f ©nyl] piperidin-hydroklorid pod sneltopuakt 178-179°. By reacting 5 g of 4-[p-(1-hydroxybutyl)-phenyl)-piperidine with o-chlorobenzyl chloride using the wood stove method in example 1, 1-(o-chlorobenzyl)-4-[p-(l -hydroxyethyl )-phenyl] piperidine hydrochloride pod sneltopuakt 178-179°.
•acsecigel 5 •acsecigel 5
Tabletter inneholdende 100 sog aktiv-stof f, l-(3»4-di-klorbenæyi)-4-(p-otylfonyl)-piperidin-hydroklorid, kan eksem-poivis f reias tilles i følgende sammensotniags- Tablets containing 100 mg of active substance f, 1-(3,4-dichlorobeneyl)-4-(p-otylphonyl)-piperidine hydrochloride can, for example, be freely added in the following composition
Fratastillin^ Fratastillin^
Aktiv-stoffet blir blandet mod m©lk©sukker©t, en dol av hvetestlvelsea og kolloidalt silisiumdioks<y>dog blandingen blir drovet gjennom en sikt, lin annen del av hvøtestiveleen blir forklistret på vannbadøt med 5~ga^ger mongde vann og pulverblandingen blir knadd sammen med klistret inntil©n svak plastisk øasfso dannes* Massen blir drevet gjennom on sikt med ca; 3 E*m Maskevidde, tørket og dot tørre granulatet blir på nytt drevet gjennom sikten. Boretter blir resterand© hvetøstivels©, talkum og magaesiumstoarat tllblondot.- Bon©rholto blaadiag The active ingredient is mixed with the milk sugar, a dollop of wheat starch and colloidal silicon dioxide, but the mixture is passed through a sieve, the other part of the wheat starch is pasted onto the water bath with 5~ga^g of water and the powder mixture is kneaded together with the paste until a weak plastic øasfso is formed* The mass is driven through a sieve with approx. 3 E*m mesh size, the dried and dot dry granules are driven through the sieve again. Borett becomes residual wheat starch, talc and magaesium stoarat tllblondot.- Bon©rholto blaadiag
blir prossøt mod tabletter på 250 ag aed bruddrill©(r). becomes prossøt mod tablets of 250 ag aed bruddrill©(s).
Em tii tilbakoløp oppvarmet suspensjon av 1,2 g -liti-, iHaaluminiusihydrid i 50 al 'absolutt totraay&rofuran blir lang» somt tilsatt en oppløsning av 19»7 g Iv°(3#4-dlc}Ctok3yboa2oyl)-k-(Z*-©tylf©nyl)-piperidin 1 50 ni absolutt tctranydrofuran og oppvarmet ytterligere 24 timer ved tllbakøløp. Etter avkjøling av reaksjonsblandingon tilsetter nma 10 ol eddik-oster og lite vann, avfUtrerer og uttrekker totrabydrofuranet. Eesidiet blir oppløst i 2a-saltsyr©og vasket med en litea mengde©tor» Den vandige fase blir innstilt alkalisk med on 2a-natronl*at og oke» traaørt m©d©tor. Sttor vasking av otorfasea. mød vann, tørking over aaga©sium3ulfat og iandampaing orhold©r man r#tt i-(3»4<=> diQetoksyb©asyl)-4-(p-©tylfonyl)-pip©ridin» som fra©taaolisk oppløsning ved tilsetning av en ekvivalent caøngde fuoarsyr©, oppløst i etanol, krystallisorto som furaarat mod ømeltopuakt 151-153°. To a reflux heated suspension of 1.2 g of -lithium-, iHaaluminusi hydride in 50 al of 'absolute totraay&rofuran is long» to which is added a solution of 19»7 g of Iv°(3#4-dlc}Ctok3yboa2oyl)-k-(Z* -©tylph©nyl)-piperidine 1 50 ni absolute tctranydrofuran and heated a further 24 hours at reflux. After the reaction mixture has cooled, about 10 ol of vinegar and a little water are added, filtered and the totrabydrofuran is extracted. The acid is dissolved in 2a-hydrochloric acid and washed with a small amount of tor. The aqueous phase is made alkaline with 2a-sodium chloride and oke" traaört with tor. Large washing of otorfasea. warm water, drying over aga©sium sulfate and iandamping orhold©r one r#tt in-(3»4<=>diQethoxyb©acyl)-4-(p-©tylfonyl)-pipe©ridine» as an aqueous solution at addition of an equivalent amount of fuaroic acid©, dissolved in ethanol, crystallisorto as furarate mod emeltopuakt 151-153°.
Utgangsæatorialet kan f.eks, på analog måt© som beskrevet i eksempel 1 fremstilles ved omsetning av 4-(p-otylfeayl)= piporidin med 3»4-dimotoksybeasoylklorido Bot smelter vod 110-112°. The starting material can, for example, be prepared analogously to that described in example 1 by reacting 4-(p-otylpheyl)=piperidine with 3'4-dimethoxybeazoyl chloride, which melts at 110-112°.
På analog måte kan man fremstille v©& omsetning av 4-(p-©tylfeayl)-piporidin med 3»4-diklorben&oylklorid over I-(3,4-diklorbonsoyl)-4-(p-etyIfenyl)-piporidin a©d smoltopunkt 77-79° l-(3,4-diklorbonayl)-k-(p-etylfenyl)-pip©ridin mod smeltepunkt 255-257°. In an analogous way, one can prepare by reacting 4-(p-ethylphenyl)-piperidine with 3'4-dichlorobenzoyl chloride over 1-(3,4-dichlorobenzoyl)-4-(p-ethylphenyl)-piperidine and melting point 77-79° 1-(3,4-dichlorobonayl)-k-(p-ethylphenyl)-piperidine against melting point 255-257°.
På analog måt©som beskrevet i eksempel 1 ©raøldor In an analogous way ©as described in example 1 ©raøldor
man ved omsetning av 4-(o-etylfeayl)-piporidin mod 3,4»diklor~ bonzylklorid 1-(3t 4-diklorbensyl)-4-(o-etylfoayl}-piperidia-aydrokloridet med smeltepunkt 250°. one by reacting 4-(o-ethylfoyl)-piperidine against 3,4»dichlorobenzyl chloride 1-(3t 4-dichlorobenzyl)-4-(o-ethylfoyl)-piperidiahydrochloride with a melting point of 250°.
Utgangsmaterialet kan fremstilles på følgoad© måt©s°.Til ea suspeasjoa av 10 g magnoslumspoa i lit©tetra-bydrofuraa tilsetter maa dråpovis under omrøring og ved uto-sluttaing av vann oa oppløsaiag av 75 g l-étyl-2-brombeas©a i 50 ml tetraaydrofuran så langsom at reaksjonstemperaturen 60° ikke overstiges. Beretter tilsotter maa i løpet av 45 mia^tter en oppløsning av 57 g £3-bens5yl-4-piporidon i 150 al tetrahydrofuran. Etter fullført tilsetning lar man omrør© yttorligor©<m tim© ved 60°. Den til 0° avkjølte reaksjoasblanding blir tilsatt 1000 ml iskaldt, mettot ammonkioridoppløsning og ekstrahert to ganger med 2x 1000 ml eter. Do organiske ekstrakter blir tørket over natriumsulfat og inadampet i vakuum. Destillasjon av diaadampnlngsresidiet 1 høyvakuum gir i don ved 175-130° (0,05 mm) kokende fraksjon 52 g av 4-hydroksy-4-(2-otyl-feaylJ-H-benæylpiperldin som fargeløs olje. The starting material can be prepared in the following manner. To a suspension of 10 g of magnoslum poa in lit©tetra-bydrofuraa, add dropwise while stirring and with constant addition of water or dissolve 75 g of l-ethyl-2-bromobeas©a in 50 ml of tetrahydrofuran so slowly that the reaction temperature of 60° is not exceeded. A solution of 57 g of £3-benzyl-4-piperidone in 150 al of tetrahydrofuran is added over the course of 45 minutes. After the addition is complete, it is allowed to stir© yttorligor©<m hour© at 60°. The reaction mixture cooled to 0° is added to 1000 ml of ice-cold, saturated ammonium chloride solution and extracted twice with 2x 1000 ml of ether. Then organic extracts are dried over sodium sulfate and evaporated in vacuo. Distillation of the dia-evaporation residue 1 high vacuum gives in don at 175-130° (0.05 mm) boiling fraction 52 g of 4-hydroxy-4-(2-othyl-phenyl)-H-beneylpiperidine as a colorless oil.
Til en oppløsning av ovenfor anførte produkt i 120 ml ls-eddik tilsetter man 40 ml konsentrert saltsyre og 30 ml vann og oppvarmer 3 timor under tilbakoløp* Deretter inndamper oa» i vakuum, innstiller med natronlut alkalisk til pH 14 og ekstraherer ved i skjelning to ganger med 1000 ml eddik-ester. Sen organisk© fase vaskes mod vann, tørkes over natriumsulfat og inndampes i vakuum. iHan erholder således rå oljeaktig l-benzyl-4-(o-etylfeayl)-1,2,3,6-tetrahydro-pyridin, som direkte vider©forarbeides. (llydroklorid: Smeltopunkt 205°). To a solution of the above-mentioned product in 120 ml of acetic acid, add 40 ml of concentrated hydrochloric acid and 30 ml of water and heat for 3 hours under reflux* Then evaporate the above in a vacuum, adjust with caustic soda alkaline to pH 14 and extract with 2 times with 1000 ml of acetic ester. The late organic phase is washed with water, dried over sodium sulphate and evaporated in vacuo. He thus obtains crude oily 1-benzyl-4-(o-ethylphenyl)-1,2,3,6-tetrahydro-pyridine, which is directly further processed. (hydrochloride: Melting point 205°).
Til ea oppløsaiag av 43»5g l-bensyl-4-(o-otylfeayl)-1,2,5,6-totrahydro-pyridin i 450 ml ls-eddik tilsetter man 48,1 ml 3,4 a-etaaolisk saltsyre og 22,5 g palladium (5>j-ig på karbon) og hydrert ved 40-45° inntil opptak av 2 ekvivalenter hydrogon. Deretter avfUtrerer man katalysatoren, inndamper filtratet i To a solution of 43.5 g of 1-benzyl-4-(o-ethylphenyl)-1,2,5,6-totetrahydro-pyridine in 450 ml of 1-acetic acid, add 48.1 ml of 3,4 α-ethaolic hydrochloric acid and 22.5 g palladium (5>j-ig on carbon) and hydrogenated at 40-45° until absorption of 2 equivalents of hydrogen. The catalyst is then filtered off, the filtrate is evaporated
vakuum til tørrhet, oppløser landarapaingsrosidiot i 300 ml vann, vacuum to dryness, dissolve landarapaing rosidiote in 300 ml of water,
w. innstiller med natriumlut til pH 14 og okstrailerer to ganger mod 500 ml eter. Dot organiske ekstraktet blir tørket over natriumsulfat og inndampot 1 vakuum til tørrhet. Xaadampaiags-residiet oppløser man i 130 ml etaaol og tilsetter ved 60° ea varm oppløsning av 15t5g fumarsyre i 350 ml varm. Dot vød av-kjøling utkrystalliserende 4«(o-etylfønyl)-pip©ridin-fumarat blir avfUtrert, vasket med etaaol og eter og tørket i vakuum ved værelsestemperatur. Smeltepunkt 195°• w. adjust with sodium hydroxide solution to pH 14 and ox trailers twice against 500 ml of ether. The organic extract is dried over sodium sulfate and evaporated to dryness under vacuum. The Xaadampaiags residue is dissolved in 130 ml of ethanol and at 60° ea a hot solution of 15t5g of fumaric acid in 350 ml of hot water is added. After cooling, the crystallized 4'(o-ethylphenyl)-piperidine fumarate is filtered off, washed with ethanol and ether and dried in vacuo at room temperature. Melting point 195°•
tksempel S example S
På analog måte som beskrevet i eksempel 1 erholder man vod omsetning av 4-(m-otylfeayl)-piporidin med 3,4-diklorboaayl-klorid 1-(3,4-diklorbonzyl)-4-(m-etylfenyl)-piporidia-hydrokloridet med smeltepunkt 249-50°. In an analogous manner to that described in example 1, water is obtained by reacting 4-(m-ethylphenyl)-piperidine with 3,4-dichlorobenzoyl chloride 1-(3,4-dichlorobenzoyl)-4-(m-ethylphenyl)-piperidine- the hydrochloride with a melting point of 249-50°.
Utgaagsmatorialet kaa fremstilles på følgeado måtes- The output material can be produced in the following way-
Omsetning av 60 g 3-etyl-broubenzea mod magnesium og Conversion of 60 g of 3-ethyl broubenzea against magnesium and
6l g N-benzyl- 4-piporidoa gir 4-aydroksy-4-(tn-etylfenyl)-K°b©a-syipiperidia med kokepunkt l<r^-200° (0,04 ami). 6l g of N-benzyl-4-piperidoa gives 4-hydroxy-4-(tn-ethylphenyl)-K°b©a-syipiperidia with boiling point 1<r^-200° (0.04 ami).
B©rav erholder "man iaod is-oddik/saltoyre blyaktig rått l-benzyl-4-(o-etylf©nyl)-l,2,3t6-totrahydro-pyridln, som tat ©a ytterligere rensning på analog måt©soo beskrovot i okooapol 7 (fredetilling av utgangsiaat©rialot) overfores ved bydreriag ved palladium (5'^-ig på karbon)- i 4-(m-otylf©nyi)-pip©ridin-fuEsaratet. From this, glacial acetic acid/saltwater lead-like crude 1-benzyl-4-(o-ethylphenyl)-1,2,3t6-totrahydro-pyridine is obtained, which undergoes further purification in an analogous manner as described in okooapol 7 (preparation of starting sialate) is transferred by bydreriag at palladium (5'^-ig on carbon)- in the 4-(m-otylf©nyi)-pipe©ridin-fuEsarate.
Lksomoel^9 Lksomoel^9
Til ea oppløsning av 3,5 g 3,4-dlklorbøazyla£ala i ICOml etaaol og 20 ml 2a-Natroalut tilsetter aaa uador omrøring ved 0° ea oppløsning av 6,7 g 3-(p°otylf eayl)-l,5-dibroa-p©ataa. i/c tor utført tilsetning blir" reaksjonsblaadiagoa oppvarmet 10 timer under tilbakeløp. Iserotter avkjøler mam til voroløestemporatur, bleker mod lit©natriumtlosulfat, iaadampGr i vakuum til tørrhot og destillerer residiet høyvakuma. Den vod 9G~i40° (0,03 mrnHg) kokende fraksjon blir videre renset kromatografIsk på kioselgol med klorbform-motanol (15:1). I-laa erholder l~(3,4~dikIorben3yl) To ea solution of 3.5 g of 3,4-dlchloroboazyla£ala in 10 ml of ethanol and 20 ml of 2a-Natroalut add aaa uador stirring at 0° ea solution of 6.7 g of 3-(p°otylf eayl)-1,5 -dibroa-p©ataa. i/c tor the addition is carried out, the reaction vessel is heated for 10 hours under reflux. Icerott cools the mam to vorol solution temperature, bleaches against lit©sodium tlosulfate, iaadvaporGr in vacuum to dryness and distills the residue under high vacuum. It vod 9G~i40° (0.03 mrnHg) boiling fraction is further purified chromatographically on Kioselgol with chloroform-mothanol (15:1).
-l»-(p-otylfoayl)-piporidin. Dette blir for karakterisering som boskrevet i.eksompol 1 overført i hydrokloridot med smeltepunkt 253-258°. 1-(3,4-diklorbeaayl)-4-(p-otylfeayl)-plperidia-fuma= ratet kan fremstilles analogt. Det smelter ved 255-257°» -1'-(p-Otylphoyl)-piperidine. For characterization, as described in Exompol 1, this is transferred into hydrochloride with a melting point of 253-258°. The 1-(3,4-dichlorobeayl)-4-(p-otylpheyl)-plperidia fumarate can be prepared analogously. It melts at 255-257°»
Dot som utgaagsmateriale anvendt 3°{p-©tyl-foayl)«=l,5,-dibrom-pentaa lar sog f.oks. på følgoad©måt©frcostilios Dot as starting material used 3°{p-©thyl-foyl)«=1,5,-dibromo-penta allows sog e.g. on followoad©way©frcostilios
Ea eppløsniag av 43 g p-etylbenzaldehyd og 52 g diotyl-fosforacetoaitril i 300 ml metyleaklorld blir iløpot av 15 minutter ved lskjøliag tilsatt di-åpevis til ea godt omrørt omul-sjoa av 6,5 g tetrabutylammonlumbromid i 180 ml 50'p-iger aatroa-lut og 150 ml motylonklorid. Tilsluttende omrører øan 30 minutter vod vorolsestempøratur. Boretter blir don organiske fase fraskilt, vasket nøytralt med vann, tørket over aatriumsualfat og inadampet i vakuum. Bet således erholt© råo pc©tyl-kaa©lsyreal-trli [olj©; JS (Cn2Cl2)s maks. 2240 cm"<1>] blir tilsatt ea opp-løsning av 8 g aatrium i 53 g maloasyrodietylostor og 400 ml ab=> solutt etaaol og oppvarmot 2 timer ved tilbakeløp. Deretter l_ inadamper man i' vakuum til ea tredjedel, tilsotter 500 ml vandig eddiksyre (0,5n) og ekstraherer 3 ganger med 500 tal©t©r. £>@n organisko fase vaskes nøytralt, tørkes ov©r aatriussulfat og iundampes i 'valmua til tørrhet. Sxomatografi av iaadampnings» rosidiet på 1 leg øilisiumdioksydgøl taed aetylenklorid soa lope-aiddoJ. gir 2-karboetokoy-3-(p-©tylf©ayi) «propan-l=>karbonsyre-©tylostor-3-aitrii so<p>fargeløs olj© [ ILI (CH2C12)Omaks.8 1?20 cm""1 (Skulder)] • A solution of 43 g of p-ethylbenzaldehyde and 52 g of diethyl phosphoracetoaitrile in 300 ml of methylene chloride is added over 15 minutes under cooling to a well-stirred solution of 6.5 g of tetrabutylammonium bromide in 180 ml of 50% aatroic lye and 150 ml of mothylone chloride. Finally, the island is stirred for 30 minutes at room temperature. After this, the organic phase is separated, washed neutrally with water, dried over sodium sulfate and evaporated in a vacuum. Bet thus obtained crude pc©tyl-ka©lsyreal-trli [oil; JS (Cn2Cl2)s max. 2240 cm"<1>] is added to a solution of 8 g of sodium in 53 g of maloacyrodiethyl ester and 400 ml of saturated ethanol and heated for 2 hours at reflux. Then it is evaporated in vacuum to a third, 500 ml is added aqueous acetic acid (0.5n) and extract 3 times with 500 tal©t©r. The organic phase is washed neutrally, dried over sodium sulfate and evaporated to dryness in poppy seeds. Chromatography of the evaporation" solution on 1 leg of silicon dioxide gel taed aethylene chloride soa lope-aiddoJ. gives 2-carboethokoy-3-(p-©tylf©ayi) «propane-l=>carbonic acid-©tylostor-3-aitrii so<p>colorless oil©© [ ILI (CH2C12)Omax. 8 1?20 cm""1 (Shoulder)] •
2-karboetokoy-3- (p-etylfeayl) -propan-l-karbonsyroetyl-©ster-3-aitril lar sog analogt til don i J. Amer. Chom. Soc.j 53, 1105 (l93l) beskrevne fremgangsmåt© oasetto til 3-(p-etylfeayl)-l,5»dibrom-peataa. ©ott© kokor vod I75-l£>5° (12 mmllg). 2-Carboethoxy-3-(p-ethylphenyl)-propane-1-carboxyroethyl-©ster-3-aitril lar sog analogously to don in J. Amer. Chom. Soc.j 53, 1105 (1931) described process© oaseto to 3-(p-ethylphenyl)-1,5»dibromo-peataa. ©ott© kokor vod I75-l£>5° (12 mmllg).
jjikseispcl 10 jjikseispcl 10
Til. en suspensjoa av 150 mg lltiumalumiaiumhydrid i To. a suspension of 150 mg of lithium aluminum hydride i
20 al absolutt tetrahydrofurasa tilsotter man under omrøring i ©xi nitrogena tenosfæro porsjoasvis 1 g 1- ( 3»4-dicotoksybonsyl)-ii-(p-otylf©nyl)-2-piporldon. deretter lar masa omrør© 1 tic© vod 60°, avkjøl© til vmrelsesteiaperatur, tilsotter dråpevis 0,5 ml vann og 0,1 cal 2n-L:atroalut og filtroror over kiesolgur. Filtratet blir- inndaeipot og det i inndampaingsr©sidiot gjoavca-rend©råe l-(3»4-dimoteksyben:3yl)-4-(4-otylf@nyl)-piperldln blir som beskrevet i eksempel 6 bvorført i fuaaratet saed F 151-153°»20 al of absolute tetrahydrofurase is added with stirring in ©xi nitrogena tenosféro 1 g 1-(3»4-dicotoxybonsyl)-ii-(p-otylf©nyl)-2-piperledone. then let the mass stir © 1 tic© vod 60°, cool © to room temperature, add drop by drop 0.5 ml of water and 0.1 cal 2n-L:atroalut and filter over kieselguhr. The filtrate is absorbed and the evaporation solution yields 1-(3-4-dimethoxyben:3yl)-4-(4-otylph@nyl)-piperlidene, as described in example 6, which is transferred to the fuarate saed F 151 -153°»
Utgangsiuaterialot kan erholdes son følgende: Output iuaterialot can be obtained from the following:
En oppløsning av 31 g 2»karbo©toksy°3-(pa,©ty^Æ<>>Q^yi),°propan-l-karbonsyrcetylester-3-nitril 1 1,6 g trletylasain og 500 sal absolutt taed©tanol blir bydrert mod & g Siaaey-nikkel til opptak av .omtrent 4 1 hydrogen. Boretter avfiltrerer " maia katalysatoren og inndamper i vakuum til tørrhet. Av inndaEspnings» rosidiet krystalliserte taed etor 3-karbo©toksy-4-(p-etylfenyl)-2-piperidoaet sted P-157-159°. A solution of 31 g of 2»carbo©toxy°3-(pa,©ty^Æ<>>Q^yi),°propane-1-carboxylic acid cetyl ester-3-nitrile 1 1.6 g trletylazine and 500 sal absolute taed© tanol is bidred mod & g Siaaey-nickel to take up .about 4 1 of hydrogen. Borette filters off the catalyst and evaporates in vacuo to dryness. From the indaEspnings rosidide, the ether 3-carbo©toxy-4-(p-ethylphenyl)-2-piperidoate crystallized at P-157-159°.
lisa oppløsning av 3 g av doa ovenfor angitte forbindelse i 110 tal etaaol, 40 ml 2n-Katronlut og 50 ml vaaa blir kokt under tilbakeløp i 45 minutter. Beretter inadampor man i vakuum til tørraet, innstiller irmdampniagsr©3idiot med 2a«aaltsyrs til pli 1 og ekstraherer med 500 ml kloroform. Dea organisk© fas©blir vasket *' ^Tlinøytralt,- tøziiot over natriumsulfat og iaadampøt i vakuum. Det i iaadampningsresidiot gjenværende rå, krystal-linet 3-karboksy-4-(4-etylfeayl)-2-piperidoa (smeltepunkt 125° spaltes) blir oppvarmot i 400 ml toluol i 30 einu&ør med fcil-bakoløp. Borettor inadamper man til©t volum på omtrent 20 ml og tilsottor ea mindre mengd© eter. Bervsd utkrystallisøror add a solution of 3 g of the above-mentioned compound in 110 tal ethanol, 40 ml 2n-Katronlut and 50 ml water is boiled under reflux for 45 minutes. Evaporate in vacuo to dryness, adjust the evaporation rate with 2% hydrochloric acid to volume 1 and extract with 500 ml of chloroform. The organic phase is washed *' ^Tlineutral,- töziiot over sodium sulfate and iaad vapor in vacuum. The crude, crystalline 3-carboxy-4-(4-ethylphenyl)-2-piperidoa remaining in the evaporation residue (melting point 125° is split) is heated in 400 ml of toluene for 30 minutes with reflux. Boretto is evaporated to a volume of approximately 20 ml and a smaller amount of ether is added. Bervsd crystallization tubes
4-(p-©tylf©nyl)-2-piperidoaet. saod F-l65°. 4-(p-©tylph©nyl)-2-piperidoate. saod F-l65°.
Til oa oppløsning av 2 g 4-(p-etylfeayl)-2-piporiaon°£3»2 g tetrabutylaoraoaiuobroiald i 40 al motylonklorid tilsettes* cran 2,3 g 3,4-dimetokeybeasylklorId og 40 al 30v--iger Matronlut. Deaae blanding blir oarørt 4 tiiraor og deretter fraskilt doa vaadigo fase. Doa organiske fase blir vasket nøy-tral mod vaaa, tørket over natriumsulfat og laadaopet. Iandacp» aiagsreStidiet blir omrørt med eter. Boa eterløslig© andel» son , inneholder *A-( 3,4-dit3otoksyboasyl)-4-(p-etyI-feayl)-2-piperi-doaot, blir iandampet og aten ytterligere reasaiag anvendt i nest©trina. To oa solution of 2 g of 4-(p-ethylfeayl)-2-piporiaon°£3»2 g of tetrabutylaoraoaiuobroiald in 40 al of motylon chloride are added* cran 2.3 g of 3,4-dimethokeybeacylchlorId and 40 al of 30v--iger Matronlut. The mixture is left undisturbed for 4 hours and then separated from the liquid phase. The second organic phase is washed neutral against water, dried over sodium sulfate and charged. Iandacp» aiagsreStidiet is stirred with ether. The ether-soluble portion, containing *A-(3,4-dithiothoxyboacyl)-4-(p-ethyl-feayl)-2-piperidoate, is evaporated and then further reasaiag used in nesting.
i£kaemgol _11_ i£kaemgol _11_
Ea oppløsning av 6,4 g l-(ni-m©tøksyb©n2yl)-4-(p-ac©« tylfeayl)-piporidin og 5 ml hydraziahydrat i 50 pl e ty lengly-kol blir tilsatt 7»5g pulverisort natriumofydroksyd og kokt 1,5 timer under tilbakeløp. Deretter avdestillerer man oa blanding av hydrasin og vaaa til sumptemporaturen 190° oppnåes. Etter avkjølingen av reaksjoasblaadlagoa blir tilsatt samme mengd©vaaa og okstrahort med©ter. £terfas©n blir tørkot ov©r natriumsulfat og iaadampot. laadampaiagsrosidiet blir krornato-grafert på et silisiumdioksydgel med metyloaklor-id/motaaol (15*1) som eluens og gir l-(m-metoksybeasyl)-4-(4-©tylf©ayl)-pip©ridia som på vaalig måt© blir overført i hydrokloridot med smoltø-puakt 157-15S<0>. To a solution of 6.4 g of 1-(ni-methoxyben2yl)-4-(p-acetylphenyl)-piperidine and 5 ml of hydrazide hydrate in 50 pl of tylenglycol is added 7.5 g of powdered sodium hydroxide and boiled for 1.5 hours under reflux. A mixture of hydrazine and water is then distilled off until the sump temperature of 190° is reached. After the reaction mixture has cooled, the same quantity of oxtrahort med©ter is added. The terphase is dried over sodium sulfate and evaporated water. The laadapaiagsroside is chromatographed on a silica gel with methylachlorid/motaalol (15*1) as eluent to give 1-(m-methoxybeasyl)-4-(4-ethylphenayl)-piperidia which is essentially is transferred into hydrochloride with smoltö-puakt 157-15S<0>.
Lksem<p>ol^^12 Lksem<p>ol^^12
På aaalog aåte som beskrevet i eksempel 1 erholder man ved omsøtaiag av 4-(p-etylfeayl)-piporidin aed p-Piuorbeasyl-klorid 1-(p-Pluorben:s<y>l)-4-(p-et<y>lfea<y>l)-<p>i<p>eridin-hydrokloridmod smeltepunkt 250-52° og aed beazylklorid l-b©azyl-4-(p-otyl°feayl)-piperidia-fumarat med smeltepunkt 183-185°• In the same way as described in example 1, one obtains by sweetening 4-(p-ethylphenyl)-piperidine and p-Pluorbeacyl chloride 1-(p-Pluoroben:s<y>l)-4-(p-et<y >lfea<y>l)-<p>i<p>eridine hydrochloridemod melting point 250-52° and aed beazyl chloride l-be©azyl-4-(p-otyl°feayl)-piperidia-fumarate with melting point 183-185°•
Lkseasgel 13 Lkseasgel 13
Få aaalog måt© som boskrovot i eksempel 1 henholdsvis 3©rholdor man ved omsetning av 4-(p-acetylfoayl)-piporidin modEj-motoksybensylbroiaid l-(m-røotoksybonzyi)-4-(p-acøtylf©nyl)« pip©ridin-fumarat med smeltepunkt 137-59°»Obtain a similar method as boskrovot in example 1 respectively 3©rholdor one by reacting 4-(p-acetylfoyl)-piperidine modEj-motoxybenzylbroiaid 1-(m-reoethoxybonzyi)-4-(p-acetylph©nyl)« pipe©ridine -fumarate with melting point 137-59°»
med 3,4-diklorbeasyIklorid l-(3,4-diklorbeazyl)-4-(p-ac©tylf©ayl) -piperidia-hydrokloridet med smeltepunkt 25&«=,60° og lasd bensylklorid l-beaisyl-4- (p-ac©tylf©nyl)-pip@ridia-fus2aratot taed©melt©punkt 161-62°. with the 3,4-dichlorobeazyl chloride 1-(3,4-dichlorobeazyl)-4-(p-acetylph©ayl)-piperidia hydrochloride of melting point 25&«=.60° and charged benzyl chloride 1-beazyl-4-(p -ac©tylf©nyl)-pip@ridia-fus2aratot taed©melt©point 161-62°.
kksetagel^ 14 kksetagel^ 14
På analog måto som beskrevet i eksempel 4 erholder can med omsetning 4-jp-(l-hydrøaeyoty1)-feayl1-pipøridia med bon« zylklorid l-benayl-4 {p-(l-hydr©ksy©tyl)-feaylJ-pipori&ia-furna» ratet saed smeltepunkt 154-15$°, m©d m-møtoksyoteasylbromid 1-(m-motoksybenzyl)-4-rg-(I-hydroksy©ty1)-fenyl] -piperidin-fuaa-ratot med smeltepunkt l60-6l° og In an analogous manner to that described in example 4, can is obtained by reacting 4-β-(1-hydroxyethyl)-feayl-1-piperidia with benzoyl chloride 1-benayl-4{p-(1-hydroxyethyl)-feayl-1-piperidia -furna»rate saed melting point 154-15$°, with m©d m-methoxyotheacyl bromide 1-(m-methoxybenzyl)-4-rg-(1-hydroxy©thy1)-phenyl]-piperidine-fuaratot with melting point 160- 6l° and
med 3,4-diklorbeassylklorld l-(3,4-diklorb©azyl)-4- jp-(1-hydroksy©tyl)-f©nyl)-piperidin-fumaratet med smeltepunkt 195-97°. 8 g 4-(p-otylfeayl)-piporidin, 4,2 g bensylklørid og 16 g vaaafritt kaliumkarbonat blir suspendert uader omrøring i 300 ml©tanol og varm©t 5 timer ved tilbakeløp. Maia avkjøler noe, avsager fra uoppløst og inadamper under forminsket trykk til tørrhet. Résidiet blir tilsatt 200 ml vaaa og uttrukkot to ganger med 2s 170 ml dietyloter. Btorokstraktea© blir samaea-ført, vaskot med 100 ml 2n-$atroalut og deretter mod 100 ml mot-tet koksaltoppløsning, tørket over natriumsulfat og iandampet til tørrhet. Man erholder l-beazyl-4-(p-etylfoayl)-piperidia, som ved oppløsning 1 etaaol og surgjøx-ing med etaaolisk saltsyre kaa overføres i - i-boazyl-4-(p-etylfeayl)-piperidin-hydroklorid. with 3,4-dichlorobeacylchlorold 1-(3,4-dichlorob©azyl)-4-jp-(1-hydroxy©thyl)-phenyl)-piperidine fumarate with melting point 195-97°. 8 g of 4-(p-otylpheyl)-piperidine, 4.2 g of benzyl chloride and 16 g of anhydrous potassium carbonate are suspended without stirring in 300 ml of ethanol and heated for 5 hours at reflux. The mixture cools slightly, precipitates from undissolved and evaporates under reduced pressure to dryness. The residue is added to 200 ml of water and extracted twice with 2 x 170 ml of diethyl ether. Btorok extract is concentrated, washed with 100 ml of sodium chloride and then with 100 ml of sodium chloride solution, dried over sodium sulfate and evaporated to dryness. One obtains 1-beazyl-4-(p-ethylfoyl)-piperidia, which, by dissolving 1 ethaol and acidifying with ethaolic hydrochloric acid, can be transferred into - i-boazyl-4-(p-ethylfeayl)-piperidine hydrochloride.
Utgaagsmaterialet kaa f.eks. erholdes på følgende måtes The source material can e.g. is obtained in the following way
£n oppløsaiag av 12,0 g alfa-^p-(4«piperidyl)-feayl] - etaaol i 120 ml is-eddik blir tilsatt 1,2 g palladium (5<r>^-ig på karboa) og hydrort ved normalt trykk ved 40-50° til opptak av 1 ekvivalent hydrogen. Deretter avfUtrerer man katalysatoren og inadamper filtratet i vakuum til tørrhet. Det i inadamp-aiagsresidiet gjeabæroade blåe 4-(4-etylf©ayl)=pip©ridin kaa ved behandling med aktiv-kull og tilsluttende overføring i hydrokloridet renses ytterligere. Smeltepunktet av hydrøkloridot utgjør 193-202° (fra etaaol-etor). To a solution of 12.0 g of alpha-[p-(4-piperidyl)-phenyl]-ethaol in 120 ml of glacial acetic acid is added 1.2 g of palladium (5<r>^-ig on carbon) and hydrogenated at normal pressure at 40-50° to absorb 1 equivalent of hydrogen. The catalyst is then filtered off and the filtrate is evaporated in vacuo to dryness. The red-blue 4-(4-ethylphenyl)=piperidine obtained in the vapor-residue by treatment with activated carbon and subsequent transfer into the hydrochloride is further purified. The melting point of the hydrochloride is 193-202° (from ethyl ether).
Eksoiapøl 16 Exoia pool 16
På analog uåte sota beskrevet i©kseap©!-15 kaa ©rad-des l-bensy1-4-(2,4-din©tyl-feay1)-l,2,5,6-t©fcra^ay&ro~pyridia ved overføriag av 34 g 4-brom-m-xylol i brøia-oaagnesiuimf orbind-eisen©tter Grignard, omsotning av dea satane taad 3& g 27-bønsyl-4-piporidan og etterfølgende vaaaavøpaitaiag voel ajølp av ctkiik-syro-såltsyro, soa koker ved 0,05 omHg v©d ca. 170°, Ilkoiedos l-benay 1-1,2,5»6-1otraaydro-4- ( p-metylfoayl)-pipøridia, seielte-puakt 40-41° (fra kold Feataa). On analogous uneaten sota described in by transfer of 34 g of 4-bromo-m-xylene in Brøia-oaagnesiuimf orbind-eisen©tter Grignard, conversion of dea satane taad 3& g of 27-bensyl-4-piperidan and subsequent vaaaavøpaitaiag voel ajølp of ctkiic-acid-saalsyro, soa boils at 0.05 omHg w©d approx. 170°, Ilkoiedos l-benay 1-1,2,5»6-1otraaydro-4-( p-methylfoayl)-piporeridia, seielte-puakt 40-41° (from cold Feataa).
Lic sotage 1^17 Lic sotage 1^17
Ea oppløsalag av '55 g l-beaayl-4-=aydroksy-4=» |>-=>(l»©ty-leadioksyetylj-foayl]-piperiiiiji 1 250 ml konsentrert saltoyre .blir oppvarmet tr©timor vod tilbakeløp. Bana inadamper saa i vakuum til tørrbet, inns tiller aed 2a-Natronlut til pli 14 og ekstraborer tr© ganger m©d 500 al diotyloter. B©organisk© fa<= ser blir øammonført, vasket nøytralt, tørket over natøiumsulfat og iaadanpot til©a tredjedel. B©t utkrystallisert© rent 1-boa25yl-l,2,5,6-t©traaydro-4-(4-acetylf©ayl)-pyridia a©d saoltø» punkt 99-100°. Ea dissolving layer of '55 g l-beaayl-4-=aydroxy-4=» |>-=>(l»©ty-leadioxyethylj-foayl]-piperiiiiji 1 250 ml concentrated brine .is heated tr©timor vod reflux. Bana evaporate in vacuum to dryness, add 2a-Sodium lye to 14 and extract three times with 500 al of diethyl ether. The organic phase is ammoniated, washed neutrally, dried over sodium sulfate and added to a third. B©t crystallized© pure 1-boa25yl-1,2,5,6-tetrahydro-4-(4-acetylphenyl)-pyridia a©d saoltø» point 99-100°.
Utgaagsciatorialet kaa f.oka. fresstill©ø på følgoad© The issue report can be found here. frestill©ø on followoad©
måtes. manner.
Til oa suspensjon av 9»tJ g magnøslæispoa i 100 al absolutt tot raaydro furan tilsetter man dråp©vis ved omtrent 50° ved fravær av vann langsomt on oppløsning av 97 g 4-brom=ac©to&s fenoa-øtylenketal i 100 ml abøolutt tetraliydr of tåraa. Så såart alt magaosiua er gått i oppløsning, avkjøler æa» til 5°©g tilsotter dråpevie oa oppløsning av 70 g W-bønzyI-4-piperidon i 100 ml absolutt totraaydrofuraa. Uttorf fullført tilsetning blir iaadampet 1 vakuum til tørraet og iaadaaipaiagsrosidiet blir opptatt i vannfritt etylotor og avfiltrort. Bet avfUtrerte blir deretter delt mollom 3- ganger 200 mi©tor og 200 ml a©ttetfikold, vaaadig aamoalumkløridoppløsaiag. B©organisk© faser blir sammeaført, vasket nøytralt, tørketo over- Natriumsulfat og iaa-datnpet 1 vakuum til tørrbet. Bet således eraolt©l-b©asyl-4-aydroksy-4- fp«(l-otyløndioksyetyl)-f eay I] -piporidin smoltet vød 114-116°. A solution of 97 g of 4-bromoacetate in 100 ml of abøolut tetraliydr is added dropwise at about 50° in the absence of water to a suspension of 9»tJ g of magnesium oxide in 100 ml of absolute tot raaydro furan of tears. As soon as all the magaosiua has dissolved, cool the mixture to 5°©g, add dropwise a solution of 70 g of W-benzoyl-4-piperidone in 100 ml of absolute totrahydrofuraa. After the addition is complete, it is evaporated under vacuum to dryness and the residue is taken up in anhydrous ethyl ether and filtered off. The defatted liquid is then divided between 3 times 200 ml and 200 ml of cold, wet amoalum chloride solution. B©organic© phases are combined, washed neutrally, dried over Sodium sulfate and iaa-datnpet 1 vacuum to dryness. Bet thus eraolt©l-b©asyl-4-hydroxy-4-fp«(1-otylenedioxyethyl)-feay I]-piperidine melted wet 114-116°.
Eksempel 18 Example 18
Til en suspensjon av 0,5 g tuagnesiutaspøn, oversiktet iued Ilte absolutt dietyleter, tilsetter man under nitrogen nomi dråper laetyljodid og etter at reaksjonen har begynt tilsettes ved 30-35° dråpevia en oppløsning av 6,3 g l-(ffl-metoksybenzyli-k-{p-klorfeny1)-piperldin i SO cal absolutt dietyieter. fctter at den størst©deien av atagnesiumet er opplost, tiisettei- ota ti lOO mg kopper-I-jodid, avkjøles til -10°, tilsetter 2,3 g etyl-broraid og lar over natten otnrøre ved -10 tii 0°. Deretter tilsettes 50 mi 2xi-natronlut, taettet m& d kokesait og ekstrahert tre ganger sued J' x 50 ml dietyieter. Den organiske fase bi i. r vasket nøytral, tørket over natriumsulfat og inndampe t i va kutta Destillasjon av inndampningsresidiet i høyvakuum og kromatograi; ved 100-150° (0,03 romlig) kokende fra&ajon på siiisiuiiidioksydgei m& d kloroform og lit©metanol som løjjeisiddei gix rått 1-(ai-ui&t-oksybenEyl)- k-(p-etyIfenyi)~piperidin (smeltepunkt av liydroklo-ridet i ,157-158°). To a suspension of 0.5 g of tuagnesiuta spøn, the overview in absolute oxygen diethyl ether, drops of ethyl iodide are added under nitrogen and after the reaction has started, a solution of 6.3 g of l-(ffl-methoxybenzyli-) is added dropwise at 30-35° k-{p-chloropheny1)-piperldine in SO cal absolute dietyiether. After the largest part of the atagnesium has dissolved, add 100 mg of copper-I-iodide, cool to -10°, add 2.3 g of ethyl bromide and leave to stir overnight at -10 to 0°. Then add 50 ml of 2x sodium hydroxide solution, thickened with baking soda and extract three times with 50 ml of diethyl ether. The organic phase was washed neutral, dried over sodium sulfate and evaporated in vacuo. Distillation of the evaporation residue in high vacuum and chromatography; at 100-150° (0.03 spatial) boiling from carbon dioxide with chloroform and lit©methanol as lyojesiddei gix raw 1-(al-ui&t-oxybenEyl)-k-(p-ethylIfenyi)~piperidine (melting point of liydrochloro- ridden in .157-158°).
Utgangsisaterialet kan f.eks• fremstilles på følgende må t e: Behandling av p-klorkanelsyreety1-ester med uatriumdi* etyimalonat til beta-fenyl-alfa,alfa,ypsilon-trikarbonsyretri-etyl-ester, deretter forsåpning med kalilut og dekarboksyierlnfe ved 110-130° fører til b©ta-p-klorfenyigiutarsyre, hvilke ved omsetning aied o-iaetoksybenzylatain ovei-føres i 1-(is-inetoksyben-2yl)-^-(p-kiori"enyl)-|>iperidin-2,6-dioii. Dette kan deretter reduseres nied iitiutaaluminiuiabydrid til ønsket i - ( m- ns e t o k y y - beriisy 1 (^-klorf eayl )-piperidin. The starting material can, for example, be prepared in the following way: Treatment of p-chlorocinnamic acid ethyl ester with sodium diethyl malonate to beta-phenyl-alpha,alpha,ypsilon-tricarboxylic acid tri-ethyl ester, then saponification with potassium chloride and decarboxylation at 110-130 ° leads to β©ta-p-chlorophenygibutar acid, which by reaction with o-iaethoxybenzylatain is transferred to 1-(is-inethoxyben-2yl)-^-(p-kiori"enyl)-|>iperidine-2,6- dioii. This can then be reduced with iitiutaaluminiuiabydrid to the desired i - ( m- ns e t o k y - beriisy 1 (^-chloroph eayl )-piperidine.
BksgG)pei._19 BksgG)pei._19
Tabletter inneholdende lOO mg aktiv-stoff, f.eks. i-benssyl-4-(p-etylfenyl)-pip©ridin, eller dets hydroklorid, eksempelvis fremstilles i følgende sammensetning: Tablets containing 100 mg of active substance, e.g. i-Benzyl-4-(p-ethylphenyl)-piperidine, or its hydrochloride, for example, is prepared in the following composition:
Fremstilling Manufacturing
Aktiv-stoffet blir blandet med melkesukkeret, endel av hvetestivelsea og med kolloidal siiisiumdioksyd og blandingen blir drevet gjennom en sikt* En annen del av bvøtootiv-elsen forklistret med 5-dobbolt mengde vann på vanhbadet og pulverblandingen blir blandet med dette klister inntil det dannes en svak plastisk masse. Ktassen blir drevet gjennom en sikt med ca. 3 mm maskevidde, tørket ogé det tørkede granulatet blir på ny drevet gjennom sikten. Deretter blir resterende hvete» stivelse, talkum og magnesiumstearat tUblandet. Den orbolto blanding blir presset til tabletter på 25G mg med bruddanvis-ning(er). The active substance is mixed with the milk sugar, part of the wheat starch and with colloidal silicon dioxide and the mixture is passed through a sieve. weak plastic mass. The ktassen is driven through a sieve with approx. 3 mm mesh size, dried and the dried granulate is driven through the sieve again. Then the remaining wheat» starch, talc and magnesium stearate are mixed in. The orbolto mixture is pressed into tablets of 25G mg with fracture indication(s).
Ekseujpol 20 Ekseujpol 20
På analog måte som beskrevet i eksemplene 5 og 19 kan man også fremstille tabletter inneholdende en annen av forbindelsene i henhold til eksemplene 1-4 og 6-13. In an analogous way as described in examples 5 and 19, tablets containing another of the compounds according to examples 1-4 and 6-13 can also be prepared.
Claims (18)
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CH733278 | 1978-07-05 |
Publications (1)
Publication Number | Publication Date |
---|---|
NO792233L true NO792233L (en) | 1980-01-08 |
Family
ID=4323474
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
NO792233A NO792233L (en) | 1978-07-05 | 1979-07-04 | PROCEDURE FOR THE PREPARATION OF PHENYL PIPERIDE INGREDIENTS |
Country Status (11)
Country | Link |
---|---|
EP (1) | EP0007067A1 (en) |
JP (1) | JPS5511592A (en) |
DD (1) | DD144770A5 (en) |
DK (1) | DK282379A (en) |
ES (1) | ES482138A1 (en) |
FI (1) | FI792076A (en) |
IL (1) | IL57720A0 (en) |
NO (1) | NO792233L (en) |
PL (1) | PL216817A1 (en) |
PT (1) | PT69871A (en) |
ZA (1) | ZA793336B (en) |
Families Citing this family (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DE3614907A1 (en) * | 1986-05-02 | 1987-11-05 | Basf Ag | N-SUBSTITUTED PYRROLIDONE AND PIPERIDINE DERIVATIVES AND THEIR SALTS |
GB9100505D0 (en) * | 1991-01-10 | 1991-02-20 | Shell Int Research | Piperidine derivatives |
US5459151A (en) * | 1993-04-30 | 1995-10-17 | American Home Products Corporation | N-acyl substituted phenyl piperidines as bronchodilators and antiinflammatory agents |
WO1997041108A1 (en) * | 1996-04-30 | 1997-11-06 | Warner-Lambert Company | Substituted piperazines and piperidines as central nervous system agents |
CO5150201A1 (en) * | 1998-09-07 | 2002-04-29 | Hoffmann La Roche | PIPERIDINE DERIVATIVES |
WO2000026187A1 (en) * | 1998-11-02 | 2000-05-11 | Synthon B.V. | Process for producing 4-arylpiperidine-3-carbinols and related compounds |
GB9912411D0 (en) * | 1999-05-28 | 1999-07-28 | Pfizer Ltd | Compounds useful in therapy |
Family Cites Families (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
GB1044309A (en) * | 1964-05-07 | 1966-09-28 | Koninklijke Pharma Fab Nv | Substituted 1-aralklyl-piperidines |
DE2101997A1 (en) * | 1971-01-16 | 1972-08-03 | Farbenfabriken Bayer AG, 509öfLeverkusen | 1-benzyl-4-subst-tetrahydropyridines - useful as intermediates for pharmaceuticals |
FR2340734A1 (en) * | 1976-02-13 | 1977-09-09 | Roussel Uclaf | NEW DERIVATIVES OF M-TRIFLUOROMETHYLPHENYL PIPERIDINE AND THEIR SALTS, METHOD OF PREPARATION AND APPLICATION AS MEDICINAL PRODUCTS |
CH636858A5 (en) * | 1977-01-17 | 1983-06-30 | Ciba Geigy Ag | METHOD FOR PRODUCING NEW PHENYLAZACYCLOAL CHANES. |
FR2380261A2 (en) * | 1977-02-11 | 1978-09-08 | Roussel Uclaf | Substd. meta-tri:fluoromethyl-phenyl piperidine cpds. - having antidepressant, antiparkinson and anorexigenic activity |
US4147872A (en) * | 1977-09-13 | 1979-04-03 | Pfizer Inc. | 3-[2-Hydroxy-4-(substituted)-phenyl]azacycloalkanes and derivatives thereof as analgesic agents and intermediates therefor |
-
1979
- 1979-07-02 FI FI792076A patent/FI792076A/en not_active Application Discontinuation
- 1979-07-03 DD DD79214075A patent/DD144770A5/en unknown
- 1979-07-03 ES ES482138A patent/ES482138A1/en not_active Expired
- 1979-07-03 PL PL21681779A patent/PL216817A1/xx unknown
- 1979-07-04 EP EP79102272A patent/EP0007067A1/en not_active Withdrawn
- 1979-07-04 DK DK282379A patent/DK282379A/en unknown
- 1979-07-04 PT PT69871A patent/PT69871A/en unknown
- 1979-07-04 ZA ZA793336A patent/ZA793336B/en unknown
- 1979-07-04 NO NO792233A patent/NO792233L/en unknown
- 1979-07-04 IL IL57720A patent/IL57720A0/en unknown
- 1979-07-05 JP JP8449079A patent/JPS5511592A/en active Pending
Also Published As
Publication number | Publication date |
---|---|
EP0007067A1 (en) | 1980-01-23 |
IL57720A0 (en) | 1979-11-30 |
JPS5511592A (en) | 1980-01-26 |
PL216817A1 (en) | 1980-03-24 |
DK282379A (en) | 1980-01-06 |
ZA793336B (en) | 1980-06-25 |
DD144770A5 (en) | 1980-11-05 |
PT69871A (en) | 1979-08-01 |
FI792076A (en) | 1980-01-06 |
ES482138A1 (en) | 1980-04-01 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US5459151A (en) | N-acyl substituted phenyl piperidines as bronchodilators and antiinflammatory agents | |
JP4980928B2 (en) | G protein-coupled receptor (GPR116) agonist and use thereof for the treatment of obesity and diabetes | |
KR920003064B1 (en) | Process for preparing hetero cyclic compounds | |
WO1993014084A2 (en) | Piperidine derivatives | |
EP0248523A1 (en) | Pyrazoles | |
IE831885L (en) | 1,2,3,6-tetrahydropyridine derivatives. | |
US4774249A (en) | Pyrimidine derivatives for treating malaria | |
JP3007419B2 (en) | Benzyl piperidine derivatives as drugs | |
US5750720A (en) | 4- (thien-3-yl)methyl!-imidazole analgesics | |
NO792233L (en) | PROCEDURE FOR THE PREPARATION OF PHENYL PIPERIDE INGREDIENTS | |
US5462945A (en) | N-substituted trifluoromethylphenyltetrahydropyridines, process for the preparation thereof, intermediates in said process and pharmaceutical compositions containing them | |
JPS6046115B2 (en) | Process for producing tetrahydropyridine and piperidine derivatives | |
US4481360A (en) | 4H-1,2,4-Triazol-3-yl compounds | |
DE2811952A1 (en) | PHENOXYALKYLAMINE AND METHOD FOR THE PRODUCTION THEREOF | |
US6313309B1 (en) | 4-thionaphthyl—1H—imidazoles which are usefulα22-adrenoceptoR agonists/ antagonists | |
IE66016B1 (en) | Azacyclic carboxylic acid derivatives their preparation and use | |
AU718719B2 (en) | 4-{(thien-2-yl)methyl}imidazole derivatives having alpha2-adrenoceptor agonistic activity | |
US4465681A (en) | Bis-(aminoalkoxy)-phenyl, pyridyl ketones, and use as immunological agents | |
US3576811A (en) | 1-alkyl-1-(beta-piperidino-ethyl)-1,2,3,4- tetrahydronaphthalen-2-ones | |
NO158736B (en) | ANALOGY PROCEDURE FOR THE PREPARATION OF TETRAHYDROPYRIDINE DERIVATIVES. | |
US4454136A (en) | Substituted benzopyranotriazoles and antiallergic use | |
JP2524731B2 (en) | Hydroxyindole ester compound | |
US4683239A (en) | 3-diphenyl substituted octahydroindolizine analgesic compounds | |
US3869461A (en) | Intermediates for quinine, quinidine and derivatives thereof | |
NO800230L (en) | PROCEDURE FOR THE PREPARATION OF CHINAZOLINE DERIVATIVES |